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“Luck is what happens when preparation meets 
opportunity.” 
    Seneca, roman philosopher 5 b.c. 
 
“ Man ist nie fertig mit der Wissenschaft, höchstens ist 
die Wissenschaft fertig mit einem.” 



























Applying dynamic combinatorial chemistry (DCC) to medicinal chemistry 
projects can be a helpful strategy for finding starting points in the drug-discovery 
process. As relevant drug target, 14-3-3 proteins play a role in several diseases 
and many biological processes. Proteins of this family engage in protein-protein 
interactions (PPIs), and can up-or down-regulate their binding partner’s activity. 
Another family of relevant targets are glucansucrases, which are important 
enzymes in the initiation and development of cariogenic dental biofilms, 
commonly known as dental plaque. In the last two chapters, endothiapepsin was 
used for protein-templated DCC (ptDCC). Endothiapepsin belongs to the family 
of the aspartic proteases, which are involved in for example the maturation of the 
HIV virus particle.  
Throughout this thesis, we focus on applying DCC to various projects. The main 
achievements are: 1) the description of the in-house protocol of DCC, in which 
aspects like solubility of building blocks and products, protein stability and more 
need to be taken in to account, 2) the application of acylhydrazone-based DCC to 
two targets, a (PPI)-target and a glucansucrase, 3) the identification of small-
molecules, which stabilise PPIs of 14-3-3/ synaptopodin, 4) expanding the 







Die Verwendung dynamisch kombinatorischer Chemie (DCC) in medizinisch-
chemischen Projekten kann eine sehr hilfreiche Strategie sein, um 
Anknüpfungspunkte für die Wirkstoffentdeckung zu finden. 14-3-3 Proteine 
spielen eine Rolle in verschiedenen Krankheiten und vielen biologischen 
Prozessen. Proteine dieser Familie beteiligen sich an Protein-Protein-
Interaktionen (PPIs) und können die Aktivität der Bindungspartner sowohl hoch- 
als auch herabregulieren. Eine andere Familie relevanter Targets sind die 
Glukansucrasen, welche wichtige Enzyme in der Initiierung und Entwicklung von 
kariogenen dentalen Biofilmen, allgemein bekannt als Plaque, sind. In den letzten 
beiden Kapiteln wurde Endothiapepsin für Protein-vermittelte DCC (ptDCC) 
verwendet. Endothiapepsin gehört zur Familie der Aspartylproteasen, welche 
zum Beispiel an der Reifung des HIV Viruspartikels beteiligt sind. 
Im Verlauf dieser Arbeit fokussieren wir uns auf die Anwendung von DCC in 
verschiedenen Projekten. Die Hauptleistungen sind: 1) die Beschreibung des 
hausinternen DCC-Protokolls, in welchem Aspekte wie Löslichkeit von 
Bausteinen und Produkten, Proteinstabilität und weiteres wichtige zu beachten 
sind, 2) die Anwendung von Acylhydrazon-basierter DCC auf zwei Targets, eine 
Glukansucrase und ein PPI-Target, 3) die Identifikation kleiner Moleküle, die 
PPIs von 14-3-3/ Synaptopodin stabilisieren, 4) die Erweiterung des 














Chapter 1  
Introduction to dynamic combinatorial chemistry 1 
1.1 Introduction 2 
1.1.1 Reversible reactions suitable for DCC 4 
1.2 A closer look on the templating protein 6 
1.2.1 Purity 6 
1.2.2 Stability 7 
1.2.3 Buffer and pH 7 
1.2.4 Functional enzyme assay 11 
1.2.5 Additives and contaminations 11 
1.2.6 DMSO 12 
1.2.7 Temperature 13 
1.3 Setting up a ptDCC experiment 13 
1.3.1 Formation of the DCLs 14 
1.3.2 Analysis of the DCLs 15 
1.3.3 DCL analysed with STD-NMR spectroscopy 16 
1.3.4 How to proceed after obtaining hits 18 
1.4 DCC in a synergistic combination with fragment linking 18 
1.5 Conclusions 20 
1.6 Outline of this thesis 20 





Chapter 2  
Molecular Insight into Specific 14-3-3 Modulators: Inhibitors and 
Stabilisers of Protein-Protein Interactions of 14-3-3 25 
2.1 Introduction 26 
2.2 Structure-based optimisation 28 
2.3 Inhibitors 29 
2.4 Stabilisers 38 
2.5 Development in the discovery of modulators of 14-3-3 proteins since 2016
 44 
2.6 Conclusions 48 
2.7 References 48 
 
Chapter 3  
Discovery of small-molecule modulators of 14-3-3 PPIs via dynamic 
combinatorial chemistry 53 
3.1 Introduction 54 
3.2 Results and Discussion 55 
3.3 Conclusions 61 
3.4 Experimental 61 
3.4.1 Materials and methods 61 
3.4.2 DCC conditions 62 
3.4.3 Synthesis 63 
General procedure for acylhydrazone formation:[16] 63 
3.4.4 Protein expression and purification 65 
3.4.5 Fluorescence polarisation assay (FP) 65 
3.4.6 Binding studies by surface plasmon resonance (SPR) 65 
3.4.7 SPR competition assays 66 
3.5 References 67 
3.6 Supporting information 69 
3.6.1 UPLC-MS analysis of DCC 69 




Chapter 4  
Design and synthesis of glucosyltransferase inhibitors: dynamic 
combinatorial chemistry approach 77 
4.1 Introduction 78 
4.1.1 Dynamic combinatorial library design 80 
4.2 Results and Discussion 81 
4.2.1 Synthesis of the building blocks 81 
4.2.2 Forming the DCLs 82 
4.2.3 Monitoring the DCLs 82 
4.2.4 Binding studies by surface plasmon resonance (SPR) 84 
4.2.5 GTF-180 activity assay 85 
4.3 Conclusions 86 
4.4 Experimental section 87 
4.4.1 Materials and methods 87 
4.4.2 General procedure for DCC experiments 87 
4.4.3 Binding studies by surface plasmon resonance (SPR) 87 
4.4.4 GTF-180 activity assay 87 
4.4.5 Synthesis 88 
4.5 References 99 
 
Chapter 5 101 
Nitrone-based DCC 101 
5.1 Introduction 102 
5.1.1 Biochemical relevance of nitrones 102 
5.1.2 Nitrone-based DCC 103 
5.2 Results and Discussion 104 
5.2.1 pH window 106 
5.2.2 protein-templated DCC 107 
5.2.3 Cytotoxicity assay 109 
5.2.4 Endothiapepsin activity assay 109 
XIV 
 
5.3 Conclusions 110 
5.4 Experimental 110 
5.4.1 Materials and methods 110 
5.4.2 DCC conditions 110 
5.4.3 Cytotoxicity assay; determination of viable cell mass 111 
5.4.4 Fluorescence-based Endothiapepsin inhibition assay 111 
5.4.5 Synthesis 111 
General procedure for hydroxylamine formation GP1: 111 
General procedure for nitrone formation GP2: 112 
5.5 References 114 
5.6 Supporting information 115 
 
Chapter 6  
Thiazolidines in protein-templated Dynamic Combinatorial 
Chemistry 125 
6.1 Introduction 126 
6.2 Results and Discussion 128 
6.2.1 Design of the libraries. 128 
6.3 Cytotoxicity assay 131 
6.4 Biochemical evaluation of hit T3A2 via a fluorescence-based inhibition 
assay 132 
6.5 Expanding the reaction scope to aromatic aminothiols 132 
6.6 Conclusions 133 
6.7 Experimental 134 
6.7.1 Materials and methods 134 
6.7.2 DCC conditions 134 
6.7.3 Cytotoxicity assay; determination of viable cell mass 135 
6.7.4 Fluorescence-based endothiapepsin inhibition assay 135 
6.7.5 Synthesis 135 
6.8 References 136 




Summary & Perspectives 141 
7.1 Context and scope of this thesis 142 
7.2 Summary 143 

















Dynamic combinatorial chemistry (DCC) is a powerful tool to identify bioactive 
compounds. This efficient technique allows the target to select its own binders 
and circumvents the need for synthesis and biochemical evaluation of all 
individual derivatives. An ever-increasing number of publications report the 
use of DCC on biologically relevant targets. The work here complements reviews 
by focusing on the experimental protocol and giving detailed examples of 
essential steps and factors that need to be considered, such as protein stability, 
buffer composition and cosolvents. 
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Since its dawn more than two decades ago, combinatorial chemistry 
approaches[1–5] have developed into target-directed dynamic combinatorial 
chemistry (tdDCC) and have matured as a hit- identification tool. There has been 
an increasing number of work published in this niche of supramolecular 
chemistry.[6–11] A growing number of groups have shown the general applicability 
and scope of tdDCC for the identification of modulators of targets.[6,12–20] tdDCC 
refers to general pharmacologically relevant targets which next to proteins also 
include DNA and RNA, whereas protein-templated DCC (ptDCC) only refers to 
proteins. Several reviews and book chapters on tdDCC have been published in 
recent years.[21–23] This chapter covers our work on ptDCC and provides the key 
features of our protocol, explaining the essential steps in designing a successful 
ptDCC experiment.  
Carefully chosen building blocks are connected in a reversible manner via 
covalent or noncovalent bonds to form a dynamic combinatorial library (DCL) 
(Figure 1). Biocompatibility, pH dependence, temperature, solubility and stability 
of the components are important factors, which should be taken into account. The 
ideal DCLs do not require cosolvents, however, it can occur that the formed 
products have a lower solubility than the building blocks and in order to keep all 
compounds in solution, a cosolvent such as dimethyl sulfoxide (DMSO) is 
commonly used. Precipitation of DCL components could lead to an undesired 
shift in the equilibrium. By contrast, a desired shift of the equilibrium can be 
obtained by the addition of an external stimulus, such as a protein target. There 
are in general two different approaches that can be followed in ptDCC: ‘adaptive 
DCC’, in which the target is present during the formation of the DCL and ‘pre-
equilibrated DCC’, in which the target is added after the DCL is established. An 
advantage of pre-equilibrated DCC is that the exchange chemistry can be applied 
in conditions which are not tolerated by the protein. A disadvantage is that the 
screening step is performed under static conditions and no amplification effects 










In ptDCC, the member(s) of DCLs, which bind best will be amplified, leading to 
an increase in their concentration compared to a control reaction without the 
external stimulus. These binders can then be further evaluated for their 
biochemical properties. 
To enable a comparative analysis of DCLs, a blank reaction, without the target, 
should be run concurrent with a templated reaction. Another approach of DCC is 
non-comparative, in which the hits can be analysed in complex with the target or 
after being released from the target. There are different techniques that can be 
used to analyse the DCLs: liquid and size-exclusion chromatography coupled to 
mass spectrometry, NMR spectroscopy, fluorescence spectroscopy and X-ray 
crystallography. Figure 2 illustrates the comparative approach versus the non-
comparative approach, which can be adopted in DCC. The reaction mixture can 
be ‘frozen’, in order to prevent the library from re-equilibrating during the 
analysis. In the case of acylhydrazone chemistry, this can be achieved by an 
increase in pH. Denaturation by heat, addition of a solvent or (ultra-fast) 













Figure 2. DCC approaches: comparative and non-comparative. In the comparative 
approach the library in presence of a target is compared to the library in absence of the 
target. In the non-comparative approaches, the hit–target complexes will be separated 
from the mixture and analysed as a complex or as released hits. The figure was adapted 




1.1.1 Reversible reactions suitable for DCC 
Only a limited number of reversible reactions have been used thus far, they are 
summarised in Scheme 1. One of the most frequently used reactions is the 
(acyl-)hydrazone formation, which combines ketone or aldehyde building blocks 
with (acyl-)hydrazides. This condensation reaction can take place in water, 
making it biocompatible.[24] The synthesis of the building blocks is generally 
straightforward or they may be commercially available. 
At physiological conditions, neutral pH and room temperature, acylhydrazone 
formation and exchange are relatively slow. At acidic pH, the equilibrium is 
reached rapidly. However, Greaney and coworkers have shown that the pH 
dependence can be influenced by the addition of a nucleophilic catalyst. They 
were able to reach equilibrium reasonably fast at a comparatively high pH of 6.2 
by using aniline, as a nucleophilic catalyst.[12] Previously Dawson and coworkers 
have shown that aniline could serve as a catalyst for acylhydrazone formation and 
oxime ligation.[25,26] Derivatives of aniline, which bear substituents at the aryl 
ring, are even more effective catalysts.[27]  
The acylhydrazone linkage is reversible under acidic conditions and stable against 
hydrolysis at physiological pH values, allowing for the ‘freezing’ of the reversible 











Scheme 1. Reversible reactions used in target-directed DCC to identify bioactive 







Scheme 1 continued. Reversible reactions used in target-directed DCC to identify 
bioactive compounds. Scheme was adapted from Van der Vlag and Hirsch.[23] 
An overview of studies published over the past five years in the field of ptDCC is 
given in Table 1. It must be noted that much more work has been published 
applying DCC for the formation of diverse libraries in the drug-discovery process. 
For example the coupling of DCC to DNA-encoded libraries, creating so called 
DNA-encoded dynamic combinatorial chemical libraries (EDCCLs). Iminobiotin 
and homotetrameric streptavidin were used as a model system to identify a 
bidentate protein/ligand interaction. The addition of an external stimulus, for 
example a target protein, can shift the thermodynamic equilibrium and hence a 
DNA amplification can be observed after sequencing.[28] 
Table 1. Protein-templated DCC studies reported over the past five years, in which a target 
was used as a template to influence the equilibrium. Therefore, only articles using an 
adaptive approach are listed, pre-equilibrated DCC examples are omitted.[29–31] The table 











Best affinity Ref. 
Wt Tau RNA Disulfide HPLC-MS 
and NMR 
21 2 days Fluorescence 
titration 
EC50 = 70 nM [32] 





Imine HRMS 297 24 h In vitro activity 
against cancer 
cell lines 
IC50 = 2.4 µM [34] 
Endothiapepsin Acylhydraz
one 
HPLC-MS 90 20 h Inhibition assay IC50 = 54.5 nM 









HPLC 11 24 h Fluorescence-
based assay and 
MIC 
KD = 3 µM 












n.a. in vivo activity 
assay 





19F-NMR 5 12 h Enzymatic 
assay 












10 5 h HPLC-based 
demethylase 
and DSF assays 














DSF = differential scanning fluorimetry, HPLC = high-performance liquid 
chromatography, IC50 = half maximal inhibitory concentration, ITC = isothermal titration 
calorimetry, KD = dissociation constant, Ki = inhibition constant, MIC = minimum 
inhibitory concentration, MS = mass spectrometry, n.a. = not available, NMR = nuclear 
magnetic resonance, SPR = surface plasmon resonance, Tm = thermal shift. 
1.2 A closer look on the templating protein 
To obtain meaningful results from DCC experiments, the quality of the input 
template is critical. As the equilibrium of the library shifts by the templating effect 
of the added protein sample, it should consist of the target protein as close to its 
native state as possible. The quantity of the used template depends on the protein 
target, there are reported successful DCC projects with 0.1 to 1.5 equivalents of 
protein. [29,42] DCC experiments are also possible with a mixture of proteins, but 
a well-defined sample eases up downstream data analysis and reduces the 
number of false positives for the desired target.[40] The condition of the protein 
sample depends on various variables. For DCC experiments the purity, 
concentration, tertiary and quaternary structure of the protein, additives and 
contaminations, as well as the pH-value are of particular importance. During the 
experiment, which can take up to several days, protein degradation and 
precipitation could occur. The tests described herein should give an overview and 
help to choose suitable experimental conditions to plan new DCC experiments. In 
the next paragraphs, we will briefly discuss the influence of those factors and 
suitable analytical methods to monitor them. 
1.2.1 Purity 
In the case of a mixed or impure protein sample, there might be several templated 
reactions proceeding in parallel. It is impossible to differentiate between a small 




protein pool showing only a weak amplification of a binder. This will result in 
overlapping data, which are difficult to analyse, and may result in false positives. 
We therefore recommend starting with the highest protein purity available. 
1.2.2 Stability 
Not only the initial state, but also the stability of the templating protein during 
the reaction should be checked by preliminary tests before conducting a DCC 
experiment. The time span over which a DCC experiment, pre-equilibrated or 
adaptive, is monitored can vary. It depends on the reaction rate and 
concentration and should ideally be monitored until the library reaches an 
equilibrium state. Usually, the DCL reaches a new equilibrium within the first few 
days, depending on the reversible reaction and conditions (Table 1). However, if 
the protein is stable for longer periods of time, longer equilibration times are 
possible, for example up to 20 days for the very stable protease endothiapepsin 
(see Section 1.2.4).[24] 
It is important that the protein is not precipitating or degrading during the 
experiment. Precipitation of the protein will remove the template from the 
solution. Denaturation of the template will lead to entirely new templates, which 
would affect the equilibrium state of the DCL. This can lead to random and 
irreproducible amplification of compounds by the unordered protein and a 
decrease of initially already amplified best binders of the native template. If the 
protein target is labile, it is therefore necessary to follow the reaction over time to 
identify the temporary, templated equilibrium of the DCC library. In this, 
compounds amplified by the native state of the template can be found.  
Eventually, after prolonged incubation time, nearly every protein will degrade 
and, by this, change the equilibrium of the DCL again. Compounds amplified in 
this step can be ignored, as they were not templated by the native protein. 
Observation of the DCC experiment for longer timeframes than the template 
integrity can be guaranteed is therefore of no use.    
1.2.3 Buffer and pH 
When choosing a buffer for DCC experiments, several different requirements 
have to be met. Attention should be paid to possible side reactions with the DCL 
or chelation effects. For example, Tris-buffer could form imines with aldehyde 
building blocks, which might influence the formation of the DCL. Some 
stabilization of the protein is beneficial, but strong interactions of the buffer with 
the target protein should also be avoided, for instance, a phosphate buffer for a 
phosphate binding protein. The phosphate could compete with possible binders; 
possible effects of competition are discussed in more detail in Section 1.2.5.  So 




Table 2 and Scheme 2. The choice of buffer is, however, not limited to the 






Scheme 2. Example of possible buffers and the pH ranges of reactions used in DCC 
experiments. 
 
Table 2. Buffers commonly used in different DCC reactions. *Tris buffer requires special 
attention. 
Reaction Buffer described in literature 
Acylhydrazone formation [6,24,36] Ammonium- and Sodium acetate, Phosphate, Tris* 
Hydrazone formation [43,44] Phosphate, Tris*  
Disulfide [45,46] Phosphate, Borate 
Thioether [47] Water/DMSO 
Imine [13] Water 
Boronate ester [14,48] Ammonium acetate, Water 
 
For many protein targets, the stability at room temperature and the optimal 
buffer conditions are not known. We therefore recommend determining these 
conditions prior to performing DCC experiments. As several interdependent 
factors, like pH, buffer, ionic strength and ions influence the stability of a protein, 
it is difficult to suggest a stepwise flow scheme for the determination of the ideal 
buffer composition for a given protein.[28] Not only the protein but also the 
exchange chemistry might be affected significantly by varying these parameters. 




range in parallel. Afterwards, a small selection (2 to 5) of the most stabilizing 
combinations can be evaluated for their long-term effect on the protein. 
Subsequently, the best condition will then be used to determine the influence of 
DMSO (Section 2.6) and, if of interest, additives (Section 2.5). The selection of 
the initial buffers could be broadened, in case no suitable condition was found. 
Two or more buffers should be screened per pH value to distinguish the influence 
of the buffer component and the pH value on the stability of the protein. It is also 
possible to use a so-called “superbuffer”,[49] a mix of three or more buffer 
components, enabling the adjustment of a wide pH-range, without changing the 
buffer composition or concentration. 
The effect of the buffer components on a protein can be measured in a 
straightforward way, by determining the melting point of the target protein via a 
thermal-shift assay / differential scanning fluorimetry (TSA /DSF).[28] In this 
method, the protein is incubated together with a lipophilic dye, for example sypro 
orange. The dye shows an increase in fluorescence after binding to the 
hydrophobic parts of a protein. These are often located at the inside of a protein 
and become exposed during temperature-induced unfolding/melting. The 
temperature–dependent increase in fluorescence can be measured in a RT-PCR 
apparatus and yields the Tm of the protein. 
Other methods, like DSC, ITC and CD (differential scanning calorimetry, 
isothermal titration calorimetry and circular dichroism spectroscopy) and the 
determination of melting points by CD could also be used to gain information on 
the interaction and possible stabilization of the protein with its buffer, but require 
a high amount of protein and/or long measurement time. The TSA, however, 
offers high throughput and a short assay time, together with already several 
published or commercially available kits in 96-well format.[50,51] These kits were 
originally intended to screen for optimal crystallization conditions and cover 
several stability-influencing conditions. When performing DCC experiments, the 
design of an individual 96-well plate layout, tailored to the buffers and conditions 
compatible with the planned DCC reaction, might be useful. This is a short time 
investment, which might pay off quickly in the future, if ptDCC is used on several 
different targets. 
After a DCC–compatible, stabilizing buffer condition has been identified, the 
protein should be checked for its long-term stability. To check for cleavage of the 
protein backbone an analysis by SDS-PAGE is of sufficient sensitivity (Figure 3). 
To determine if the protein folding is affected, TSA is again the method of choice, 
since the signal directly depends on the unfolding process of the protein. With 
prolonged degradation, the melting point decreases slightly. As a secondary effect 




points and an overall decrease in signal intensity and resolution. A fully 
denatured enzyme will just show a decreasing fluorescence signal with no peak 
from protein unfolding. As controls, a fresh and a heat-treated sample of the 
target protein should be included in the experiment.  
The tendency of a protein to precipitate is concentration-dependent. Because of 
this, the assays determining the protein stability should be performed with the 
same protein concentration that is intended to be used in the DCC experiment. If 
this is not possible, due to limited protein availability, the first experiments might 
be done with less protein. However, at least for the chosen final condition, the 
stability assessment should be repeated with the protein concentration that will 











Figure 3. 12% SDS-PAGE of different homologues of the enzyme 5-Deoxyxylulose 
5-Phosphate Synthase (DXS) after incubation at RT. The protein on the upper gel shows 
no sign of degradation. The second protein, shown on the lower gel, shows signs of 
degradation, starting already at day one with a very faint band around 50 kDa. From day 
6 on a decrease of the main protein band also becomes clear. In the top left corner a gel-






1.2.4 Functional enzyme assay 
For enzymatic protein targets, a functional assay can be used instead of TSA and 
PAGE measurements for the assessment of long-term stability. The analysis of 
activity data of a functional assay to determine the best experimental conditions 
of the DCC experiments leaves less room for interpretation than the analysis of 
the results of a melting-point analysis. Therefore, if a functional assay is available, 
and the enzyme is showing catalytic activity in the desired pH range of the DCC 
reaction, the activity assay should be the method of choice.   
In a previous study from 2014, we could monitor the activity of the target protein 
endothiapepsin by performing a fluorescence-based assay (Figure 4). The pH-
optimum of endothiapepsin is 4.5, and the enzymatic activity was not affected 
even after 20 days incubation at RT and a pH of 4.6. Considering this high 







1.2.5 Additives and contaminations 
During the purification, the protein might be in contact with different buffers and 
conditions. Some of the buffer components might remain bound to the protein, 
even after a buffer exchange. These contaminants might influence the 
experiment. It is therefore recommended to critically evaluate the composition of 
the protein sample. Not only should the protein storage buffer be evaluated, but 
also the origin of the sample. 
Common substances that could be found in protein samples are for example 
imidazole as a leftover from an IMAC (immobilised metal affinity 
chromatography) purification step. Protein samples are often supplemented with 
reducing agents like 2-ME, DTT or TCEP (2-Mercaptoethanol, Dithiothreitol or 
Tris(2-carboxyethyl)phosphine) in concentrations up to 10 mM to keep the 
Figure 4. Activity of endothiapepsin, a pepsin-like aspartic protease, in a fluorescence-
based assay at different time intervals of incubation at room temperature. Figure was 




protein in a reducing environment. If disulfide formation is the reversible 
reaction of choice, the final reducing agent concentration should be evaluated to 
make sure that the formation of disulfide bonds is not inhibited.  
The effect of additives and contaminations is related to the volume of the protein 
sample used in the individual DCC experiments. This not only determines the 
final concentration of protein, but also the concentrations of the contaminants. If 
the batch-to-batch concentration of the protein varies and its volume is adjusted 
to reach the same final concentration in the DCC experiment, it should be noted 
that the concentrations and effects of the additives in the DCC experiment might 
vary. 
Compounds that remain in the protein sample can have an influence on the DCC 
reaction or on the target protein. One should critically check every buffer 
component on possible interference with the planned exchange chemistry. 
Screening literature for known reactions between the DCL members and sample 
components can be considered. Performing a control experiment with all buffer 
components, in the absence of protein, can assure that no side reactions are 
taking place. If the exact composition of the protein sample is unknown, a small 
volume of the buffer might be gained by concentration of the protein using an 
ultrafiltration device and using the flow-through for the control experiment.  
Some agents used during protein purification, such as cryoprotectants like 
glycerol or detergents like Tween, will interact in a non-specific way with the 
protein surface. From our experience, if there is no hint that they might affect the 
experiment, leftover cryoprotectants and detergents can be tolerated. Special care 
should be taken if cofactors, coenzymes or ions are supplemented during the 
purification process to stabilise the enzyme. The same holds true for buffer 
components structurally related to those supplements. Everything that binds to 
the targeted binding pocket is competing with the DCC library. If a natural, tight 
binding cofactor is present during the experiment, it could prevent the building 
blocks from binding and therefore also inhibit their amplification. However, the 
use of tight binders can be beneficial in control experiments. If a compound with 
a known binding site is inhibiting the formation of some previously observed 
binders this can be taken as a hint that the templated binders are targeting the 
same protein pocket. 
1.2.6 DMSO 
Addition of a small percentage of DMSO to the reaction solution is a common 
practice in the design of enzymatic assays to improve the solubility of 
hydrophobic compounds. For biochemical assays, DMSO concentrations up to 




In DCC experiments, the building blocks of the library are typically dissolved in 
DMSO stock solutions to enable the easy assembly of a library. Depending on the 
library composition and number of compounds used, the final DMSO 
concentration would vary. To keep the reaction conditions comparable, we 
recommend adding DMSO up to a concentration that can be kept constant for all 
experiments of a project. This fixed concentration should be evaluated and 
chosen beforehand, to ensure the protein tolerates it.  
DMSO has a very broad range of effects on proteins, it can even decrease the 
solubility and induce precipitation.[53] Both, rate acceleration, as well as 
inhibition of the enzyme-catalysed reaction by DMSO have been observed. An 
influence of already low percentages of DMSO on the enzymatic activity often 
hints to DMSO acting as an unspecific effector, interacting with the active site of 
the enzyme.[54] If the enzymatic activity is reduced by DMSO at higher 
concentrations (>10% DMSO ), it is often by influencing the overall protein 
conformation by displacing water molecules bound to the surface and unfolding 
the protein.[55] On the other hand, there are  DMSO-tolerant enzymes known 
which show activity up to 80% DMSO.[54] Enzyme activity assays are the method 
of choice to estimate the effect of DMSO on an enzyme. If no activity assay is 
available, the effect of DMSO could also be measured using TSA, however, 
interactions with the active site are difficult to detect with this method. We often 
observe a small effect on the Tm of a protein, but a strong effect on the enzymatic 
activity. Taken together, the DMSO concentration has several effects on the 
protein structure. The benefits of DMSO addition need to be weighed against the 
risk of creating an artificial enzymatic fold, which could amplify compounds that 
would not bind under native conditions. Therefore, the DMSO concentration 
should be as low as possible, in our lab up to 5% are regularly used. 
1.2.7 Temperature 
To speed up the rate at which the DCL reaches equilibrium, the experiments are 
normally performed at room temperature. For labile proteins, a lower reaction 
temperature may be necessary, which can improve the stability of the proteins. 
At the same time, the equilibration rate is decreased, leading to a prolonged 
incubation time. The optimal temperature for protein stability in DCC could vary 
from enzyme to enzyme and thus needs to be evaluated in each individual case 
but room temperature is used in most cases.  
1.3 Setting up a ptDCC experiment 
When crystal structures are available, or even cocrystal structures, a structure-
based approach can be undertaken to design promising building blocks. In this 
case also non-binders could be designed as control elements, which are not 




selected because it influences the molecular recognition by the target. For 
example, the acylhydrazone linkage resembles the amide functionality; and 
features hydrogen-bond donors and acceptors. We showed that by combining 
DCC with de novo structure-based design, the risks associated with this attractive 
approach are reduced.[24] 
1.3.1 Formation of the DCLs 
The building blocks might have to be dissolved in DMSO, allowing them as well 
as the formed products to stay soluble in the final mixture. In principle, they could 
also be dissolved in the desired buffer, which would be most ideal. In 2014, we 
coupled DCC to saturation-transfer difference (STD)-NMR spectroscopy, which 
requires lower concentrations of protein than a general DCC experiment (Table 
3). STD-NMR spectroscopy enables selection of the binders from the DCL, since 
the intensity of these signals is stronger due to a more efficient saturation 
transfer. As a result of only observing binders, STD-NMR spectra cannot be used 
to determine concentrations of DCL members and therefore amplification cannot 
be calculated. In follow-up experiments, it is possible to determine the KD value 
of a ligand via STD-NMR or other biophysical assays.[56] 
The ratio of hydrazides versus aldehydes should allow for the formation of all 
possible products, therefore at least one equivalent of each hydrazide per 
aldehyde should be used. For example, if three aldehydes are used then at least 
three equivalents of each hydrazide should be added, making sure that there is an 
excess of hydrazides. When required, a nucleophilic catalyst like aniline could be 
added. The most frequently used concentration of DMSO lies around 5–10%. 
Table 3. General protocol for DCC and protocol for DCC coupled to 1H-STD-NMR. * 
Aniline or another nucleophilic catalyst could be added when required. ** In a control 
experiment, no protein is added. *** Buffer conditions to guarantee protein stability 
should be determined a priori. 
 Final concentration in general DCC 
Final concentration used in DCC coupled 
to 1H-STD-NMR[24] 
Aldehyde 0.1 mM 0.4 mM 
Hydrazide 0.1–0.3 mM 1 mM (for each of the five hydrazides) 
DMSO 5–10^% 5–10^% 
Aniline* 10 mM – 
Protein** 10–100 µM 4 µM 
Buffer*** 0.1 M Ammonium acetate in D2O (0.1 M, pH 4.6) 






Control experiments should be considered, which should clarify where binding of 
molecules to the protein occurs and if it is specific or unspecific. This could for 
example be performed by the addition of a known inhibitor. If the previously 
observed amplification is not observed any longer, then the hit compounds are 
competitive binders. Based on the work of Danieli et al., B. Ernst and coworkers 
propose that the use of bovine serum albumin (BSA), as a negative control 
template for which no amplification is expected since the binding pocket is 
different, is not a good control since it could influence the library composition, 
whilst the use of a competitive inhibitor is better. BSA has been used in DCC to 
show that the applied library only gives hits with the real target and that BSA 
would yield the same result as the blank.[21,57] BSA is commonly known for its 
stability and was thought not to interfere with biological reactions, however 
recently DCC experiments have even been used to target BSA.[58] 
1.3.2 Analysis of the DCLs 
Different techniques such as fluorescence-polarization, SPR, ITC, MST, STD-
NMR, crystallography and others can be used to evaluate and possibly optimise 
obtained hits. We and Rademann and coworkers have reviewed the analytical 
methods used in protein-templated dynamic combinatorial chemistry to detect 
hit compounds. [23][59]  
A commonly applied method to analyse DCC experiments is the recording of 
HPLC-MS chromatograms of the libraries. As an illustrative example of the 
comparative approach, we drew HPLC chromatograms of a blank library and a 
target library (Figure 5). When we compare both chromatograms, we see that 
peak number five has increased in the library containing the target, whereas 
peaks three and six have decreased. The total amount of building blocks stays the 
same, only the equilibrium can be shifted towards one or more products. 
In order to accurately determine the amplification or decrease of peaks, their 
relative peak areas (RPA) should be compared. The fictional RPAs of both 
chromatograms in Figure 5 are given in Table 4. The amplification factor in 
percentage can be calculated by equation 1, where the amplification factor in ‘fold’ 
is given by equation 2. Using these two equations, the product at peak five has 
increased by 100% or twofold. Frei et al. report on a particularly thorough 
analysis of a DCL using the lectin FimH as a target, using HPLC analysis with an 
optimised DCC protocol.[36] 
Equation 1: amplification factor (%) = 
𝑅𝑃𝐴𝑡𝑎𝑟𝑔𝑒𝑡–𝑅𝑃𝐴𝑏𝑙𝑎𝑛𝑘
𝑅𝑃𝐴𝑏𝑙𝑎𝑛𝑘
∗ 100%  














Figure 5. Schematic example of HPLC chromatograms: a) blank library chromatogram, 
b) target library chromatogram. 





area in blank (%) 
Relative peak 





in ‘fold’  
1 10 10 - 1 
2 15 15 - 1 
3 20 16 –20% 0.8 
4 16 16 - 1 
5 12 24 100% 2 
6 27 19 –30% 0.7 
Total 100% 100%   
1.3.3 DCL analysed with STD-NMR spectroscopy 
Inspired by the work of Ramström and coworkers[20], we analysed the formed 
DCLs by STD-NMR spectroscopy (Scheme 3). We used the model enzyme 
endothiapepsin as target. As a control with a known binder we used saquinavir 
(Ki = 48 nM), a potent peptidic inhibitor, to differentiate specific from nonspecific 
binding. Each sub-library contained all five hydrazides and one of the aldehyde 
building blocks and was allowed to equilibrate for 24 hours before adding the 
target. By analysing the imine-type proton signals of the acylhydrazone products 
in the 1H-STD-NMR spectra (Figure 6) we identified in total eight binders. To 
confirm the results from STD-NMR, we performed an enzyme-inhibition assay 
and showed that the hits were inhibitors with IC50 values ranging from 12.8 µM to 
365 µM. The high hit rate in this publication is due to use of five sublibraries 
detecting the best binder of each library, whereas in a regular ptDCC setup only 




result of the synergistic combination of de novo structure based drug design 
(SBDD) and DCC. In STD-NMR the protein is used as a tool to analyse the library, 






Scheme 3. Formation of dynamic combinatorial library and enzymatic selection of the 















Figure 6. DCL generated from H1–5 + A4: (aromatic region) a) 1H-STD-NMR spectrum 
of H1–5 + A4, b) 1H-NMR spectrum of H1–5 + A4, c) 1H-NMR spectrum of H3+A4, 
d) 1H-NMR spectrum of H4+A4 (2 singlets correspond to the E/Z isomers), e) H1+A4, f) 
H2+H4 and g) H5+A4. Figure was adapted from Mondal et al.[24] 
1.3.4 How to proceed after obtaining hits 
Having obtained a validated hit, identified by de novo structure-based drug 
design in combination with DCC and STD-NMR, we have used a structure-based 
design approach to improve the molecular recognition by the target.[60] In this 
specific case, we were fortunate to have an x-ray crystal structure of the target 
endothiapepsin in complex with the hit. If this is not the case, optimization is still 
possible, relying on structure–activity relationships. 
1.4 DCC in a synergistic combination with fragment 
linking 
For fragment linking, two or more fragments have to bind to different but 
adjacent sites of the enzyme active site.[61] This approach introduces one 
additional component into the ligand system: a linker moiety. Finding the right 
linker motif, whilst maintaining the binding poses of both fragments, which 
orients the individual fragment units in the favourable geometry in relation to 
each other without introducing too much flexibility, can be challenging. The 
combination of two fragments with rather low affinity could result in significantly 
higher affinity and has the potential to result in ‘superadditive’ contributions of 
both binding motifs. The challenge in fragment linking is the exploration of the 
binding mode of both fragments and the identification of an optimal linker fitting 











translates into synergistically improved affinity. By binding of a fragment to a 
target protein, rotational and translational entropy is lost. This entropy penalty 
has to be overcompensated by attractive interactions formed between the ligand 
and the target. When two fragments bind in parallel to adjacent sites, each has to 
pay this entropy penalty. When these two fragments are linked together in an 
ideal way, the resulting singular compound only encounters the loss of rigid body 
entropy once. Hence, the observed affinity will be much greater than only the sum 
of the individual affinities.[62] The additional binding energy gained, is often also 
referred to as linker energy. To overcome the challenges associated with fragment 
linking, we pioneered a synergistic combination with DCC. For this proof-of-
concept study, we again used the model enzyme endothiapepsin.[35] X-ray crystal 
structures of endothiapepsin in complex with fragment inhibitors 1 and 2 (PDB 
IDs: 4KUP and 3T7P) identified by DCC were used as a starting point for fragment 
linking studies facilitated by DCC. Hits 1 and 2 display IC50 values of 12.8 µM and 
14.5 µM and LEs of 0.27 and 0.29, respectively. The linking of 1 and 2 should 
generate an inhibitor that occupies two binding pockets of endothiapepsin 
(Figure 7). 
 
Figure 7. Structures of hits 1 and 2 and linked bisacylhydrazone linked inhibitors 3 and 
4.[35] 
The homo-bis-acylhydrazones 3 and 4 were hits from the DCC experiments and 
were synthesised and evaluated accordingly. Compared to compound 2, the 
potency of inhibitor 3 was increased 240-fold, yielding an IC50 value of 0.054 µM 
and a LE value of 0.29. For inhibitor 4 an IC50 of 2.1 µM and a LE value of 0.25 
was determined (Figure 7).[35] Obviously, only the symmetric linking modality 






There are a number of steps which should be carefully taken into account, in order 
to obtain active hits by DCC. If information on the target is available, e.g. a crystal-
structure, one could consider a structure-based design when choosing the 
building blocks. The type of reversible linkage to be used can be chosen at this 
stage. Conditions necessary for the equilibration to take place should be 
compatible with the target. After establishing conditions, which will ensure the 
target remains folded, the actual DCC experiment can be started. To do so, stock 
solutions of building blocks, catalyst and protein should be prepared. The formed 
DCLs can be analysed by different techniques such as STD-NMR or HPLC-MS. 
Compounds that have been selected by the target, and their biochemical 
properties should be evaluated and possibly optimised in further studies. 
1.6 Outline of this thesis 
Dynamic combinatorial chemistry (DCC) has evolved over the past decades from 
a tool to easily generate a pool of derivatives to an efficient technique to find hit 
compounds when applied on a target. To be able to use target-directed DCC 
(tdDCC), a number of criteria must be met ranging from biocompatibility, 
solubility, stability, pH dependence to temperature and type of reversible 
reaction.  
The protein family of 14-3-3 has been selected as a target, since it allows for all of 
these criteria to be met. 14-3-3 proteins are involved in protein-protein 
interactions (PPIs) in many different biological processes, ranging from diseases 
to cell-cycle control and signal transduction. Modulating 14-3-3 proteins for 
binding is therefore an important class of research.  
The first aim of this thesis is applying DCC on biological relevant targets; such as 
14-3-3 proteins and glucansucrases. The second aim of this thesis is on extending 
the list of reversible reactions, which can be applied in tdDCC. This allows 
medicinal chemists more freedom, by being able to use different scaffolds. 
Therefore, the overall objective is to find new applications of DCC to medicinal 
chemistry. 
In chapter 3, we apply tdDCC on the 14-3-3ζ isoform. We use the PPI complex of 
14-3-3ζ/synaptopodin in acylhydrazone-based DCC, aiming to find small drug-
like molecules which can stabilise this PPI.  
Chapter 4 describes the application of tdDCC on a glucantransferase, which is 
found to be causative for adhesion of bacteria to the tooth enamel, which can lead 




Finally, in chapters 5 and 6 the design and first applications of new scaffolds for 
tdDCC is described. In chapter 5, the application of nitrone-based DCC with 
endothiapepsin is evaluated. And in chapter 6, the thiazolidine scaffold is 
investigated and DCC conditions optimised for endothiapepsin.  
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Molecular Insight into Specific 14-3-3 Modulators: 







The 14-3-3 protein family is implicated in several diseases and biological 
processes. Several recent reviews have summarised knowledge on certain 
aspects of 14-3-3 proteins, ranging from a historic overview to the structure, 
function and regulation. This chapter focuses on the structures and molecular 
recognition of the modulators by the 14-3-3 proteins, and small modifications of 
certain modulators are proposed where cocrystal structures have been 
reported. Our analysis opens up possibilities for the optimisation of the reported 
compounds. It is very timely to analyse the current status of recently developed 
modulators given that the field has seen a lot of activity in recent years. This 
chapter provides an overview combined with a critical analysis of each class of 





This chapter has been published as a review article: 






Protein-protein interactions (PPIs) play a significant role in many diseases. While 
a single polypeptide chain can have enzymatic or structural activity, interactions 
with other proteins allow an infinite variety of ways to modulate the activity. It is 
assumed that between 130,000 and 650,000 PPIs exist, making PPIs important 
therapeutic targets. This especially holds for diseases, which are difficult to treat, 
for example when targets like ion channels, enzymes and GPCRs have not yet 
been identified or are not present at all.[1] 
One class of proteins in which PPIs play an important role is the 14-3-3 protein 
family. This protein family consists of seven isoforms in humans: beta (β), epsilon 
(ε), eta (η), gamma (γ), tau (τ), sigma (σ) and zeta (ζ). Each of these human 
isoforms is encoded by a distinct genetic sequence. While plants have been shown 
to have more than ten isoforms, eukaryotic micro-organisms have fewer isoforms, 
for instance, two isoforms have been revealed in yeast.[2] All isoforms have a high 
conformational and functional conservation. The two isoforms found in yeast can 
be interchanged with plant or mammalian isoforms and still be active.[2] It has 
been shown that the binding groove of all isoforms has three conserved binding 
motifs: RSXpSXP (mode 1), RXXXpSXP (mode 2) and pS/TX-COOH (mode 3), 
in which pS stands for a phosphoserine residue.[3,4] 14-3-3 proteins primarily 
form dimers, which both feature a U-shaped binding groove.[5,6] A 
superimposition of the seven isoforms is shown in Figure 1, illustrating the 
conserved conformation of the monomers.[7] Wang and Shakes have made 
multiple alignments of forty-six sequences of plant, animal and fungal species to 
determine the molecular evolution of the 14-3-3 protein family.[8] Wilkert et al. 













The 14-3-3 monomers are acidic (pI ≈ 4.6)[10], have a molecular weight of 25–30 
kDa and can combine to form homo- and heterodimers.[11] The non-trivial name 
14-3-3 was assigned to this protein family by the researchers who first identified 
it from a classification study on brain proteins, due to position of the bands on 
2D diethylaminoethyl (DEAE)-cellulose chromatography and starch gel 
electrophoresis. 
The 14-3-3 family is implicated in several diseases and biological processes. 
Studies on binding partners of the 14-3-3 proteins have revealed over 500 
proteins, and this number will continue to grow with ongoing research.[12] Among 
these binding partners are many biologically relevant targets. In some diseases, 
the 14-3-3 proteins have inhibitory effects, while in other cases they lead to 
stabilisation. It is even observed that binding of 14-3-3 enhances the activity of 
the enzyme N-acetyltransferase (AANAT).[3] Examples of such processes are: 
regulation of metabolism, signal transduction, cell-cycle control, apoptosis, 
protein trafficking, transcription, stress response and malignant 
transformation.[5] A few examples of the many diseases in which 14-3-3 proteins 
are involved are presented in Table 1. 
Table 1. Few examples of many diseases in which 14-3-3 proteins are involved. 
14-3-3 isoform Disease/ function Binding partner 
(σ) and (ζ) Noonan Syndrome[13] C-Raf 




Oncogenesis and cellular response in 
DNA damage[9,16] 
p53 
all Mutant (breast) cancer[17,18] Raf 
(σ) and (ζ) Alzheimer’s[19] Tau 
 
In order to develop treatments for these diseases, it will be necessary to modulate 
PPIs of the relevant proteins.  An approach to modulate the PPIs is by the use of 
small-molecule modulators. Modulators of the PPIs of 14-3-3 with partner 
proteins can come in two types: inhibitors or stabilisers. Small-molecules 
modulators are usually derived from natural products such as proteins, peptides 
or secondary metabolites. These modulators have complex structures, making 
them specific and selective for 14-3-3 proteins.[20] As the isoforms are encoded by 




uniqueness it might be possible to selectively modulate a single isoform, leaving 
the other isoforms untouched. Notably, this selectivity is quite essential from a 
therapeutic point of view, as the drug should not disturb any other biological 
processes. Research into the discovery and optimisation of small-molecule 
modulators should therefore take the selectivity of the compounds into 
consideration, wherever applicable.  
Here, we systematically explore the binding of small-molecule modulators of 
14-3-3 proteins at the molecular level, that is, the exact binding of the modulators 
to the amino acid residues lining the binding groove, aiming to provide an insight 
into the way these modulators work. For almost all modulators in this chapter of 
which a crystal structure is known we propose modifications based on a structure-
based analysis. Therefore, this chapter gathers knowledge, which can be used for 
structure-based design of (new) modulators. Several recent reviews have 
summarised knowledge on other aspects of  14-3-3 proteins: the structural 
basis,[6] insights from genome-wide studies,[21] a historic overview,[22] the 
structure, function and regulation,[7] an update on 14-3-3 sigma related to human 
cancer[11] and small-molecule modulators with a focus on the discovery and the 
biochemical relevance of the compounds.[12] 
2.2 Structure-based optimisation 
There are cocrystal structures available of almost all 14-3-3 isoforms (some of 
which are in complex with interaction partners). 14-3-3 can therefore be 
conveniently targeted using a structure-based approach. The analysis of the 
binding modes of the modulators described in this chapter gives insight into 
where the compounds might be extended or modified in order to achieve higher 
affinity.  
For the known cocrystallised modulators, we suggest small modifications, based 
on a first inspection of the experimentally determined binding mode analysed in 
silico. More advanced docking studies and biochemical evaluations should be 
performed to confirm the improved affinities. The computer programme SeeSAR 
was used for the evaluation, using the in-built scoring function HYDE.[23–25] As 
explained by Reulecke et al., HYDE focusses on hydration and desolvation, taking 
into consideration the local hydrophobicity, solvent accessible surface and 







The first compounds reported to inhibit the PPIs of 14-3-3 with partner proteins 
were 1 and its dimer difopein (dimeric fourteen-three-three peptide inhibitor) (2) 
(Figure 2).[26] The former, a 20-amino acid peptide of Mw 2309.6, was identified 
by Wang et al. from a phage display to 14-3-3(τ).[27] Petosa et al. showed via a 
crystal structure (Figure 3) that R18 binds in the amphipathic groove and that the 
central WLDLE motif is hosted in the part of the pocket that binds phosphonic 
acids, also called the phospho-accepting pocket.[28] Moreover, the peptide does 
not require phosphorylation to bind to 14-3-3, as the negatively charged Asp and 
Glu mimic the contact points of phosphoserine.[7,26] As seen from HYDE scoring 
in the programme SeeSAR, there are multiple favourable and some unfavourable 
interactions between 1 and 14-3-3(ζ) (Figure S1 in the supporting 
information).[23,24] The C-terminal Leucine of 1 is involved in lipophilic 
interactions with Gly169 and Ile217. The carboxylic acid terminal group of 1 
shows electrostatic interactions with Arg56 and Arg127. Also the oxygen atom of 
the most left amide bond shows to lose energy due to desolvation. 
Compound 1 does not have selectivity between isoforms of 14-3-3. However, it is 
selective for 14-3-3 proteins.[26] Binding by 1 inhibits binding of partners like Raf-
1, ASK1 and exoenzyme S from binding to 14-3-3 in vitro. Fu and Masters 
reported that 2, enhances the ability of the antineoplastic drug cisplatin to kill 
cells. Compound 2 can bind competitively to one or two monomers of 14-3-3 
given that the two 1 repeats are separated by a flexible linker. Cao et al. showed 
that 2, as a general antagonist of 14-3-3, effectively hinders proliferation and 
triggers apoptosis of tumour cells, which were implanted in nude mice. Via flow 
cytometric analysis it was shown that apoptosis is time-dependent.[29] 
The first small-molecule inhibitor of 14-3-3 proteins was compound 3 (Figure 4), 
which specifically and competitively inhibits 14-3-3/ligand binding in vitro. Wu 
et al. demonstrated that 3 also causes apoptosis and cell-cycle arrest in mammals. 
The central motif of 3 is a phosphorylated peptide-like small molecule; its non-
phosphorylated analogue shows no activity in competing with 14-3-3(σ)/ligands. 
Molecular docking was used by the authors to confirm the binding mode of 3 with 
14-3-3(σ); no cocrystal structure is available.[30] Optimisation of 3 led to 
compound 4. This prodrug is a phosphoserine mimetic and potent 14-3-3 
inhibitor. When compound 4 is used as a prodrug, the active compound, the 











Figure 2. Structure of the WLDLE motif which is found in the phospho-accepting pocket 









Figure 3. Cocrystal structure of 14-3-3(ζ) with 1 (PDB code: 1A38). Colour code: protein 
surface: grey; interacting residues: sticks; inhibitor skeleton: C: yellow; N: blue; O: red, Cl: 
green; H-bonds, below 3.2 Å: green, dashed lines. This colour code is maintained 





Figure 4. Inhibitors 3 and prodrug 4, identified via an small-molecule microarray (SMM) 
technique consisting of fragment-based high-throughput identification combined with a 




Almost concurrently with the discovery of 4, Corradi and et al. disclosed the non-
peptidic small-molecule 5, an inhibitor of the 14-3-3/c-Abl complex (Figure 5). 
The authors used an in silico virtual screening campaign and docking 
simulations, based on a structure-based pharmacophore model, against 200.000 
compounds. Compound 5 can be used to treat Bcr-Abl-associated diseases, which 
are resistant to traditional drugs.[32] Unfortunately, it was found that 5 is 
chemically unstable, as it cyclises at room temperature.[33] The authors carried 
out a virtual-screening campaign with the aim of identifying compounds that 
score better than 5. Compounds 6 and 7 emerged as hits that are cytotoxic against 
Bcr-Abl-expressing Ba/F3 cells, and according to molecular modelling bind to 







Figure 5. Inhibitors 5, 6 and 7, identified via a virtual screening campaign.[32] 
Another small-molecule inhibitor of all 14-3-3 isoforms in 14-3-3 PPIs, 
FOBISIN101 (8), was reported in 2011 (Figure 6).[34] FOBISIN (FOurtien-three-
three BInding Small molecule INhibitor) 101 is a phosphoSer/Thr-mimetic agent, 
which upon X-ray irradiation covalently binds to 14-3-3(ζ) at Lys120. 
Furthermore, it has lipophilic interactions with Pro167, Gly171 and Ile219 and 
polar interactions to the flexible Lys49. Zhao et al. observed a colour change from 
bright orange before X-ray irradiation to brownish then yellowish and finally 
colourless after irradiation. In addition to this covalent linkage, which plays a role 
in its inhibitory activity, the authors suggest that the phosphate moiety might play 
a critical role. This conclusion was drawn from the observation that a non-
phosphorylated derivative of 8 is significantly less effective in blocking 
14-3-3/ligand binding. Mutation of Lys120 to Glu was shown to inactivate 
14-3-3(ζ), this was observed in an assay to determine the activation of ExoS ADP-
ribosyltransferase. Therefore, this indicates that Lys120 plays an important role 
in the binding to ligands/modulators.[34] The authors noted that another covalent 
linkage might also occur through imine formation, which was proposed later by 




involving imine hydrolysis to a pyridoxal-phosphate (PLP) intermediate followed 
by imine formation with Lys122 of 14-3-3(ζ).[35] The differences in experimental 
conditions appear to determine whether the covalent linkage takes place. With 
the Cu-Kα edge radiation they did not observe a colour change/covalent linkage 
as previously described. However, synchrotron irradiation did result in the 
covalent modification at Lys120 as described before. They agree that the risk of 
nonspecific imine formation might be prevented by eliminating the aldehyde 






Figure 6. Inhibitors FOBISIN101 (8) and the covalent adduct 9 with 14-3-3(ζ). 
Compound 8 was identified from a fluorescence polarisation-based 14-3-3 binding assay, 











Figure 7. Cocrystal structure of 9: compound 8 covalently linked to Lys122 of 14-3-3(σ) 




Shortly after the publication on 8, Park et al. reported on xanthine (10) and 
lacosamide (11) derivatives as specific binders of 14-3-3(ζ) (Figure 8). Using in 
vitro labelling, they showed that the enantiomer R-11 binds specifically to 
14-3-3(ζ). The stereoisomer S-11 was found to be less active, and R-12 
outcompetes R-11 for binding to 14-3-3(ζ). The authors were unable to explain 






Figure 8. Modulator Xanthine (10) and inhibitors lacosamide (R) and (S)-11 and 
derivative (R)-12. 14-3-3 was identified as a binding partner to these compounds from a 
ligand affinity and chemical reporter strategy.[37] 
A high-throughput screen using an in vitro fluorescence-polarisation assay 
afforded another class of scaffolds that modulate 14-3-3/ligand interactions, 
namely compounds with the core structure 13 (Figure 9).[38] The main part of the 
PRLX-scaffold is a 1,2,4-thiadiazole, decorated with substituents (R), which were 
not specified as they were patented compounds. There is no x-ray crystal 
structure published with these modulators. The authors used multiple 
biophysical assays to assess the activity of the compounds, starting with isolated 
cells and followed by intact tissue. Five different 14-3-3 isoforms from E. coli ((β, 
ζ η, ε and γ) were tested and it was found that the compounds had highest binding 
affinity for the (γ) isoform.[38] The origin of this specificity was left uninvestigated. 
The thiadiazole scaffold of compound 13 (Figure 4) inhibits the interaction of 









In 2011, the inhibitor 14 was identified in a study aimed at making derivatives of 
the natural product class of the moverastins, which target cell migration of 
tumour cells for a possible treatment of tumour metastasis. Compound 14 
(Figure 10) was found to interact differently than moverastins, therefore 
suggesting a different target than the original target of the study, 
farnesyltransferase (FTase).[39] A follow-up study confirmed 14-3-3(ζ) as the 
target, and from the seven human isoforms it was found that (ζ) had the strongest 
binding affinity. The authors suggest that this selectivity stems from the fact that 
the C-terminal region of 14-3-3 is involved in the binding, which is the most 
variable region of the isoforms. Compound 14 presumably inhibits cell migration 




Figure 10. Inhibitor 14, a moverastin derivative that targets 14-3-3(ζ).[39] 
In 2012, Yan et al. identified Blapsins A (15) and B (16) as potent small-molecule 
inhibitors. These compounds (Figure 11) were isolated from Blaps japanesis, 
characterised and evaluated for their inhibitory potencies on 14-3-3(γ).[41] They 
were found to inhibit 14-3-3 binding to the fluorescence-labelled TMR-Raf 





Figure 11. Inhibitors Blapsin A (15) and Blapsin B (16), isolated from Blaps japanesis.[41] 
A virtual-screening campaign and subsequent experimental validation revealed 
compound 17 (Figure 12) as a potent inhibitor of 14-3-3(ζ).[43] Compound 17 has 
a structure similar to that of 15, except that 17 has a phosphonic acid, which 
serves as an anchor in the binding pocket of 14-3-3. The authors screened the 
ZINC all now subset in order to find a non-peptidic and non-covalently binding 
small-molecule inhibitor of the extracellular PPI of 14-3-3 with the membrane 
receptor aminopeptidase N (APN). In addition to disruption of the 14-3-3(σ)/ 




matrix metalloproteinase (MMP)-1 in human fibroblasts, which was induced by 
signalling of 14-3-3 proteins. The binding mode of 17 to 14-3-3 proteins was 
validated by solving a cocrystal structure in complex with 14-3-3(σ) (Figure 
13).[43]  
Compound 17 binds strongly due to the phosphonic acid. Analysis with the 
programme SeeSAR revealed that both chloride atoms are involved in lipophilic 
interactions with Arg60, Arg56 and Ala57, the oxygen atoms at the phosphonic 
acid anchor are involved in strong H-bonding interactions with Arg129 and 
Arg56. The carbon atom para to the phosphonic acid does not contribute to 
affinity. This problem might be overcome by installing a hydroxyl moiety on that 
carbon, as was modelled in the SeeSAR programme (see the supporting 
information Figure S2 and S3).  
 
 








Figure 13. Crystal structure of virtual-screening hit 17 in complex with  14-3-3(σ) (PDB 
code: 4DHU).[43] 
In 2014, Glas and coworkers reported that constrained peptides can serve as 
inhibitors of pathogenic PPIs. They used target-adapted cross-links to stabilise 
secondary structures in order to inhibit the interaction of 14-3-3 with virulence 
vector exoenzyme S (ExoS).[15] The ESp sequence was used as a starting point for 
the design of macrocyclic structures. This ESp sequence, 420QGLLDALDLAS430, 
had previously been identified as a binding motif.[14] The authors compared the 




solving the crystal structure of both ligands with 14-3-3(ζ) (Figure 15 and 
supporting information Figure S4). Both ligands were shown to lie in the same 
binding site, 18, however, has a 20-fold higher binding affinity. The authors 
suggest, via NMR, CD and ITC experiments, that the improved binding entropy 




















Figure 15. Structure of the constrained peptide 18, an inhibitor of 14-3-3(ζ).[15] 
A novel modulator of 14-3-3/ligand complexes was introduced by Milroy et al.. 




design inhibitors, since they found that the region on 14-3-3 where 19 binds 
partially overlaps with the region where known inhibitors bind. The part of the 
active site from which stabilisation is observed lies next to the part where 
inhibition is observed, that is, there is a small interface between the modulating 
effects of these parts. The Tau pSer214 epitope was modified with different 
amines to obtain higher affinity. Milroy et al. hypothesised that using the OMe 
substituent of 19 would give high affinities due to interactions with the FC pocket, 
consisting of Phe, Met and Lys residues.[19] 
The Tau epitope, AcNH-RTPpSLPTP-OH, decorated with compound 20 (Figure 
16) showed to have good affinities for 14-3-3 due to the OMe group. Yet, tau 
epitope expanded with 21 emerged as the most active inhibitor, the bulky 
aromatic groups increased the affinity. This compound inhibits the binding of 
phosphorylated full-length Tau (protein) to 14-3-3. It has a 225-fold higher 
affinity than the Tau epitope. Inhibitors of 14-3-3/Tau might be useful in the 
treatment of Alzheimer’s disease. However, the cocrystal structure they reported 
is in complex with amine 20, which has a fifteen-fold worse IC50 value than 21 









Figure 16. Cocrystal structure of 14-3-3(σ) and phosphorylated Tau epitope with amine 






The natural product fusicoccin A (19) was reported as the first stabiliser of PPIs 
of 14-3-3/ligands. This diterpene glycoside, member of a class of diterpenes 
bearing a 5-8-5 ring structure called fusicoccanes, was found to bind to 14-3-3 
receptors.[44] 19 molecularly glues together the 14-3-3/ plasma membrane 
ATPase complex (PMA), while it does not bind to the individual partners.[45] The 
PMA is bound at the C-terminus via a phosphorylated Thr. The scaffold of 19 
provides a starting point for the design of further stabilisers of 14-3-3/ligand 
complexes, as it interacts on multiple sites with both protein and ligands.  
19 was found to not only stabilise the plant plasma membrane pump but also the 
binding of 14-3-3 to estrogen receptor alpha (ERα). The ERα is an anticancer 
target given that stabilising the 14-3-3/ERα complex has a downstream effect and 
leads to decreased cell proliferation.[18] 
Binding of 19 to PMA2 can probably be enhanced by changing the oxygen on the 
oxane ring for a carbon atom (Figure 17 and supporting information Figures S6  ̶ 
S8). In this case, the programme SeeSAR predicts a better affinity, and Hyde 
evaluation only reveals favourable interactions. A similar improvement can be 
achieved in 19 with the 14-3-3/ cystic fibrosis transmembrane conductance 
regulator (CFTR) complex: the oxygen atom bridging the two rings is found to 
partially disrupt binding. The binding is predicted to improve when the oxygen is 










Figure 17. Crystal structure of the stabiliser fusicoccin (19)-plasma membrane ATPase 











Figure 18. Fusicoccin A (19) and cystic fibrosis transmembrane conductance regulator 
R6-domain with 14-3-3(ζ) (PDB code: 5D3F).[47] 
Using 19 as a starting point, Anders et al. have made a semisynthetic derivative 
(22) (Figure 19). This derivative targets 14-3-3 in the human potassium channel 
TASK-3 and interacts in the mode 3 motif of the conserved binding groove. 22 










Figure 19. Cocrystal structure of fusiccocin-derivative (22) bound to 14-3-3(σ) (PDB 
code: 3SPR).[48] 
This potent stabiliser has some clashes of the oxygen atom of the oxane ring with 
the carbonyl of Asn42, as observed from analysing the cocrystal structure. This 
unfavourable interaction can be avoided by replacing the oxygen for a carbon 




interactions and a better affinity than 22 (see supporting information Figures S12  
̶  S14). 
Cotylenin A (CN-A) (23) is a natural product closely related to 19. Compound 23 
has anti-tumour activity by stabilising certain PPIs involved in human cancers. It 
is assumed that the hydroxyl moiety on the cyclopentenyl ring in 19 might 
determine the structural specificity compared to 23 and related fusicoccanes.[49] 
Four years after the work of Ottmann, Molzan et al. reported that the 14-3-3/C-
Raf complex is stabilised by 23 (Figure 20). Cotylenin A interacts with pSer233 
and pSer259 of C-Raf. At these positions, 14-3-3 binding inhibits C-Raf, whereas 
at pSer621, 14-3-3 binding activates C-Raf.[50,51] The in vivo activity of 23 on 
14-3-3/C-Raf is increased compared to the in vitro activity. This difference 










Figure 20. Cocrystal structure of stabiliser cotylenin A (23) and C-Raf in 14-3-3(ζ) (PDB 
code: 4IHL).[17] 
Compound 23 displays an unfavourable interaction at the oxygen atom bridging 
the two ring structures. Substituting this oxygen for a nitrogen atom could 
increase the affinity by having an additional H-bond towards Asp-213 (Figures 
S15  ̶  S17 in the supporting information). The two six-membered rings are now 
less involved in binding, however changing the bridging oxygen atom for a 
nitrogen atom should lead to an increased affinity. 
In 2010, Rose et al. identified small-molecule stabilisers of 14-3-3 PPIs, namely 
a tri-substituted pyrrolidone (24), and a dipeptide epibestatin (25). The authors 




(GFP) fused with 14-3-3 against binding to surface-immobilised gluthatione S-
transferase fused with PMA2-CT52. The selective stabilisation of 14-3-3/PMA2 
by 25 displays a slower association than 19 and 24, but a similar Kd to 19. In 
other words, stabilising the PPI with 25 is relatively slow but once it has been 
established it will bind strongly (Figure 21).[52] It was found that compound 26 
has a stabilising effect on 14-3-3/PMA2 that is three times stronger than that of 
24 (Figures 21 and 22), presumably because more contact points with the PMA2 









Figure 21. Crystal structure of stabiliser epibestatin (25)-plasma membrane ATPase 
complex 2-CT30 in 14-3-3 (PDB code: 3M50). 25 was identified by screening a compound 
library against binding of 14-3-3 to plasma membrane ATPase complex 2-C52.[52] 
The programme SeeSAR was used to suggest some modifications.[23] Substituting 
the free amine in epibestatin (25) by a carbon atom, for instance, enhances the 
binding to the PMA moiety. However, this still gives clashes; changing it into a 
hydroxyl group makes it a bit smaller and again an H-bond acceptor/donor. With 
an alcohol moiety the affinity most probably increases again, but clashes are still 
seen with Leu929 and His930 (see Figures S18 ̶ S20 in the supporting 
information). 
The hydroxyl group of the central five-membered ring in 24 appears to have some 
unfavourable interactions with Val45 and Asn49. Replacing the hydroxyl group 
for an amine improves the affinity a bit, going to fluoride improves the binding 











Figure 22. Stabilisers 24 and 26, identified by screening a compound library against 
binding of 14-3-3 to plasma membrane ATPase complex 2-CT52.[52] 
Mizoribine (27), or bredinin (Figure 24), is a compound isolated from 
Eupenicillium brefeldianum and found to have activities in multiple animal 
studies as well as an immunosuppressive activity.[54] This imidazole nucleoside 
enhances the interaction of glucocorticoid receptor (GR) with 14-3-3(η) in 
vitro.[55] Mizoribine has been an approved drug in Japan for many years for the 
treatment of lupus nephritis, rheumatoid arthritis and for immunosuppressive 







Figure 23. Cocrystal structure of stabiliser 24 and plasma membrane ATPase complex 





Figure 24. Stabiliser mizoribine (27), isolated from Eupenicillium brefeldianum, 




The most recently published small-molecule stabiliser 28 holds promise to be 
used in new therapeutic approaches to target Gab2-related cancers. Gab2 is a 
signalling protein,[56] which is correlated to the mitogen-activated protein kinase 
(MAPK) pathways involved in certain cancer types (e.g., breast cancer).[57] Bier et 
al. showed in an elaborate study that the FC-derivative 28 stabilises the binding 
of pT391 peptides, which are derived from the binding moiety of Gab2 (Figure 
25). The stabilisation is specific for the pT391 motif, as no enhanced binding was 
observed for the other phosphorylation site of Gab2, the Gab2pS210 binding 
motif. The authors examined the binding interactions of Gab2pT391 and 
Gab2pS210 via cocrystal structures.[58] It was shown that, in the pT391 motif, 
Leu392 of Gab2 can be best accommodated in the hydrophobic contact surface of 
Leu172, Ile217 and Leu220 of 14-3-3(ζ). Gab2 motifs are anchored through the 
phosphonic acid in the binding triad of Arg56, Arg127 and Tyr128, as is frequently 
observed and described in this chapter. The cocrystal structure of 14-3-3(ζ) with 
Gab2 and 28 is given in Figure 26. The hydrophobic pocket in 14-3-3(ζ), 
consisting of the following amino acids Val46, Phe117, Met121, Pro165, Ile166, 
Gly169 and Ile217, is accommodated by the terpenoid core of 28 and by Leu392 
of Gab2. The Gab2pT391 peptide has a sharp turn, most probably induced by 
Pro393, which therefore gives space for 28 to bind and stabilise the complex. This 
turn is not observed in Gab2pS210, which leads to the postulation by the authors 
that the difference of one or two amino acids in the 14-3-3 recognition motifs of 
























Figure 26. Cocrystal structure of stabiliser 28 and Gab2pT391 peptide in 14-3-3(ζ) (PDB 
code: 5EXA).[58] 
The programme SeeSar was used to analyse the binding affinity of 28 to 
Gab2pT391 peptide and 14-3-3(ζ). The methoxy carbon atom at the terpenoid 
core has strong interactions with Met121 and Phe117. The remaining carbon 
atoms are also involved in hydrophobic interactions with the protein. For 
example, the isopropyl moiety has strong interactions with Asp213, Ile217 and 
Leu392. However, the bridging oxygen atom towards the two six-membered rings 
shows to be non-favourable. It forms an intramolecular H-bond, but it loses 
affinity due to desolvation. Substituting this oxygen atom for a carbon atom might 
improve the binding affinity, as this carbon atom could then have lipophilic 
interactions with Asp213. The terpenoid core should remain in the hydrophobic 
part, and the two six-membered rings which are solvent exposed move slightly. 
(Figures S24  ̶  S26 in the supporting information).[59] 
2.5 Development in the discovery of modulators of 14-
3-3 proteins since 2016 
Eighteen years ago Camoni et al. have shown that Adenosine 5’-Monophosphate 
(AMP) inhibits 14-3-3 proteins binding to the plant plasma membrane 
H+-ATPase (PMA). At a concentration of 1 mM, 5´-AMP inhibits binding of 14-3-3 
to a peptidic analogue of the binding site of the H+-ATPase.[60] However, it has 
been shown in 2016 that AMP can also act as a stabiliser. This small molecule was 
found to stabilise the complex of 14-3-3 with carbohydrate-response element-




where under the same conditions no binding was observed to the complex 
partners alone.[61] 
Cyclotides, plant-derived circular peptides, are a promising class of molecules in 
drug discovery and development. Hellinger et al. have used photo-affinity 
crosslinking of the circular peptide [T20K]kalata B1 (Table 2) and found that it 
targets 14-3-3 proteins. It was found that this cyclotide exerts a stabilizing effect 
on the 14-3-3/Foxo3a protein complex. By stabilizing the complex, [T20K]kB1 
inhibited the function of Foxo3a with an IC50 of 5.3 ± 0.7 µM. A similar way of 
stabilizing 14-3-3 complexes as is known for fusicoccin-A, was observed for the 
cyclotide.[62] 





Kalata B1 (kB1) CGETCVGGTCNTPGCKCSWPVCTRNGLPV 2917.19 
 
In a joint effort, teams of the University of Eindhoven, University of Duisburg-
Essen and AstraZeneca reported on the first small-molecule stabiliser of the 
14-3-3—p53 interaction in 2017. They showed that fusiccocin-A 19 stabilises the 
PPI of 14-3-3 with p53, rather than the previously hypothesised opposite. 
Biophysical experiments show a clear stabilising effect, however the cocrystal 
structure showed more disorder. The authors hypothesise that this could be due 
to artefacts of soaking the crystal or that 19 acts allosterically instead of the 
expected mode-of-action as a `molecular glue´. The binding of p53 C-terminal 
domain 15mer peptide to 14-3-3 was found to be stabilized by 19 by a factor of 
4.5 — 8 (Kd 23.6 ± 2.2 µM in absence of 19, and 5.40 ± 0.84 µM in presence).[63] 
In 2018, Andrei et al. have reported on the rational design of new semisynthetic 
analogues of fusiccocin-A to stabilise PPIs (Figure 27). They included a hydrogen-
bond donor by exchanging the 19-acetoxy group for an acetamide, moreover they 
removed the 3´-acetyl group which did not significantly contributed to the 
potency. The stabilisation factor S was increased by 29 and 30 up to 16-fold for 
different 14-3-3 complexes, compared to 19. In a cell growth assay, using a human 
ovarian carcinoma cell line, EC50 values of 4.3 ± 0.3 µM for 29 and 2.5 ± 0.1 µM 











Figure 27. Semisynthetic analogues of fusicoccin-A (19) via Structure-based design and 
molecular dynamics.[64] 
In a different study by this author, it was demonstrated that full length Tau 
protein could be inhibited from binding to 14-3-3 by synthetic peptide analogues 
of Tau. These compounds bind 14-3-3σ with Kd values in the range of 2.7—20.6 
µM.[65] 
The groups of Schmuck and Ottmann have recently put forth a new class of 
supramolecular peptide-based ligands which stabilise 14-3-3ζ and two effectors, 
Tau and C-Raf. The binding by positively charged compounds is designed around 
the anionic region in the central binding channel of 14-3-3 (Figure 28). They 
implemented a guanidiniocarbonyl pyrrole (GCP) moiety, an arginine mimic, to 
form stable ion pairs with carboxylates and phosphates. Compound 31 was the 
most potent derivative, enhancing the interaction of 14-3-3ζ to C-Raf and Tau 
with S factors of 84 and 26. Binding partner C-Raf´s Kd value improved from 
16.00 ± 0.60 µM to 0.19 ± 0.01 µM and binding partner Tau´s Kd value improved 







Figure 28. Supramolecular peptide-based ligands, 31, 32 and 33, stabilising 14-3-3ζ and 
two effectors, Tau and C-Raf. Binding was mainly due to the formation of ion pairs through 




Another recent publication was inspired by 5 (BV02) in order to find chemically 
more stable compounds. It was found that the bioactive form of 5 is the 
phtalimide 34, which is formed via a hydration/dehydration pathway 
(Figure 29). Botta and coworkers have removed a carbonyl group of 34, which 
was found to take place in the hydrolysis and made the chemically more stable 
compound 35. It was found, in an in vitro antiproliferative activity study, that 35 
has an IC50 value of 7.7 ± 2.0 µM, similar to the IC50 value of 5.2 ± 0.7 µM for 34.[67] 
 
Figure 29. Bioactive form of 5 was shown to be the phtalimide 34. Botta and coworkers 
synthesised 35 in order to increase the chemical stability of the small-molecule inhibitor 
of 14-3-3.[67] 
The interaction of 14-3-3 with a phosphorylated motif derived from Estrogen 
Receptor α (ERα-pp) was used as a PPI complex in a site-directed fragment-based 
screening campaign. Based on disulfide trapping of fragments, Ottmann and 
coworkers have found orthosteric stabilisers, increasing the 14-3-3/ERα affinity 
up to 40-fold (Figure 30). The apparent Kd value of 14-3-3σ/ERα-pp improved 





Figure 30. Small-molecule 36, found via disulfide trapping with 14-3-3, stabilising the 






Research has focussed, for almost 20 years now, on the development of 14-3-3 
inhibitors and stabilisers. We have analysed the structures of the reported 
inhibitors and stabilisers. Visual inspection of the cocrystal structures of the 
published small-molecule modulators at the molecular level aided by the 
programme SeeSAR has led to the proposal of small modifications, which might 
improve the binding affinity. The knowledge gained from exploring the cocrystal 
structures sets the stage for structure-based design of (new) modulators. 
Designing molecules to stabilise or even activate 14-3-3/partner protein 
complexes has the potential to become an important part of modulating 14-3-3 
PPIs, since research has focussed so far more on inhibiting PPIs. 
Since there are seven isoforms, with a high degree of conservation, it might be 
wiser to target the interaction partner rather than 14-3-3. This approach might 
lead to more specific small-molecule modulators that target a specific PPI instead 
of all PPIs from the 14-3-3 protein. This would require a paradigm shift, as 
research has focussed on binding to 14-3-3. Focussing on the interaction partner 
might give more freedom and creativity when aiming to influence PPIs. 
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Discovery of small-molecule modulators of 14-3-3 PPIs 





Protein-protein interactions (PPIs) play an important role in many biological 
processes such as cell-cycle regulation and multiple diseases. The family of 
14-3-3 proteins is an attractive target as they serve as binding partner to 
various proteins, and are therefore capable of regulating their biological 
activities. Discovering small-molecule modulators of such complexes via 
traditional screening approaches is a challenging task. Herein, we pioneered 
the first application of dynamic combinatorial chemistry (DCC) to a PPI, to find 
modulators of 14-3-3 proteins. The amplified hits from the DCC experiments 
were evaluated for their binding affinity via surface plasmon resonance (SPR) 
technique, indicating that they are 14-3-3/synaptopodin PPI stabilisers. 
Ongoing crystallization studies will hopefully provide with structural 
knowledge.   
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The family of 14-3-3 proteins is present in all eukaryotic cell types, and its 
members are involved in several processes in the human body.[1] They play 
significant roles ranging from signal transduction, regulation of metabolism to 
cell-death, and they are correlated to diseases such as Alzheimer’s and Noonan 
Syndrome.[2,3] This is attributed to the ability of 14-3-3 to establish protein–
protein interactions (PPIs) with more than 500 protein partners.[4] There are 
seven human isoforms of 14-3-3 known: beta (β), epsilon (ε), eta (η), gamma (γ), 
tau (τ), sigma (σ) and zeta (ζ). The binding partners feature three conserved 
binding motifs for the binding groove in 14-3-3: RSXpSXP (mode 1), RXXXpSXP 
(mode 2) and pS/TX-COOH (mode 3), where pS denotes a phosphoserine 
residue.[5–7] 14-3-3 proteins are potential drug targets and an increasing number 
of chemical classes that modulate 14-3-3 PPIs have been reported, as was listed 
in Chapter 2. Modulators of 14-3-3 PPIs can be inhibitors, mostly small synthetic 
molecules, and stabilisers, which include bigger scaffolds (e.g., pyrrolidone1) and 
(semi-) natural products, e.g., fusicoccin-A.[8–12] Dynamic combinatorial 
chemistry (DCC) has become an established technique for hit identification. 
Briefly, it allows a target-based amplification of the best binder(s) from a pool of 
reacting building blocks and the corresponding products existing under 
thermodynamic equilibrium. The types of reversible linkages that can be applied 
in DCC, reaction conditions, and analysis of the dynamic combinatorial library 
(DCL) have been comprehensively reviewed before.[13–15] In the presented work, 
we exploited the power of DCC to identify new PPI modulators targeting the 14-
3-3(ζ) isoform. For the DCC experiments, we used acylhydrazone formation from 
the corresponding hydrazide and aldehyde as a reversible reaction. The 
acylhydrazone linkage can take part in binding with the desired target, as it offers 
H-bond donor and -acceptor sites. The acylhydrazone formation is sufficiently 
reversible in acidic media, but also stable against hydrolysis.[16] In basic media 
the reaction is too slow, therefore high pH values are used to freeze the 
equilibrium prior to DCL analysis. Bhat et al. showed that the use of aniline can 
accelerate the formation of the equilibrium to only six hours at the near 
physiological pH value of 6.2.[17] As a prerequisite for the acylhydrazone-based 
DCC, we studied the stability of our target protein 14-3-3(ζ) under acidic 
conditions using different buffers and pH values. We found that in MES buffer at 
pH 6.5, 14-3-3(ζ) is stable at room temperature up to seven days. Therefore, we 
selected these conditions in the presence of 10 mM aniline as a nucleophilic 
catalyst for the DCC experiments. In order to confirm that the protein is folded 
correctly, we measured the circular dichroism (CD) of 14-3-3. The obtained CD-




3.2 Results and Discussion 
The initial design of the DCL and choice of building blocks were inspired by 
compound 1, a small-molecule inhibitor of 14-3-3 that was discovered by virtual 
screening.[19] We envisioned the acylhydrazone linkage between the two aromatic 
rings, resulting in compound 2 (Figure 1). This modification should maintain the 
length of the linker between the two aromatic moieties of 1 owing to the restricted 
flexibility of the acylhydrazone group. Accordingly, compound 2 was synthesised 
in three consecutive steps starting with a condensation reaction between the 
commercially available 2-iodobenzhydrazide and 2,3-dichlorobenzaldehyde to 
form the acylhydrazone 3 (Scheme 1). A palladium-catalysed coupling between 
the aryl iodide 3 and triethyl phosphite followed, to afford the phosphate ester 4. 
This was achieved by first formation of a palladium phosphonate complex at 
150 °C, followed by the addition of the acylhydrazone 3 at 100 °C. It was 
important to lower the temperature before adding the acylhydrazone 3 in order 
to prevent its decomposition. Deprotection of 4 was achieved by TMSBr, resulting 
in the target compound 2. Noteworthy, trials to prepare the hydrazide building 
block with o-phosphonic acid moiety, required for DCC, using the above-
mentioned coupling conditions were unsuccessful, and only an intramolecular N-
arylation product was obtained. We therefore had to use compound 2 in our DCC 
















We evaluated compound 2 for its biochemical properties via fluorescence 
polarisation (FP) assay and surface plasmon resonance (SPR) (Figure 2 and 
supporting information Figure S5). The FP assay is based on the decrease of 
fluorescence polarisation of liberated fluorophore in this case a fluorescently 
labelled 21 amino acid long peptide (synaptopodin). A known stabilising 
molecule, fusicoccin, was used as a positive control, it results an increase of FP 
signal upon increased concentration (Figure 2). In agreement with our design 
approach, titrating compound 2 to the protein–peptide complex, lowers the 
signal, indicating an inhibitory effect with an EC50 value of 120 µM (Figure 2). 
Evaluation of the binding affinity using SPR revealed that compound 2 shows low 











Encouraged by these results we designed a DCL based on compound 2 (Figure 1 
and Scheme S1). However, when we ran the DCC experiment, not all of the 
possible acylhydrazones bearing o-phosphonic or o-sulfonic acid moieties could 
be observed by LC-MS analysis (Supporting information Figure S1). We therefore 
modified the DCL by omitting the acidic motifs as shown in Scheme 2. The DCL 
consisted of 3 aldehydes A1–A3 and 6 hydrazides H1–H6. Consequently, we ran 
three DCC experiments: (a) a library in which building blocks were present in 
combination with the 14-3-3(ζ)/unlabelled synaptopodin complex as a PPI 
model; (b) a library containing the building blocks and 14-3-3 protein; and (c) a 
‘blank’ in which only building blocks were present (Scheme 2). 
The DCLs were allowed to equilibrate for 6 h and were analysed via HPLC-MS, 
resulting in the chromatograms shown in Figure 3. The most obvious differences 
Figure 2. Fluorescent polarisation assay of compound 2: Titration of 2 to 400 nM 14-3-3ζ 
with 10 nM fluorescently labelled peptide synaptopodin, resulting in the displacement of 





are the two peaks at retention times of 13.5 and 13.9 minutes corresponding to 
the compounds A1H3 and A2H3, respectively. In the presence of 14-3-3(ζ) only 
and in the PPI-complex (14-3-3(ζ)/synaptopodin), these two acylhydrazones 
show a significant amplification (> 2-fold, 148%) compared to the DCL in the 
absence of protein. Table 1 shows the ratios of the relative areas of each peak 
compared to the blank DCL. These two hits were then synthesised to confirm the 
identity of peaks (Figure S3) and for biochemical characterisation. Synthesis was 
accomplished through the reaction of the hydrazide H3 with a stoichiometric 
amount of the appropriate aldehyde at room temperature overnight to afford the 
corresponding acylhydrazones in a good to quantitative yield (Scheme 3). 
 
Scheme 2. Dynamic combinatorial library (DCL) of acylhydrazones with aldehydes 
(100 µM each), hydrazides (300 µM each), DMSO (5%), aniline (10 mM) and: a) 14-3-3(ζ) 
(10 µM) and synaptopodin (10 µM); b) control with 14-3-3(ζ) (10 µM); and c) control 
without protein or synaptopodin.  
 
Figure 3. UV-chromatograms at 290 nm of DCLs in duplicates, blank (B), in the presence 
of protein (P), and in the presence of protein plus synaptopodin (PS) at 6 h. Compounds 











Table 1. Amplification factors of the products formed in the DCC experiments analysed 
via the relative surface areas of peaks in the UV-chromatograms. The experiments were 














A3H2 4.76 –59.0 –44.0 
A3H4 5.66 –33.9 –35.9 
A3H6 6.62 –25.7 –16.4 
A3H1 7.93 –33.1 –18.1 
A1H2 & 
A3H5 
8.21 –32.3 –35.1 
A2H2 & 
A1H4 
9.09 –28.0 –26.0 
A2H4 9.73 –36.7 –32.9 
A1H1 & 
A1H6 
10.66 –20.4 –23.1 
A3H3 10.79 –1.3 –15.0 
A2H6 11.29 –22.5 –23.6 
A2H1 11.49 32.2 29.5 
A1H5 11.91 –12.2 –16.0 
A2H5 12.49 12.8 14.6 
A1H3 13.46 148.0 148.4 





Scheme 3. Synthetic route towards compounds A1H3 and A2H3. 
We used SPR binding assays to follow binding events of the synthesised DCC hits 
to the 14-3-3(ζ) protein. We checked first whether the immobilised protein is still 
in the native folded state and can engage in PPIs by determining the binding 
affinity (KD) of synaptopodin to 14-3-3(ζ). The small peptide showed a clear 
binding response with the same KD value of 1.38 µM obtained from either the 
Langmuir isotherm or the kinetic curves (Supporting information, Figure S6). 
Encouraged by this result, we determined the affinity and binding kinetics of the  
hit compounds in a similar manner. The acylhydrazones A1H3 and A2H3 
showed low micromolar affinity to 14-3-3(ζ) (KD values 16 and 15 µM, 




rate and longer residence time compared to A1H3 although they have similar 
binding affinities (Table 2 and supporting information, Figure S7 and S8). 
Table 2. Kinetic parameters of hit compounds A1H3 and A2H3 to 14-3-3(ζ). Data 
obtained from single experiments. 
Compound Rmax (RU) kon (M–1 s–1) koff (s–1) KD (µM) Res sd 
A1H3 4.6 ± 0.2 




16 ± 1 0.38 
A2H3 4.5 ± 0.2 




15 ± 1 0.50 
Rmax: maximum analyte binding capacity; kon: association rate constant; koff: dissociation 
rate constant; KD: equilibrium dissociation constant; Res sd: residual standard deviation. 
Intrigued by these findings, we next investigated the mode of binding of the new 
14-3-3 PPIs modulators (compounds 2, A1H3, and A2H3) by SPR competition 
assays using synaptopodin as a reference, which occupies the 14-3-3 main 
binding pocket. Modulators that inhibit 14-3-3 PPIs bind in the phosphorylation 
binding pocket, whereas stabilisers bind allosterically to the binding pocket or at 
the interface between 14-3-3 and its protein partners.[20] To check whether the 
compounds bind to the active site or elsewhere, compound 2 (1000 µM), 
synaptopodin (1 µM), and a mixture of both at the same concentration were 
injected in sequence over immobilised 14-3-3(ζ). The obtained response unit 
(RU) value of the mixture was compared to the theoretical sum of the RU values 
for the individual compounds. If 2 bound to the main binding pocket of 14-3-3, it 
would compete with synaptopodin and the response of the mixture should be less 
than the sum of RU values determined for the single compounds. On the other 
hand, if 2 bound allosterically to the active site, no competition would occur and 
the response of the mixture should be equal to the sum of RU values of the 
individual compounds. We found that the RU value of 2 in combination with 
synaptopodin was less than the sum of the individual responses (Figure 4 and 
S9). This suggests that compound 2 competes with synaptopodin for the same 
binding pocket, however no compound could completely displace the other at the 
tested concentrations. To verify this, the sum of responses was recalculated 
considering a fractional occupancy (FO) of 2 and synaptopodin according to 
Perspicace et al.[21] Indeed, the experimental RU value of the mixture was equal 
to the new estimated one (Figure 4), indicating that the compounds compete for 
the same binding site. The same results were obtained using different 
concentrations of 2 and synaptopodin (1000 µM vs 25 µM; and 200 µM vs 1 µM), 




these results clearly indicate that compound  2 binds to the active site of 14-3-3, 
leading to disruption of PPIs. 
 
Figure 4. SPR responses of compounds 2, A1H3, and A2H3 in the competition assays, 
using synaptopodin as a reference compound binding to the active site of 14-3-3.   
Using the same approach, the DCC hit compounds A1H3 (25 µM) and A2H3 (25 
µM) were injected alone and as a mixture with synaptopodin (1 µM) over  
immobilised 14-3-3, and their binding responces were analysed (Figure 5). 
 
Figure 5. SPR competition assay: (a) Sensorgram overlay of A1H3 (25 µM, blue), 
synaptopodin (1 µM, red) and a A1H3–synaptopodin mixture (black), showing an additive 
effect,  indicating a non-competitive binding; (b) Overlay of sensorgrams of A2H3 (25 µM, 
blue), synaptopodin (1 µM, red) and a A2H3–synaptopodin mixture (black), showing a 
synergistic effect, indicating a non-competitive binding and a stabilising effect. Curves 





Interestingly, the RU values of the mixtures containing A1H3 or A2H3 with 
synaptopodin were equal to or more than the sum of the individual responses 
(Figure 4 and 5). This indicates that these two compounds bind to 14-3-3 in a 
different pocket than that of synaptopodin. Moreover, the increased binding 
response of the mixture compared to the calculated sum indicates a stabilising 
effect of the acylhydrazones to the complex of synaptopodin with 14-3-3(ζ). This 
confirms our findings from the DCC experiments, where the same amplification 
factors for these hits were obtained in the presence of 14-3-3 alone as well as the 
14-3-3(ζ)/synaptopodin complex (Table 1). Therefore, their binding site could be 
allosteric to the main binding pocket or at the interface of the 
14-3-3(ζ)/synaptopodin complex. Co-crystallisation studies are ongoing and 
would help to confirm the exact binding pocket of the 14-3-3 protein. 
3.3 Conclusions 
We set out to develop novel PPI-modulators targeting the versatile 14-3-3 protein 
family. Firstly, we pursued a ligand-based design of the acylhydrazone 2, which 
turned out to be an inhibitor of 14-3-3 PPIs. Next, we applied a DCC approach, 
using 14-3-3(ζ) in complex with synaptopodin as a PPI model, resulting in the 
discovery of two modulators A1H3 and A2H3. No significant change was 
observed in the DCL composition in the presence of only 14-3-3 compared to the 
14-3-3(ζ)/synaptopodin complex, indicating that the hit compounds  bind 
independently to a different site than the main binding-groove of 14-3-3 involved 
in PPIs. Finally, we determined the binding affinities and kinetics of the hits via 
SPR and investigated their binding site on 14-3-3. Results of the SPR competition 
assays support our initial findings from the DCC experiments, suggesting that 
these small molecules stabilise the 14-3-3(ζ)/synaptopodin complex either 
directly or allosterically. Cocrystallisation studies are ongoing in order to 
determine their exact binding site. 
3.4 Experimental 
3.4.1 Materials and methods 
Chemicals were purchased from commercial suppliers and used without 
pretreatment. Solvents used for the experiments were reagent-grade and dried, if 
necessary, according to standard procedures. The reactions were performed 
under nitrogen atmosphere, unless otherwise stated. The yields were calculated 
for the analytically pure compounds and were not optimised. The purifications 
were performed using column chromatography with Macherey-Nagel Silica 60 M 
0.04–0.063 mm. Preparative high-performance liquid chromatography (HPLC, 
Ultimate 3000 UHPLC+ focused, Thermo Scientific) purification was performed 
on a reversed-phase column (C18 column, 5 μm, Macherey-Nagel, Germany). The 




(0.1% formic acid), or EtOAc and DCM. 1H-, 13C and 31P-NMR spectra were 
measured on a Bruker Fourier 500 spectrometer (500, 126 or 202 MHz), 
respectively. The chemical shifts were reported in parts per million (ppm) relative 
to the corresponding solvent peak. The coupling constants of the splitting 
patterns were reported in Hz and were indicated as singlet (s), doublet (d), triplet 
(t) and multiplet (m). Due to the presence of isomers for acylhydrazones, some of 
the signals are doubled. UPLC-MS and HRMS measurements were performed 
using Thermo Scientific systems, see supporting information.  
3.4.2 DCC conditions 
The corresponding acylhydrazides (each 3 μL, stock solutions 100 mM in DMSO) 
and the aldehydes (each 1 μL, stock solutions 100 mM in DMSO) were added to a 
MES buffer (0.1 M, 2 mM MgCl2, pH 6.5). Aniline (10 µL, stock solution 1 mM), 
synaptopodin (10 µL, stock solution 1 mM) and 14-3-3(ζ) (5.35 µL, stock solution 
1.87 mM) were added accordingly. DMSO was added to reach a final 
concentration of DMSO in the DCL of 5%. The end-volume was 1 mL. Final 
concentrations in the DCLs are shown in Table 3. The DCL was left shaking at 
room temperature and was frequently monitored via UPLC-MS. The reactions 
were performed in 1.5 mL Eppendorf cups and stirred on a Rotating Mixer 
(Benchmark Scientific). 
Table 5. Final concentrations in the DCLs. 
 14-3-3/synaptopodin 14-3-3 Blank 
DMSO 5% 5% 5% 
Aniline 10 mM 10 mM 10 mM 
Aldehyde 100 µM (each) 100 µM (each) 100 µM (each) 
Hydrazide 300 µM (each) 300 µM (each) 300 µM (each) 
Protein 10 µM 10 µM - 
Synaptopodin 10 µM - - 
 
For monitoring via UPLC-MS, 10 μL of the corresponding library was withdrawn 
and diluted in 90 µL acetonitrile, the pH was raised to pH > 8 by adding 2 µL 
NaOH (1.0 M) to freeze the reaction. The mixture was centrifuged at 10.000 rpm 






General procedure for acylhydrazone formation:[16]  
To the hydrazide (1 eq.) dissolved in MeOH, the corresponding aldehyde (1.2 eq.) 
was added. The reaction mixture was stirred at room temperature or refluxed 
until completion. After cooling to room temperature, the reaction mixture was 
concentrated in vacuo. Purification was performed by column chromatography, 
affording the corresponding acylhydrazone in 60 – 99% yield. 
(E/Z)-N'-(2,3-dichlorobenzylidene)-2-iodobenzohydrazide (3)  
The acylhydrazone was synthesised at room temperature 
following the general procedure, using 2-
iodobenzohydrazide (1.00 g, 3.82 mmol) in MeOH (7.6 mL) 
and 2,3-dichlorobenzaldehyde (0.607 g, 3.47 mmol). After 
purification by column chromatography (DCM/EtOAc 1:0 → 0:1), the 
acylhydrazone 3 was obtained as a mixture of E and Z isomers (E:Z = 3:2) as a 
white solid (866 mg, 60%). 1H-NMR (500 MHz, DMSO-d6) δ= 12.22 (s, 1H, Z), 
12.15 (s, 1H, E), 8.73 (s, 1H, E), 8.49 (s, 1H, Z), 8.07 – 7.14 (m, 7H, mixture E/Z); 
13C-NMR (126 MHz, DMSO-d6) (combined peaks of E/Z) δ= 171.03, 165.11, 
143.64, 141.92, 140.86, 139.82, 139.27, 138.35, 133.77, 133.73, 132.41, 131.79, 
131.59, 131.38, 131.08, 130.81, 130.57, 128.63, 128.57, 128.46, 128.28, 128.19, 
127.80, 125.56, 124.85, 94.02, 93.59, 40.11, 40.02, 39.94, 39.85, 39.78, 39.69, 
39.61, 39.52, 39.35, 39.19, 39.02; HRMS (ESI) calcd for C14H9Cl2IN2O [M+H]+: 
418.9209, found 418.9190. 
Diethyl (E/Z)-(2-(2-(2,3-dichlorobenzylidene)hydrazine-1-
carbonyl)phenyl)phosphonate (4) 
The phosphonic ester was synthesised according to an 
adapted protocol of Benin et al.[22] Triethyl phosphite (1.3 
mL, 7.6 mmol) was added to [PdCl2] (16.9 mg, 0.10 mmol) 
under N2 atmosphere and heated at 150 °C for 3 h. The 
mixture was cooled to 100 °C, and compound 3 (400 mg, 
0.95 mmol) was added. The reaction mixture was stirred for two days until 
complete conversion was observed. Water and DCM were added after the mixture 
had cooled down to room temperature. The organic layer was washed with water 
(3 x 5 mL), a saturated aqueous solution of NaHCO3 (1x), dried over MgSO4, 
filtered, and the solvent was evaporated in vacuo. The crude material was purified 
by column chromatography (SiO2; DCM/EtOAc 3:1 → 0:1). The product 4 was 
obtained as a mixture of E and Z isomers (E:Z = 3:2) as a colourless oil (113 mg, 
28%). 1H-NMR (500 MHz, DMSO-d6) δ= 12.11 (s, 1H, Z), 12.01 (s, 1H, E), 8.69 (s, 




mixture E/Z), 1.16 (dt, J = 53.0, 7.0 Hz, 6H, mixture E/Z); 13C-NMR (126 MHz, 
DMSO-d6) (combined peaks of E/Z, and coupling with 31P)  δ= 170.9, 170.9, 
164.6, 164.6, 142.9, 140.2, 140.1, 139.3, 139.2, 138.7, 134.0, 133.8, 133.0, 133.0, 
132.5, 132.4, 132.4, 132.4, 132.3, 132.0, 132.0, 131.7, 131.1, 131.0, 130.6, 129.8, 
129.7, 128.8, 128.7, 128.6, 128.3, 128.2, 127.6, 127.5, 127.4, 126.1, 125.9, 125.5, 
124.7, 124.6, 62.0, 61.9, 61.7, 61.6, 40.1, 40.0, 40.0, 39.9, 39.8, 39.7, 39.5, 39.4, 
39.2, 39.0, 16.1, 16.0, 15.9, 15.9; 31P-NMR (202 MHz, DMSO-d6) δ= 15.55 (dd, J = 
45.1, 4.5 Hz); HRMS (ESI) calcd for C18H19Cl2N2O4P [M+H]+: 429.0517, found 
429.0516. 
(E/Z)-(2-(2-(2,3-Dichlorobenzylidene)hydrazine-1-
carbonyl)phenyl)phosphonic acid (2) 
The phosphonic acid was obtained by deprotection of the 
ester by TMSBr. Compound 4 (93 mg, 0.2 mmol) was 
dissolved in 2.2 mL dry MeCN under N2 atmosphere. To this 
mixture, was added TMSBr (143 µL, 1.08 mmol) and stirred 
at 35 °C for 3 h. The solvent was evaporated in vacuo, water/THF (1:1) was added, 
and the mixture was stirred at room temperature for 1 h. The crude mixture was 
lyophilised and purified by reversed-phase prep-HPLC (water (0.1% formic 
acid)/MeCN (0.1% formic acid), 9:1 → 1:9). Product 2 was obtained as a mixture 
of E and Z isomers (E:Z = 7:3) as a white solid (21.2 mg, 24%). 1H-NMR 
(500 MHz, DMSO-d6) δ= 12.33 (s, E, 1H), 11.94 (s, Z, 1H), 8.68 (s, E, 1H), 8.37 (s, 
Z, 1H), 8.05 – 7.18 (m, 7H); 13C-NMR (126 MHz, DMSO-d6) δ= 171.6, 168.0, 142.9, 
138.2, 137.6, 134.0 (d, J = 11.0 Hz), 132.4, 132.2, 131.6, 130. 9 (d, J = 16.6 Hz), 
129.7 (d, J = 12.6 Hz), 128.5, 128.2, 125.4; 31P-NMR (202 MHz, DMSO-d6) δ= 10.6 
(s); HRMS (ESI) calcd for C14H11Cl2N2O4P [M+H]+: 372.9906, found 372.9902. 
(E/Z)-N'-(3-Bromobenzylidene)-4,5,6,7-
tetrahydrobenzo[b]thiophene-2-carbohydrazide (A1H3) 
The acylhydrazone was synthesised by following the 
general procedure by using 4,5,6,7-tetrahydro-1-
benzothiophene-2-carbohydrazide (43.5 mg, 0.22 
mmol) in MeOH (1.6 mL) and 3-bromobenzaldehyde 
(40 µL, 0.34 mmol) and heating to reflux. After purification via column 
chromatography (DCM/EtOAc, 9:1 → 1:9), the acylhydrazone was obtained as a 
mixture of E and Z isomers (E:Z = 3:2) as a white solid (81 mg, quantitative). 1H-
NMR (500 MHz, CDCl3) δ= 9.35 (s, E, 1H), 7.92 (s, 1H), 7.89 – 7.74 (m, 1H), 7.70 
(d, J = 7.7 Hz, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.31 (t, J = 7.8 Hz, 1H), 2.86 (t, J = 
5.8 Hz, 2H), 2.67 (t, J = 5.8 Hz, 2H), 1.92 – 1.79 (m, 4H); 13C-NMR (126 MHz, 
CDCl3) δ=136.0, 133.2, 130.6, 130.5, 126.3, 123.1, 25.4, 25.4, 23.4, 22.8; HRMS 






The acylhydrazone was synthesised by following the 
general procedure by using 4,5,6,7-tetrahydro-1-
benzothiophene-2-carbohydrazide  (34.4 mg,  0.18 
mmol) in MeOH (1.6 mL) and 2,3-
dichlorobenzaldehyde (27.8 mg, 0.16 mmol) and heating to reflux. After 
purification via column chromatography (DCM/EtOAc, 9:1 → 1:9), the 
acylhydrazone was obtained as a mixture of E and Z isomers (E:Z = 3:2) as a white 
solid (38.2 mg, 68%). 1H-NMR (500 MHz, CDCl3) δ= 8.97 (s, E, 1H), 8.27 (s, Z, 
1H), 8.10 (d, J = 7.9 Hz, 1H), 7.85 (s, 1H), 7.51 (dd, J = 7.9, 1.4 Hz, 1H), 7.31 (t, J 
= 7.9 Hz, 1H), 2.85 (t, J = 6.0 Hz, 2H), 2.66 (t, J = 6.0 Hz, 2H), 1.92 – 1.77 (m, 
4H);13C-NMR (126 MHz, CDCl3) δ=133.5, 132.5, 131.7, 127.8, 126.2, 25.5, 25.4, 
23.4, 22.8; HRMS (ESI) calcd for C16H14Cl2N2OS [M+H]+: 353.0277, found 
353.0274.  
3.4.4 Protein expression and purification 
14-3-3ζ was expressed according to the general protocol as was published by 
Andrei et al..[23] 
3.4.5 Fluorescence polarisation assay (FP) 
The performed FP assays were based on the protocol that was published by 
Andrei et al..[23] 
FP assays were performed in 10 mM HEPES, pH 7.4, 150 mM NaCl, 1.0 mg/mL 
BSA and 0.01% v/v Tween-20 buffer. Fluorescently labelled peptides were 
dissolved to 10 nM in FP buffer as a mastermix. The desired compounds were then 
added from DMSO stock as required, to a final DMSO content of 1%. This solution 
was used to fill Corning Low-binding Black Round Bottom 384-well plates 
(Corning #4514) with a final volume of 10 µL per well. A two-fold dilution series 
was then performed with 14-3-3(ζ), starting from 243 µM. FP was then measured 
in a Tecan Infinite F500 platereader, using 485 (20) nm excitation and 535 (20) 
nm emission filters. The obtained anisotropy values were then plotted and fitted 
against a 4-parameter one-site binding model in GraphPad Prism. 
3.4.6 Binding studies by surface plasmon resonance (SPR) 
The SPR experiments were based on the procedure that was published by Henn 
et al..[24] 
The SPR experiments were performed using a Reichert SR7500DC surface 
plasmon resonance spectrometer (Reichert Technologies, Depew, NY, USA), and 




(XanTec Bioanalytics, Düsseldorf, Germany). Double distilled (dd) water was 
used as the running buffer for immobilisation. HBS-EP buffer (10 mM HEPES, 
150 mM NaCl, 3 mM EDTA, 0.005% v/v tween 20, pH 7.4) containing 5% v/v 
DMSO was used as the running buffer for binding study. All running buffers were 
filtered and degassed prior to use. The 14-3-3 (30.3 kDa) was immobilised in one 
of the two flow cells by standard amine-coupling procedure. The other flow cell 
was left blank to serve as a reference. The system was initially primed with borate 
buffer 100 mM (pH 9.0), then the carboxymethyldextran matrix was activated by 
a 1:1 mixture of N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC) 100 mM and N-hydroxysuccinimide (NHS) 100 mM at a flow 
rate of 10 µL/min for 7 min. The 14-3-3 was diluted to a final concentration of 57 
μg/mL in 10 mM sodium acetate buffer (pH 4.5) and was injected at a flow rate of 
10 µL/min for 7 min. Non-reacted surface was quenched by 1 M ethanolamine 
hydrochloride (pH 8.5) at a flow rate of 25 µL/min for 3 min. A series of 10 buffer 
injections was run initially on both reference and active surfaces to equilibrate 
the system resulting in a stable immobilisation level of approximately 2500 µ 
refractive index unit (μRIU). Binding experiments were performed at 20 °C. 
Compounds dissolved in DMSO were diluted with HBS-EP buffer (final DMSO 
concentration of 5% v/v) and were injected at a flow rate of 30 μL/min. Single-
cycle kinetics were applied for KD determination. The association time was set to 
60 s, and the dissociation phase was recorded for 120 s. Ethylene glycol 80% in 
the running buffer was used for regeneration of the surface. Differences in the 
bulk refractive index due to DMSO were corrected by a calibration curve (nine 
concentrations: 3–7% v/v DMSO in HBS-EP buffer). Data processing and 
analysis were performed by Scrubber software (Version 2.0c, 2008, BioLogic 
Software). Sensorgrams were calculated by sequential subtractions of the 
corresponding curves obtained from the reference flow cell and the running 
buffer (blank). SPR responses are expressed in resonance unit (RU). The KD 
values were calculated by global fitting of the kinetic curves.  
3.4.7 SPR competition assays 
The compounds were prepared as 100 µL samples in the same manner as 
mentioned above in the SPR binding assays. For each competition experiment, a 
series of 12 injections was applied including two blanks, the acylhydrazone, a 
blank for surface regeneration, synaptopodin, ethylene glycol 80% in buffer for 
surface regeneration, two blanks, acylhydrazone/synaptopodin mixture with the 
same concentrations of the single compounds, ethylene glycol 80% in buffer, and 
two blanks, respectively. Samples were injected at a flow rate of 30 µL/min for 60 
s and the dissociation phase was recorded for 120 s. Data processing and analysis 
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3.6 Supporting information 
3.6.1 UPLC-MS analysis of DCC 
UPLC-MS was carried out on a ThermoScientific Dionex Ultimate 3000 UHPLC 
System coupled to a ThermoScientific Q Exactive Focus with an electrospray ion 
source. An Acquity Waters Column (BEH, C8 1.7 µm, 2.1 x 150 mm, Waters, 
Germany) equipped with a VanGuard Pre-Column (BEH C8, 5 x 2.1 mm, 1,7 µm, 
Waters, Germany) was used for separation. At a flow rate of 0.250 mL/min, the 
gradient of H2O (0.1% formic acid) and acetonitrile (0.1% formic acid) was held 
at 5% acetonitrile for 1 min and then increased to 95% over 16 min. It was held 
there for 1.5 min before the gradient was decreased to 5% over 0.1 min where it 
was held for 1.9 min. The mass spectrum was measured in positive mode in a 
range from 100 – 700 m/z. 
3.6.2 HRMS analysis 
High-resolution mass spectra were recorded with a ThermoScientific system 
where a Dionex Ultimate 3000 RSLC was coupled to a Q Exactive Focus mass 
spectrometer with an electrospray ion source. An Acquity UPLC® BEH C8, 
150 x 2.1 mm, 1.7 µm column equipped with a VanGuard Pre-Column BEH C8, 5 
x 2.1 mm, 1,7 µm (Waters, Germany) was used for separation. At a flow rate of 
250 µL/min, the gradient of H2O (0.1% FA) and ACN (0.1% FA) was held at 10% 
B for 1 min and then increased to 95% B over 4 min. It was held there for 1.2 min 
before the gradient was decreased to 10% B over 0.3 min where it was held for 1 
min. The mass spectrum was measured in positive mode in a range from 120 – 







Scheme S1. Original dynamic combinatorial library (DCL), from which not all products 
could be observed. Aldehydes (100 µM each), hydrazides (100 µM each) and A2H7 
(compound 2) (100 µM), DMSO (5%), aniline (10 mM), and a) blank without protein; b) 





Figure S1. UV-chromatograms at 290 nm of DCLs of a) blank without protein; and b) 
library with 14-3-3(ζ) (10 µM). Data obtained from single experiment. 
Products with H8 and H7 could not all be observed, but A1H3 and A2H3 show 
amplification in protein compared to blank. Therefore, we modified the DCL and 
omitted these structures, resulting in the DCL shown in Scheme S2. 
 
Scheme S2. Adapted dynamic combinatorial library (DCL) with aldehydes (100 µM 
each), hydrazides (300 µM each), DMSO (5%), aniline (10 mM) and: a) 14-3-3(ζ) (10 µM) 
and synaptopodin (10 µM); b) control with 14-3-3(ζ) (10 µM); and c) control without 











Figure S2. UV-chromatograms at 290 nm of DCLs in duplicate, blank (B), protein (P) 
and protein plus synaptopodin (PS) at 6 h. 
 
Figure S3. UV-chromatograms at 290 nm of a) the blank DCL at 6 h, b) synthesised 
A1H3, and c) synthesised A2H3. The synthesised compounds both have a bit longer 
retention time (0.12 min) due to being dissolved in pure MeCN, where the DCL also 





Figure S4. UV CD spectra of 14-3-3(ζ) 1µM protein in MiliQ. Measured on a J-1500 CD 















Figure S5. SPR binding assay of 2: a) Overlay of sensorgrams (black) of 2 at 
concentrations of 1.6–1000.0 µM running over an immobilized 14-3-3(ζ). Global fitting of 
the association and dissociation curves (red), b) Langmuir binding isotherm (KD = 1.01 ± 







Figure S6. SPR binding assay of synaptopodin: (a) Overlay of sensorgrams (black) of 
synaptopodin at concentrations of 0.003–2.0 µM running over an immobilised 14-3-3(ζ). 
Global fitting of the association and dissociation curves (red). (b) Langmuir binding 
isotherm (KD = 1.38 ± 0.02 µM). Data obtained from single experiment. 
Table S1. The kinetic parameters of compound 2 and synaptopodin binding to 14-3-3. 
Data obtained from single measurement. Rmax: maximum analyte binding capacity; kon: 
association rate constant; koff: dissociation rate constant; KD: equilibrium dissociation 




kon (M-1 s-1) koff (s-1) KD (µM) Res sd 
2 86.0 ± 
1.0 
1.32 ± 0.04 
×102 




Synaptopodin 52.0 ± 
5.0 














Figure S7. SPR binding assay of A1H3: a) Overlay of sensorgrams (black) of A1H3 at 
concentrations of 3.1–50 µM running over an immobilized 14-3-3(ζ). Global fitting of the 
association and dissociation curves (red), b) Langmuir binding isotherm of A1H3 (KD 
=16 ± 1 µM). Data obtained from single experiment. 
 
Figure S8. SPR binding assay of A2H3: a) Overlay of sensorgrams (black) of A2H3 at 
concentrations of 3.1–50 µM running over an immobilized 14-3-3(ζ). Global fitting of the 
association and dissociation curves (red), b) Langmuir binding isotherm of A2H3 (KD 


















Figure S9 and Table S2. SPR competition assay: Overlay of sensorgrams of 2 (1000 µM, 
blue), synaptopodin (1 µM, red) and 2–synaptopodin mixture (black) in duplicate. RU 
values of the mixture are less than the sum of the individual RU responses (29–33% 








Figure S10. SPR competition assay: Overlay of sensorgrams of 2 (1000 µM, blue), 
synaptopodin (25 µM, red) and 2–synaptopodin mixture (black) in duplicate.  
  
 Compound 2 (1000 µM) 
Synaptopodin 
(1 µM) 
2 (1000 µM) + 
Synaptpodin (1 µM) 
RU(experiment 1) 
42.08 22.21 49.67 
RU(experiment 2) 
36.93 18.39 43.55 
RU(average) 




Table S3. SPR competition assay in duplicate. RU values of the mixture are less than the 
sum of the individual RU responses (30–33% decrease of 2 response and 20–22% 




Synaptopodin (25 µM) 
2 (1000 µM) + 
Synaptpodin (25 µM) 
RU(experiment 1) 
39.99 60.35 87.03 
RU(experiment 2) 
37.18 55.73 81.94 
RU(average) 











Synaptopodin (1 µM) 
2 (200 µM) + 
Synaptpodin (1 µM) 
RU(experiment 1) 10.55 16.90 24.85 
RU(experiment 2) 11.20 17.69 24.69 
RU(average) 
10.88 (± 0.5) 17.30 (± 0.6) 24.77 (± 0.1) 
 
Figure S11 and Table S4. SPR competition assay: Overlay of sensorgrams of 2 (200 µM, 
blue), synaptopodin (1 µM, red) and 2–synaptopodin mixture (black) in duplicate. RU 
values of the mixture are less than the sum of the individual RU responses (25–37% 




Design and synthesis of glucosyltransferase inhibitors: 







Dynamic combinatorial chemistry was applied to find inhibitors of 
glucosyltransferase (GTF) 180. GTFs are the major producers of extracellular 
polysaccharides, which are important factors in the initiation and development 
of cariogenic dental biofilms. These biofilms are also known as dental plaque 
and are causative for caries. The work described herein focusses on the design 
and synthesis of building blocks for DCC, the analysis of the dynamic 
combinatorial libraries (DCLs) via UPLC-MS and evaluation of the synthesised 
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Cariogenic dental biofilms, also known as dental plaque, are causative for dental 
caries. Important factors for the initiation and development of this oral disease 
are the fermentation of dietary carbohydrates, of which sucrose is considered 
most cariogenic. It is a substrate for the synthesis of extracellular (EPS) and 
intracellular (IPS) polysaccharides, which form the biofilm, having glucan as one 
of the main components. The biofilm hosts bacteria and can promote their 
adhesion to the tooth enamel. Glucosyltransferases (GTFs) are the major 
producers of EPS, and are secreted by different strains of bacteria. These GTFs, 
also known as glucansucrases, are therefore potential targets in order to inhibit 
biofilm formation and therefore prevent dental caries.[1–3]  
Glucansucrases are enzymes which are part of the glycoside hydrolase family 
GH70, consisting of four catalytically important conserved sequence motifs. To 
the superfamily of GH-H also belong the glycoside hydrolase families 13 and 77.[4] 
Cocrystal structures, containing the catalytic and C-terminal domains, of 
glucansucrase of Lactobacillus reuteri 180 were previously reported and 
provided evidence for an α-retaining double displacement mechanism using one 
nucleophilic residue.[5] After the glycosidic bond is cleaved, the glucosyl moiety 
can elongate a glucan chain, or it can be transferred to a water molecule or an 











Figure 1. Reaction scheme of the proposed catalytic mechanism of GTF-180 via an a-
retaining double displacement, leading to retention of the stereochemistry.[5,6] 
Glucansucrases can be inhibited by small-molecules, as well as natural 




bacteria, as was the case for acarbose (Figure 2). In 1977, researchers of Bayer 
published the finding of α-amylase inhibitors from broths of Actinoplanes strains 
SE 50, SE 82 and SB18, of which BAY g 5421 (acarbose) was the most potent. 
Schmidt et al. postulated that acarbose could be a transition-state anologue.[7] 
Since then, acarbose has been used as an antidiabetic drug throughout the world, 
and was found to have cardiovascular benefits.[8–10] Newbrun et al. showed that 





Figure 2. Acarbose, an α-glucosidase inhibitor acting as transition-state analogue. 
Identified from culture broths of Actinoplanes.[7]  
To identify hit compounds, dynamic combinatorial chemistry (DCC) has become 
an attractive strategy.[12–14] One of the most frequently used reversible reactions 
in DCC, in order to find bioactive molecules, is the acylhydrazone formation. DCC 
allows a target protein to alter the equillibrium of a product mixture, also known 
as the dynamic combinatorial library (DCL). Due to the change in equilibrium by 
the protein, good binders get amplified and will therefore be found as hits 
(Scheme 1). 
 
Scheme 1. Schematic illustration of target-directed DCC using the acylhydrazone linkage, 
formed by the reaction between a glucose derived aromatic aldehyde and representative 
hydrazides. The protein target causes a change in equilibrium, which leads to the 





4.1.1 Dynamic combinatorial library design 
We chose the acylhydrazone formation reaction for DCC. It is a reversible reaction 
between an aldehyde and a hydrazide. Inspired by the structure of acarbose, we 
designed the basic scaffold of our molecules. An aryl aldehyde linked to glucose 
and maltose (A-1 and A-2, Scheme 2). We then selected eighteen chemically 
different and commercially available hydrazides (H-1—H-18) and divided them 
into two separate groups (Figure 3). Each aldehyde (A-1 and A-2) was reacted 
separately with the two sets of hydrazides (Hydrazides-I and Hydrazides-II), 
resulting in four different DCLs (DCL-1–4, Scheme 2) which were analysed via 
UPLC-MS. DCL-1 is the library formed by aldehyde A-1 with the first set of 
hydrazides (A1HI). DCL-2 is the library formed by A-2 with first set of 
hydrazides (A2HI). DCL-3 is the library formed by A-1 with the second set of 
hydrazides (A1HII), and DCL-4 is the library formed by A-2 with the second set 




Scheme 2. Each aldehyde was reacted separately with the two hydrazide libraries, 
resulting in the formation of four dynamic combinatorial libraries (A1H1–8 (DCL1), 

















Figure 3 continued. Hydrazide groups used in the DCC experiments. 
4.2 Results and Discussion 
4.2.1 Synthesis of the building blocks 
The aldehyde building blocks were synthesised according to the routes shown in 
Schemes 3 and 4. α-D-Glucose penta-acetate (1) was reacted with a solution of 
HBr in acetic acid, resulting in brominated glucose tetra-acetate (2). Without 
purification, 2 was coupled to 4-hydroxybenzaldehyde, using silver(I) oxide and 
yielding product 3.[15] Deprotection of the acetate groups by sodium methoxide 
using the classical Zemplen deacetylation gave aldehyde A-1 in quantitative yield 
(Scheme 3).[16] The same route was used for the synthesis of A-2, however β-






Scheme 3. Synthetic route towards aldehyde A-1. Reagents and conditions: (a) Ac2O, 
HBr in AcOH 33%, 0˚C – rt, 15 h, 70%; (b) Ag2O, MeCN, rt, overnight  40%; (c) NaOMe, 







Scheme 4. Synthethic route towards aldehyde A-2. Reagents and conditions: (a) Ac2O, 
HClO4, AcOH, rt, 1 h; (b) 33% HBr in AcOH, 0˚C – rt, 15 h, 52% yield over two steps; (c) 




4.2.2 Forming the DCLs 
Each library consisted of one aldehyde, one group of hydrazides, aniline and 
DMSO in sodium acetate buffer. Aniline was added to enhance the rate at which 
the acylhydrazone formation reaches equilibrium, as it serves as nucleophilic 
catalyst to form Schiff bases with the corresponding aldehydes.[18] The use of 
DMSO as a cosolvent allows the building blocks and products to be soluble, 
preventing an undesired shift in equilibrium due to precipitation. A desired shift 
in the equilibrium, also known as the template effect, was achieved by the 
addition of the target protein GTF-180. The protein was added after pre-
equilibrium was reached in the blank library. 
4.2.3 Monitoring the DCLs 
The DCL was left shaking at room temperature and was frequently monitored via 
UPLC-MS. Samples for UPLC-MS were prepared by taking 100 µL of the 
corresponding library and diluting it with 100 µL acetonitrile. The pH was raised 
to > 8 by the addition of 8 µL NaOH (2 M), to freeze the equilibrium. The mixture 
was centrifuged at 10,000 rpm for 2 minutes, and the supernatant was analysed 
via UPLC-MS. 
The formation of the acylhydrazones reached equilibrium within three hours. It 
was at this time point that we added the GTF enzyme and continued the analysis 
via UPLC-MS. The distribution of the products in the DCLs of the blank library 
versus the protein library can be compared by the relative peak areas from the 
UV-chromatograms (Figure 4 and Table 1, and Figures S1–S3 and Tables S1–3). 
We selected the most amplified structure of each library and synthesised these 
compounds (Figure 5). For two product members of DCL-2 (A2H2 and A2H8), 
the glycosidic bond between the two sugar rings was cleaved after 6 hours (Figure 
S1 and Table S1) resulting in A1H2 and A1H8. This indicates that these 
compounds enter the active site and get cleaved by the enzyme. Along with the 
hits, the cleaved products (A1H2 and A1H8) will also be tested for their 
activities.  
 
Figure 4. DCL-1. Dynamic combinatorial libraries of aldehyde A-1 with hydrazide 
library 1: a) UV-chromatogram at 290 nm of the blank reaction at 6 h; b) UV-









Table 1. Amplification folds of the formed products in DCL-1; analysed via the relative 
surface areas of peaks in the UV-chromatograms of the protein-templated reaction (P) and 






A1H1 9.6 0.9 
A1H2 8.1 1.8 
A1H3 7.5 1.1 
A1H4 9.0 0.8 
A1H5 5.8 0.8 
A1H6 3.8 1.2 
A1H7 4.5 0.9 



















4.2.4 Binding studies by surface plasmon resonance (SPR) 
We immobilised GTF-180 to a sensor chip via amine coupling and followed the 
change in surface plasmon resonance upon injecting our hit compounds. Firstly, 
we ran a measurement with acarbose as a positive control, which showed that the 
setup was working. We then injected our hit compounds and the data are given 
in Table 2. Most hit compounds showed solubility problems above 1.5 mM, when 
5% DMSO was used as cosolvent. We therefore could not reach the plateaus and 
could only fit the available data. In addition, the responses for most of the 
compounds were relatively low, as can be seen in the sensorgrams at the end of 
the experimental section (S4 – S10). Due to a very low response, the sensorgram 
obtained for compound A2H6 could not be evaluated, and therefore its binding 
affinity could not be determined. As can be seen from Table 2, almost all 
compounds show weak binding, except for acarbose (10.7 µM). Compound 
A1H12 showed to be the most promising binder with micromolar affinity.  Since 
the active site of GTF-180 is polar, it is a very challenging task to address the 
binding pockets. We were therefore pleased to find A1H12 as moderate binder.  
Table 2. Binding study results obtained from surface plasmon resonance (SPR). Data 
obtained from single experiments. 
Compound Rmax (RU) kon (M–1 s–1) koff (s–1) KD (mM) Res sd 
Acarbose 1.36 ± 0.03 







A1H2 4.7 ± 0.2 




1.4 ± 0.1 0.41 
A1H8 32 ± 4 18 ± 3 
0.142 ± 
0.004 
8 ± 1 0.53 
A1H12 8.7 ± 0.3 







A2H2 40 ± 20 8 ± 5 
0.099 ± 
0.006 
12 ± 8 0.74 
A2H12 1000.0 ± 
3000 






Rmax: maximum analyte binding capacity; kon: association rate constant; koff: dissociation 





4.2.5 GTF-180 activity assay 
The activity of the protein can be followed via glucose oxidase/peroxidase 
(GOPOD) analysis. We followed the hydrolysis of sucrose, which forms glucose, 
and also monitored the transferase product fructose. The enzyme was incubated 
for half an hour at 37 °C with the compounds before sucrose was added. Figure 6 
shows the results of the analysis of the hit compounds in the GTF activity assay. 
As can be seen from this figure, hardly any inhibition was observed. We used 
acarbose as a positive control, however it should be mentioned that acarbose is a 
moderate to weak inhibitor of GTF-180. The assay condition contained 20% of 
DMSO, which could have a bad influence on protein–ligand binding.[19] We have 
screened the binding affinities via SPR at 5% DMSO and the compounds were 
binding with low mM affinities. These results are in line with each other and 
therefore, repeating the activity assay at lower DMSO percentages will most 
probably not change the outcome  
 
 
Figure 6. GTF-180 activity assay based on the hydrolysis of sucrose. No significant 
inhibition was observed for the hit compounds at 500 µM, and moderate inhibition by 






In this work, we showed the first application of DCC to glucansucrases. We have 
designed our compounds to bear a glucose or maltose head group, which 
resembles natural substrates, as a proper starting point. These molecules were 
then expected to grow into the pocket by eighteen different aromatic or aliphatic 
tails via DCC. By separating the complex libraries into four individual 
sublibraries, we were able to analyse the DCC experiments over time. 
Interestingly, we observed in the presence of enzyme that the glycosidic bond 
between the two glucose molecules in maltose was cleaved, indicating that it 
could also serve as a substrate for glucansucrases. Maltose is formerly known to 
be an acceptor for the glucosyl moiety. No cleavage was observed for the glycosyl 
moiety in the glucose derivative.  
LC-MS analysis of the sublibraries resulted in six hit compounds, which were 
synthesised and analysed for their biophysical and biochemical properties via 
SPR and a GTF-activity assay. In comparison to acarbose, the hit compounds 
showed only moderate to low affinities or activities as inhibitors of GTF-180. The 
results of the SPR measurements are in line with the activity assay, even though 
they were performed at different concentrations of DMSO. In both SPR as the 
activity assay, acarbose was used as a positive control. It showed moderate 
binding, as well as moderate activity. 
The first DCC approach for the quest of hits for GTFs leads to some interesting 
findings concerning solubility issues, active site of the enzyme and design of the 
scaffold. We may have failed in reaching strong binders since the active site is 
rather polar. This makes it difficult for compounds to enter and inhibit the active 
site. The cleavage of the glycosydic bond is a good indication that our compounds 
could enter the active site, but most likely they are not binding strong enough to 
inhibit the enzyme. This could be due to the fact that acylhydrazones are rather 
rigid and flat, possibly hindering the cavity to be filled properly. 
Future work should focus on making these products more soluble to be able to 
test their activity with the least amount of DMSO possible. Moreover, mimicking 
the transition state, like acarbose does, might be the most rewarding strategy to 
achieve stable inhibitors. Furthermore, compounds should be flexible enough to 





4.4  Experimental section 
4.4.1 Materials and methods 
See section 3.4.1. 
4.4.2 General procedure for DCC experiments 
The reaction mixture composition for each sublibrary was obtained by adding the 
hydrazides (each 3 μL, stock solutions 100 mM in DMSO) and the aldehyde (3 μL, 
stock solutions 100 mM in DMSO) to a sodium acetate buffer (590.5 µL, 0.1 M, pH 
5.2). Aniline (5.55 µL, stock solution 1.8 M) was added as well as DMSO, to reach 
a final concentration of DMSO in the DCL of 10%. Protein (309.5 µL, stock 
solution 96.93 µM) was added accordingly after 3 h of equilibration.  Final 
concentrations in the DCL were: aniline (10 mM), aldehyde (300 µM), hydrazides 
(300 µM each), protein (30 µM) and DMSO (10%). The DCL was left shaking at 
room temperature and was frequently monitored via UPLC-MS. After 6–7 h of 
shaking with protein, the mixture was analysed via UPLC-MS.  
For monitoring via UPLC-MS, 100 μL of the corresponding library was diluted in 
100 µL acetonitrile, the pH was raised to pH > 8 by adding 8 µL NaOH (2.0 M) to 
freeze the reaction equilibrium. The mixture was centrifuged at 10,000 rpm for 
2 min, and the supernatant was analysed via UPLC-MS. 
4.4.3 Binding studies by surface plasmon resonance (SPR) 
See section 3.4.6. Instead of 14-3-3, GTF-180 (5 µM, 117 kDa) was immobilised on 
the surface.  
4.4.4 GTF-180 activity assay 
In an 8-well PCR strip, 50 µL sodium acetate buffer (100 mM, pH 4.7, 8 mM 
CaCl2), 40 µL DMSO, inhibitor 20 µL (5 mM), 20 µL GTF-180∆N (4.5 µM) and 70 
µL Milli-Q H2O were added and incubated for 30 min at 37 °C. To the wells of a 
96-wells PCR plate was added 12.5 µL NaOH (0.4 M). The wells of a different 8-
well PCR strip were filled with 200 µL sucrose solution (100 mM) and incubated 
for 5 min before the start of the assay.  
To start the assay, 20 µL of the 100 mM sucrose stock was added to the wells 
containing inhibitor and enzyme. Every 30 seconds, 25 µL sample was taken and 
mixed with 12.5 µL NaOH (0.4 M). After the last time point at 3.5 min, 12.5 µL 
HCl (0.4 M) was added to neutralise the samples. 
For the glucose oxidase/peroxidase (GOPOD) analysis, 12.5 µL sample was mixed 





General procedure for acylhydrazone formation (GP1):[20]  
To the hydrazide (1 eq.) dissolved in MeOH, the corresponding aldehyde (1.2 eq.) 
was added. The reaction mixture was stirred at room temperature or refluxed 
until completion. After cooling to room temperature, the reaction mixture was 
concentrated in vacuo. Purification of acetylated products was performed by 
column chromatography and deprotected sugars were purified by preparative 
high-performance liquid chromatography, affording the corresponding 
acylhydrazone in 60% to quantitative yields. For acylhydrazones, some 13-NMR 
signals doubled due to presence of two isomers (E & Z). 
General procedure for the deprotection of the acetyl groups 
(GP2):[16] 
The classical Zemplén deacetylation method of the O-acetyl protecting groups 
with sodium methoxide in methanol at room temperature was used. The O-acetyl 
protected sugar was dissolved in methanol (0.01 M), and a catalytic amount of 
sodium methoxide (0.15 eq) was added. The reaction mixture was stirred at room 





The acylhydrazone was synthesised according to GP1 
by using 1-Boc-isonipecotic acid hydrazide (26 mg, 0.1 
mmol) in methanol (1.0 mL) and para-glucose-
benzaldehyde (14.5 mg, 0.05 mmol). After purification, 
the acylhydrazone was obtained as a mixture of E and 
Z isomers (E:Z = 7:3) as a white solid (12 mg, 46%). 1H-
NMR (500 MHz, MeOD) δ = 8.06 (s, 1H, E), 7.90 (s, 
1H, Z), 7.72 (d, J = 8.8 Hz, 1H), 7.62 (d, J = 8.8 Hz, 1H), 
7.13 (dd, J = 8.8, 4.0 Hz, 2H), 5.00 – 4.95 (m, 1H), 4.14 
(d, J = 13.3 Hz, 2H), 3.93 – 3.86 (m, 1H), 3.71 (dd, J = 12.1, 5.6 Hz, 1H), 3.52 – 
3.44 (m, 3H), 3.44 – 3.37 (m, 1H), 2.47 (tt, J = 11.4, 3.7 Hz, 1H), 1.89 – 1.76 (m, 
2H), 1.75 – 1.56 (m, 2H), 1.47 (s, 9H), 1.36 – 1.26 (m, 1H), 1.15 (d, J = 6.2 Hz, 1H), 
0.94 – 0.83 (m, 1H); 13C-NMR (126 MHz, MeOD) δ = 178.6, 173.9, 161.0, 160.6, 
156.4 (d, J = 10.1 Hz), 149.3, 145.5, 130.2, 129.8, 129.5, 117.9 (d, J = 10.7 Hz), 
101.9 (d, J = 6.1 Hz), 81.1 (d, J = 12.8 Hz), 78.2 (d, J = 3.5 Hz), 77.9 (d, J = 4.2 
Hz), 74.8, 71.3 (d, J = 3.1 Hz), 62.5, 42.7, 39.5, 29.5, 28.9, 28.7; HRMS (ESI) calcd 









The acylhydrazone was synthesised according 
to GP1 by using 1-boc-isonipecotic acid 
hydrazide (38 mg, 0.15 mmol) in methanol 
(1.0 mL) and para-maltose-benzaldehyde (22 
mg, 0.05 mmol). After purification, the 
acylhydrazone was obtained as a mixture of E 
and Z isomers (E:Z = 3:2) as a white solid (9.1 
mg, 28%); 1H-NMR (500 MHz, MeOD) δ = 
8.07 (s, 1H, E), 7.90 (s, 1H, Z), 7.73 (d, J = 8.8 
Hz, 1H), 7.63 (d, J = 8.8 Hz, 1H), 7.13 (dd, J = 
8.8, 3.5 Hz, 2H), 5.21 (d, J = 3.8 Hz, 1H), 5.01 (dd, J = 7.8, 1.9 Hz, 1H), 4.14 (d, J 
= 13.4 Hz, 2H), 3.95 – 3.42 (m, 13H), 2.47 (tt, J = 11.5, 3.8 Hz, 1H), 1.90 – 1.77 
(m, 2H), 1.77 – 1.57 (m, 3H), 1.47 (s, J = 6.5 Hz, 9H); 13C NMR (126 MHz, MeOD) 
δ 178.57 (s), 173.93 (s), 160.73 (d, J = 40.2 Hz), 156.45 (d, J = 10.2 Hz), 149.25 
(s), 145.48 (s), 130.25 (s), 129.54 (d, J = 8.3 Hz), 117.84 (d, J = 11.2 Hz), 102.94 
(s), 101.71 (d, J = 6.4 Hz), 81.14 (d, J = 12.5 Hz), 80.83 (d, J = 5.5 Hz), 77.66 (d, J 
= 3.9 Hz), 76.80 (d, J = 2.8 Hz), 75.08 (s), 74.85 (s), 74.44 (s), 74.18 (s), 71.50 (s), 
62.76 (s), 61.90 (s), 42.69 (s), 39.54 (s), 29.51 (s), 28.67 (s); HRMS (ESI) calcd 




(methylsulfonyl)acetohydrazide        (A2H6) 
The acylhydrazone was synthesised according to GP1 
by using 2-(methylsulfonyl)acetic acid hydrazide 
(12.8 mg, 0.08 mmol) in methanol (0.8 mL) and 
para-maltose-benzaldehyde (30.2 mg, 0.07 mmol). 
After purification, the acylhydrazone was obtained as 
a mixture of E and Z isomers (E:Z = 3:2) as a white 
solid (4.1 mg, 10%). 1H-NMR (500 MHz, MeOD) δ = 
8.10 (s, 1H, E), 7.95 (s, 1H, Z), 7.75 (d, J = 8.8 Hz, 1H), 
7.66 (d, J = 8.8 Hz, 1H), 7.14 (d, J = 8.8 Hz, 2H), 5.21 
(d, J = 3.8 Hz, 1H), 5.01 (dd, J = 7.7, 4.5 Hz, 1H), 4.15 (s, 1H), 3.94 – 3.43 (m, 




= 15.2 Hz), 160.8, 150.8, 146.8, 130.5, 129.8, 129.4, 129.1, 117.9 (d, J = 6.4 Hz), 
102.9, 101.7 (d, J = 5.4 Hz), 80.8 (d, J = 5.4 Hz), 77.7 (d, J = 3.2 Hz), 76.8, 75.1, 
74.8, 74.4, 74.2, 71.5, 62.8, 61.9 (d, J = 2.2 Hz), 60.0, 57.4, 49.6, 49.5, 49.3, 49.3, 
49.2, 49.0, 48.8, 48.7, 48.5, 42.6, 42.0, 40.4; HRMS (ESI) calcd for C22H32N2O14S 
[M+H]+: 581.1647, found 581.1620. 
(2R,3R,4S,5R,6S)-2-(Acetoxymethyl)-6-(4-((Z)-(2-(2-(2-
chlorophenoxy)acetyl)hydrazineylidene)methyl)phenoxy)tetrahydro
-2H-pyran-3,4,5-triyl triacetate (Acetylated A1H12) 
The acylhydrazone was synthesised according to GP1 
by using 2-chlorophenoxyacetic acid hydrazide (26.6 
mg, 0.13 mmol) in methanol (1.8 mL) and para-(O-
acetylatedglucose)-benzaldehyde (50.0 mg, 0.11 mmol). 
After purification, the acylhydrazone was obtained as a 
mixture of E and Z isomers (E:Z = 3:2 ) as a white solid 
(43 mg, 61%). 1H-NMR (500 MHz, MeOD) δ = 8.19 (s, 
1H, E), 7.93 (s, 1H, Z), 7.72 (dd, J = 54.3, 8.8 Hz, 2H), 
7.40 (ddd, J = 24.3, 7.9, 1.6 Hz, 1H), 7.31 – 7.20 (m, 1H), 
7.14 – 6.92 (m, 4H), 5.44 – 5.35 (m, 2H), 5.25 (s, 1H), 5.20 – 5.08 (m, 2H), 4.75 
(d, J = 6.6 Hz, 1H), 4.31 (dd, J = 12.3, 5.3 Hz, 1H), 4.20 – 4.06 (m, 2H), 2.10 – 
1.95 (m, 12H); 13C-NMR (126 MHz, MeOD) δ = 171.9 (d, J = 82.7 Hz), 171.4 (s), 
171.3 (s), 171.1 (s), 167.1 (s), 159.9 (d, J = 44.7 Hz), 155.3 (d, J = 74.1 Hz), 150.6 
(s), 146.1 (s), 131.4 (d, J = 19.4 Hz), 130.6 (s), 130.3 (s), 130.1 (s), 129.8 (s), 129.3 
(s), 128.9 (s), 124.4 (s), 124.1 (s), 124.0 (s), 123.1 (s), 117.9 (d, J = 10.9 Hz), 116.1 
(s), 115.3 (s), 99.1 (d, J = 6.4 Hz), 74.1 (s), 73.0 (s), 72.6 (s), 69.7 (d, J = 3.6 Hz), 
69.2 (s), 67.3 (s), 63.1 (d, J = 4.4 Hz), 20.9 – 20.1 (m); HRMS (ESI) calcd for 
C29H31ClN2O12 [M+H]+: 635.1638, found 635.1638. 
2-(2-Chlorophenoxy)-N'-((Z)-4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-
6-(hydroxymethyl)tetrahydro-2H-pyran-2-
yl)oxy)benzylidene)acetohydrazide    (A1H12) 
The acylhydrazone was synthesised according to GP2 by 
using acetylated A1H12 (26.1 mg, 0.04 mmol) in 
methanol (4 mL) and sodium methoxide (0.33 mg, 0.006 
mmol). After purification, the acylhydrazone was 
obtained as a mixture of E and Z isomers (E:Z = 3:7) as a 
white solid in quantitative yield (20 mg). 1H-NMR (500 
MHz, DMSO) δ = 11.53 (bs, 1H), 8.22 (s, 1H, E), 7.96 (s, 
1H, Z), 7.64 (t, J = 8.4 Hz, 2H), 7.44 (ddd, J = 12.5, 7.9, 
1.5 Hz, 1H), 7.33 – 7.22 (m, 1H), 7.10 – 7.04 (m, 2H), 7.04 




OH), 4.96 – 4.91 (m, 1H), 4.74 (s, 1H), 4.58 (s, 1H), 3.69 (d, J = 11.3 Hz, 1H), 3.47 
(s, 1H), 3.29 – 3.21 (m, 2H), 3.17 (t, J = 9.0 Hz, 1H); 13C-NMR (126 MHz, DMSO) 
δ =168.4, 158.7, 153.7, 143.6, 130.1, 130.0, 128.6, 128.4, 128.3, 128.1, 127.7, 122.1, 
121.5, 121.1, 116.4, 116.4, 114.1, 113.8, 100.0, 77.1, 76.6, 73.2, 69.7, 65.3, 60.6; 
HRMS (ESI) calcd for C21H23ClN2O8 [M+H]+: 467.1216, found 467.1205. 
(2R,3R,4S,5R,6S)-2-(Acetoxymethyl)-6-(4-((Z)-(2-(2-
cyclopentylacetyl)hydrazineylidene)methyl)phenoxy)tetrahydro-2H-
pyran-3,4,5-triyl triacetate (Acetylated A1H8) 
The acylhydrazone was synthesised according to GP1 by 
using 2-Chlorophenoxyacetic acid hydrazide (18.9 mg, 
0.13 mmol) in methanol (1.8 mL) and para-(O-
acetylatedglucose)-benzaldehyde (50.0 mg, 0.11 mmol). 
After purification, the acylhydrazone was obtained as a 
mixture of E and Z isomers (E:Z = 7:3) as a white solid (59 
mg, 93%). 1H-NMR ( 500 MHz, MeOD) δ = 8.05 (s, 1H, E), 
7.89 (s, 1H, Z), 7.69 (dd, J = 60.2, 8.8 Hz, 2H), 7.07 (d, J = 
8.8 Hz, 2H), 5.45 – 5.34 (m, 2H), 5.22 – 5.06 (m, 2H), 4.37 
– 4.25 (m, 1H), 4.21 – 4.08 (m, 2H), 2.74 (d, J = 7.4 Hz, 1H), 2.30 (d, J = 1.9 Hz, 
2H), 2.08 – 1.96 (m, 12H), 1.85 (m, 2H), 1.74 – 1.64 (m, 2H), 1.63 – 1.54 (m, 2H), 
1.34 – 1.18 (m, 2H); 13C-NMR (126 MHz, MeOD) δ = 172.3 (d, J = 12.7 Hz), 171.4 
(d, J = 42.3 Hz), 171.1, 159.9, 148.6, 130.3, 129.5, 117.9, 117.8, 99.1, 74.1, 73.1, 72.7, 
69.7, 63.1, 49.6, 49.5, 49.5, 49.3, 49.2, 49.0, 48.8, 48.7, 48.5, 41.6, 39.4, 38.6, 
38.0, 33.5, 33.4, 25.9, 20.6, 20.5; HRMS (ESI) calcd for C28H36N2O11 [M+H]+: 




The acylhydrazone was synthesised according to GP2 by 
using compound acetylated A1H8 (23.0 mg, 0.04 mmol) 
in methanol (4 mL) and sodium methoxide (0.32 mg, 0.006 
mmol). After purification, the acylhydrazone was obtained 
as a mixture of E and Z isomers (E:Z = 7:3) as a white solid 
(13 mg, 82%). 1H-NMR ( 500 MHz, MeOD) δ = 8.05 (s, 1H, 
E), 7.88 (s, 1H, Z), 7.73 (d, J = 8.8 Hz, 1H), 7.61 (d, J = 8.8 
Hz, 1H), 7.13 (dd, J = 8.8, 1.9 Hz, 2H), 4.98 – 4.95 (m, 1H), 
3.94 – 3.86 (m, 1H), 3.71 (dd, J = 12.1, 5.6 Hz, 1H), 3.52 – 
3.44 (m, 3H), 3.44 – 3.36 (m, 1H), 2.74 (d, J = 7.5 Hz, 1H), 2.34 – 2.24 (m, 2H), 
1.92 – 1.78 (m, 2H), 1.74 – 1.64 (m, 2H), 1.64 – 1.49 (m, 2H), 1.34 – 1.18 (m, 2H); 




129.9, 129.6, 129.4, 117.9, 117.8, 101.9, 101.9, 78.2, 78.0, 77.9, 74.9, 71.3, 71.3, 62.5, 
62.5, 41.6, 39.4, 38.5, 38.0, 33.5, 33.4, 25.9, 25.9;HRMS (ESI) calcd for 




-2H-pyran-3-yl)oxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate  
(Acetylated A2H12) 
The acylhydrazone was synthesised according 
to GP1 by using 2-Chlorophenoxyacetic acid 
hydrazide (8.9 mg, 0.04 mmol) in methanol 
(0.5 mL) and para-(O-acetylatedmaltose)-
benzaldehyde (25.0 mg, 0.03 mmol). After 
purification, the acylhydrazone was obtained as 
a mixture of E and Z isomers (E:Z = 3:2) as a 
white solid (30 mg, 48%). 1H NMR (500 MHz, 
MeOD) δ = 8.19 (s, 1H, E), 7.92 (s, 1H, Z), 7.71 
(dd, J = 53.8, 8.8 Hz, 2H), 7.45 – 7.36 (m, 1H), 
7.32 – 7.20 (m, 1H), 7.14 – 6.91 (m, 4H), 5.47 – 
5.34 (m, 4H), 5.24 (s, 1H), 5.07 (dt, J = 13.6, 9.4 Hz, 2H), 4.88 (dd, J = 9.9, 3.3 
Hz, 1H), 4.76 (s, 1H), 4.58 – 4.51 (m, 1H), 4.30 (dd, J = 10.8, 8.3 Hz, 1H), 4.27 – 
4.11 (m, 1H), 4.09 (d, J = 6.3 Hz, 2H), 2.23 – 1.89 (m, 21H); 13C NMR (126 MHz, 
MeOD) δ = 172.3 (d, J = 6.0 Hz), 171.9, 171.8, 171.6, 171.3, 171.2, 167.1, 160.1, 159.7, 
155.5, 154.9, 154.8, 150.6, 146.1, 131.5, 131.4, 131.4, 130.6, 130.3, 130.0, 129.8, 
129.3 (d, J = 6.5 Hz), 128.9, 124.4, 124.1, 124.0, 123.9, 123.1, 117.9, 117.8, 116.1, 
115.7, 115.3, 98.7 (d, J = 4.7 Hz), 97.3, 76.4, 74.94 (d, J = 7.6 Hz), 73.6, 73.3, 71.7, 
70.7, 69.9, 69.7, 69.2, 68.8, 67.3, 64.3, 63.1, 21.2, 20.8 (d, J = 3.5 Hz), 20.6 (d, J 
= 6.1 Hz), 20.6 (d, J = 1.4 Hz).; HRMS (ESI) calcd for C41H47ClN2O20 [M+H]+: 







yl)oxy)benzylidene)acetohydrazide    (A2H12) 
The acylhydrazone was synthesised according to 
GP2 by using compound acetylated A2H12 
(27.0 mg, 0.03 mmol) in methanol (3 mL) and 
sodium methoxide (0.36 mg, 0.007 mmol). After 
purification, the acylhydrazone was obtained as 
a mixture of E and Z isomers (E:Z = 3:2) as a 
white solid (17.2 mg, 93%). 1H NMR (500 MHz, 
MeOD) δ = 8.19 (s, 1H, E), 7.93 (s, 1H, Z), 7.70 
(dd, J = 56.2, 8.8 Hz, 2H), 7.40 (ddd, J = 25.3, 
7.9, 1.6 Hz, 1H), 7.32 – 7.20 (m, 1H), 7.17 – 6.92 
(m, 4H), 5.26 (s, 1H), 5.21 (d, J = 3.7 Hz, 1H), 5.01 (dd, J = 7.7, 5.7 Hz, 1H), 4.76 
(s, 1H), 3.98 – 3.42 (m, 12H); 13C NMR (126 MHz, MeOD) δ = 171.36, 167.10, 
161.10, 160.73, 155.57, 155.00, 150.95, 146.43, 131.51, 131.34, 130.48, 129.71, 
129.30 (d, J = 5.5 Hz), 128.90, 124.43, 124.13, 124.02, 123.11, 117.85 (d, J = 7.0 
Hz), 116.09, 115.24, 102.94, 101.70 (d, J = 5.6 Hz), 80.83 (d, J = 4.9 Hz), 77.67 (d, 
J = 3.1 Hz), 76.82, 75.09, 74.85, 74.45, 74.19, 71.51, 69.18, 67.30, 62.78, 61.92; 






Figure S1. DCL-2. Dynamic combinatorial libraries of aldehyde A-2 with hydrazide 
library 1: a) UV-chromatogram at 290 nm of the blank reaction at 3 h; b) UV-















Table S1. Amplification folds of the formed products in DCL-2; analysed via the relative 
surface areas of peaks in the UV-chromatograms of the protein-templated reaction (P) and 






A2H1 9.2 0.8 
A2H2 7.8 0.9 
A2H3 7.3 0.8 
A2H4 8.7 0.8 
A2H5 5.6 0.7 
A2H6 3.8 1.5 
A2H7 4.5 1.1 
A2H8 7.3 0.8 
A1H2 8.1 16.4 
A1H8 7.4 4.4 
  
 
Figure S2. DCL-3. Dynamic combinatorial libraries of aldehyde A-1 with hydrazide 
library 2: a) UV-chromatogram at 290 nm of the blank reaction at 3 h; b) UV-
chromatogram at 290 nm of the protein-templated reaction at 6 h. Data obtained from 
single experiment. 
Table S2. Amplification folds of the formed products in DCL-3; analysed via the relative 
surface areas of peaks in the UV-chromatograms of the protein-templated reaction (P) and 






A1H9 5.9 0.8 
A1H10 10.9 0.7 
A1H11 6.5 1.2 
A1H12 8.2 2.1 
A1H13 9.2 1.1 
A1H14 9.2 1.1 
A1H15 5.4 0.8 
A1H16 7.4 1.0 
A1H17 5.4 0.8 









Figure S3. DCL-4. Dynamic combinatorial libraries of aldehyde A-2 with hydrazide 
library 2:(a) UV-chromatogram of the blank reaction at 3 h; b) UV-chromatogram of the 
protein-templated reaction at 6 h. Data obtained from single experiment. 
 
Table S3. Amplification folds of the formed products in DCL-4; analysed via the relative 
surface areas of peaks in the UV-chromatograms of the protein-templated reaction (P) and 






A2H9 5.7 1.0 
A2H10 10.6 1.0 
A2H11 6.2 1.0 
A2H12 7.9 3.2 
A2H13 8.9 0.6 
A2H14 8.9 0.6 
A2H15 - - 
A2H16 7.2 2.2 
A2H17 5.2 0.1 











Figure S4. Sensorgram of the immobilisation procedure for GTF180-ΔN on CMD500M 
sensor chip: (1) Four injections of cleaning solution, (2) activation solution, (3) GTF180-
ΔN, and (4) quenching solution. The blue, red, and magenta curves represent the left 
(active) channel, right (reference) channel, and the difference, respectively. 
 
Figure S5. Overlay of sensorgrams (black) of acarbose at concentrations of 0.8–500 µM 
running over an immobilised GTF-180. Global fitting of the association and dissociation 
curves (red). Data obtained from single experiment. 
(4) 
Surface quenching 



















Figure S6. Overlay of sensorgrams (black) of A1H2 at concentrations of 7.6–2000 µM 
running over an immobilised GTF-180. Global fitting of the association and dissociation 
curves (red). Data obtained from single experiment. 
 
Figure S7. Overlay of sensorgrams (black) of A1H8 at concentrations of 7.6–2000 µM 
running over an immobilised GTF-180. Global fitting of the association and dissociation 
curves (red). Data obtained from single experiment. 
 
Figure S8. Overlay of sensorgrams (black) of A1H12 at concentrations of 7.6–500 µM 
running over an immobilised GTF-180. Global fitting of the association and dissociation 





Figure S9. Overlay of sensorgrams (black) of A2H2 at concentrations of 7.6–1500 µM 
running over an immobilised GTF-180. Global fitting of the association and dissociation 
curves (red). Data obtained from single experiment. 
 
Figure S10. Overlay of sensorgrams (black) of A2H12 at concentrations of 7.6–1000 µM 
running over an immobilised GTF-180. Global fitting of the association and dissociation 
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The reaction scope for dynamic combinatorial chemistry (DCC) is relatively 
limited. Since special requirements for proteins have to be met in protein-
templated (pt) DCC, the reversible linker has to be biocompatible. Requirements 
like buffered aqueous media, relatively low DMSO concentrations and neutral 
pH values have therefore limited an extension of the portfolio of chemical 
reactions. In this chapter, we show the first proof of principle of ptDCC based on 
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As discussed in Chapter 1, the reaction scope for protein-templated dynamic 
combinatorial chemistry (ptDCC) is rather small (Scheme 1).[1–3] This is mostly 
due to the fact that the reaction needs to be biocompatible, performed at 
physiological pH values and most often cosolvents have to be added to guarantee 
solubility of building blocks and products. In this chapter, we describe our work 
on the first application of nitrone-based protein-templated DCC. We chose the 















5.1.1 Biochemical relevance of nitrones 
The nitrone functionality can be found in drug candidates, ranging from having 
anticancer activities (NXY-059), as antioxidant for neurodegenerative disorders 
(glycolipidic nitrone), as free radical-scavenger in the treatment of acute ischemic 
strokes (TBN), and as acidic and microbial corrosion inhibitors (Figure 1).[4–9] 
 
Scheme 1. Reversible reactions used in target-directed DCC to identify bioactive 








Figure 1. Examples of nitrone-based clinical candidates.[4,6,9] 
5.1.2 Nitrone-based DCC 
In 2005, M. Hochgürtel reported on the generation of a dynamic combinatorial 
library (DCL) using nitrone formation.[10] The patent reports on the reversible 
nitrone formation from aldehydes and hydroxylamines, reversible nitrone 
exchange between nitrone and aldehydes, reversible nitrone exchange between 
nitrone and hydroxylamines and the scrambling of nitrones. The general 
formation of DCLs was described using aliphatic hydroxylamines and aliphatic 
aldehydes, both possibly bearing chemically different substituents. Then in 2008, 
a PhD thesis by J. Sadownik illustrated the use of nitrone-based DCC for evolving 
complex systems. Nitrones were also used in reversible exchange with imines and 
the DCLs were afterwards coupled to the irreversible formation of 
cycloadducts.[11] In 2008, the Philp group published that nitrones can be formed 
reversibly in chloroform at room temperature.[12] 
Sadownik concluded in his thesis that the choice of solvent proved to be a great 
challenge. The libraries were either formed in chloroform or DCM which were 
saturated with p-toluenesulfonic acid monohydrate. An important remark was 
made that both water and acid promote the exchange, and removing them slows 
down the exchange to a great extent. Having an aqueous system would therefore 
be a benefit for the nitrone formation. Aromatic building blocks were used for the 
applied exchange reaction between nitrones and imines, in contrast to the 
aliphatic building blocks in the patent. 
We were interested if the aromatic nitrone exchange could take place in aqueous 
media at physiological pH and in a reasonable time frame (Scheme 2). We 
therefore set out to investigate the formation and reversibility of aromatic 
nitrones in a pH window of 5–8. Subsequently, we wanted to apply it for the first 
time in a protein-templated DCC experiment. 
  
 
Scheme 2. Reversible formation of nitrones based on the condensation reaction of 




5.2 Results and Discussion 
In order to prove the reversibility of nitrone formation under physiological 
conditions, we performed three experiments. The solvent of choice was a 10 mM 
ammonium acetate buffer at pH 5.0 using DMSO (v/v 5%) as a colsovent. In the 
first experiment, we showed that nitrones can be formed under the specified 






Scheme 3. Dynamic combinatorial library-N1: reversible formation of aromatic 
nitrones. 
For the analysis of the library, a sample was diluted with acetonitrile, and the pH 
was increased > 7 by the addition of NaOH. This mixture was then analysed via 
UPLC-MS/MS. The relative peak area of the ion counts of each peak was 
determined and monitored over time (Figure 1). As can be seen from Figure 1, the 
equilibrium was reached after 6.5 hours.  
 
Figure 2. Analysis of dynamic combinatorial library-N1 at pH 5.0, relative peak area of 



































To prove that the nitrones can be formed reversibly, we used the pre-synthesised 
nitrone H1A1 (20 µM) and added a hydroxylamine H2 (200 µM, Scheme 2). We 
then monitored, via LC-MS, for the decrease in concentration of H1A1 and the 
increase in concentration of H2A1 (Figure 3). 
 










Figure 3. Analysis of dynamic combinatorial library-N2 at pH 5.0, relative peak area of 
each product over time. Data obtained from single experiment. 
Over time, the concentration of H2A1 is lowered, as H1A1 is being formed. The 
concentrations of both products have not reached equilibrium yet, as can be seen 
from Figure 3. However, the formation of H2A1 indicates that the nitrone linkage 
is indeed able to be broken and formed again. This shows that the system is 
reversible, when hydroxylamines like H2 are added to pre-formed nitrones.  
In the next experiment, DCL-N3, we showed the reversibility of the nitrone H1A1 
(20 µM) in presence of aldehyde A2 (200 µM, Scheme 5). For the nitrone H1A2 
being formed, the pre-synthesised nitrone H1A1 must first undergo hydrolysis to 


















































Figure 4. Analysis of dynamic combinatorial library-N3 at pH 5.0, relative peak area of 
each product over time. Data obtained from single experiment. 
Just like in DCL-N2, equilibrium was not reached after 2 days. However, the 
formation of H1A2 clearly shows that reversibility of the nitrone linkage is 
possible through a hydrolysis mechanism. 
5.2.1 pH window 
Most proteins have a pH optimum around 7.4, for this reason we set out to 
determine the pH window of the nitrone-exchange reaction. To investigate if the 
nitrone-exchange reaction could be applied on a wide range of protein targets. 
Therefore, we made buffer solutions of pH 5.5 (10 mM sodium acetate), 6.0, 6.5, 
7.0, 7.5 and 8.0 (10 mM potassium acetate). We repeated the libraries N1, N2 and 
N3 with the different pH values, and took samples up to three days (see 
supporting information).  
In DCL-N1, we could observe product formation from the individual building 
blocks up to pH 6.5. However, no product was observed at pH 7.0, 7.5 and 8.0. 





































concentrations did not change significantly. To test if the library mixture would 
be stable under the analytical conditions, acetonitrile and pH > 7, we re-analysed 
the sample at pH 5.5 after 24 hours in the LC-MS vial. Previously observed strong 
signals of nitrones H1A1 and H1A2 in the fresh samples were not observed after 
24 h. This indicates that samples need to be measured directly after being taken, 
and cannot be left for longer time periods in acetonitrile and pH > 7. 
In DCL-N2, we observed the formation of nitrone H2A1 at all pH values. 
Indicating that the reaction is reversible when sufficient amount of nucleophile is 
present.  
In DCl-N3, the formation of nitrone H1A2 was observed for pH values up to 5.5. 
At pH 6.0, hardly any H1A2 could be detected. At pH 6.5 and higher, only nitrone 
H1A1 could be detected, as this was added as a pre-synthesised product. The 
reversibility of the nitrone by an aldehyde was therefore limited to a maximum 
pH 5.5 – 6.0. However, this opens up the possibility of `freezing` the reaction 
when the aldehydes are used in excess, by adjusting the pH to > 7. An important 
observation from DCL-N3 is that nitrone H1A1 seems to be stable against 
hydrolysis from pH 6.5 – 8.0. Therefore, ‘freezing’ the reaction by an increase in 
pH will most likely not change the library composition. The stability problem in 
the LC-MS vial, observed in DCL-N1, must therefore be related to acetonitrile and 
not to the pH. 
5.2.2 protein-templated DCC 
We then performed a protein-templated DCC, using the aspartic protease 
endothiapepsin as a model enzyme. The library consisted of three 
hydroxylamines (H1–H3, 20 µM each) and five aldehydes (A1–A5, 200 µM 
each). In the blank reaction, only DMSO was added to reach v/v 5%. In the 
templated reaction, also 5% DMSO was used, and endothiapepsin (100 µM) was 
added (Scheme 6). Both reactions were monitored via UPLC-MS over time. 
Again, the mass of each product was selected, and the corresponding peak area of 
the ion counts was obtained. Relative peak areas where calculated by dividing the 
ion counts of each product by the sum of the ion counts of all products, and 
multiplied by 100%. The relative peak areas where used to compare products in 
the protein sample to the blank sample, yielding the corresponding amplification 










Scheme 6. Dynamic combinatorial library-N4: building blocks for the libraries in 
presence and absence of the protein endothiapepsin. 
 
Figure 5. Amplification folds of products over time of DCL-N4: product’s relative peak 
area of the sample with protein divided by the relative peak area in the blank reaction. 
Data obtained from single experiment. 
Almost all compounds in DCL-4 showed a similar fold of amplification at day 1 as 
at day 2. We have therefore not taken samples after 2 days. In Figure 5, we have 
removed outliers for clarity reasons. The amplification fold of H1A3 fluctuates 
too much, which might be due to the instability of the compound. H1A4 and 
H2A3 have exactly the same mass and the same retention time. Their 
amplification folds fluctuate too much, which might also be due the instability of 
the compounds. In general, it is important to monitor the stability of the 
































that products H2A2 and H2A4 are hardly or not formed in the blank, but they 
are formed in the protein sample. For these products, no amplification can be 
calculated. Determining hit compounds only from amplification folds would have 
therefore overlooked these two compounds. They should, however, be considered 
as hits, since the only difference between both libraries is the absence/ presence 
of protein. 
5.2.3 Cytotoxicity assay 
We were interested to see if the hit compounds (H1A1, H2A2, H2A4) as well as 
the hydroxylamines (H1—H3) would show toxicity against a human cell line. A 
cytotoxicity assay, in which the viable cell mass is determined via OD 
measurements, would be sufficient for a first screening. We chose the HepG2 cell 
line, and determined the growth inhibition by the compounds at 100 µM each. 
None of these compounds showed inhibition of the growth. Therefore, none are 
cytotoxic. This preliminary result is in line with the fact that nitrones were already 
used in clinical studies.  
5.2.4 Endothiapepsin activity assay 
The same compounds as in the cytotoxicity were evaluated for their activity on 
the protein target, endothiapepsin. As a positive control we used saquinavir 
(supporting information, Figure S15). We considered H1A1 as a negative control, 
since the amplification fold in DCL-4 is 1. The two hits of DCL-4, H2A2 and 
H2A4, have moderate inhibition values, where H1A1 indeed is having a lesser 
effect (Figure 6). Hydroxylamines H1 – H3 show weak inhibition of 










Figure 6. Endothiapepsin activity assay: showing that H1A1, H2A2 and H2A4 are 































Based on the work of Hochgürtel and Sadownik, we extended the DCC of nitrones 
to a protein-templated setting. First, we showed that the nitrone reaction can take 
place in aqueous environment, with DMSO as co-solvent. Next, we determined 
the pH-range where nitrone formation is still reversible. Under slightly acidic 
conditions, ammonium acetate buffer (10 mM, pH 5.0), the equilibrium was 
reached within one day. We applied these conditions to ptDCC where 
endothiapepsin, an aspartic protease, was used as protein target. From this 
library, we obtained two hit compounds, which we then synthesised and analysed 
for their biochemical activities. The hit compounds, as well as the hydroxylamine 
building blocks, showed no toxicity at 100 µM on HepG2 cells. This founding is in 
line with the fact that nitrones are being used in clinical studies. From the activity 
assay we showed that H1A1, as negative control, hardly has any inhibitory effect. 
The two hit compounds, H2A2 and H2A4, show moderate inhibitory activity. 
This finding is in line with the outcome of DCC experiment DCL-4. The 
hydroxylamines H1 – H3 showed similar weak activities as H1A1, indicating that 
the activity of the hit compounds are authentic. The work described herein, allows 
the medicinal chemist to choose from one more reversible linkage, when planning 
to apply DCC in drug-discovery processes.   
5.4 Experimental 
5.4.1 Materials and methods 
See section 3.4.1. 
5.4.2 DCC conditions 
The corresponding hydroxylamines (each 0.2 μL, stock solution 100 mM in 
DMSO) and the aldehydes (each 2.0 μL, stock solution 100 mM in DMSO) were 
added to an ammonium acetate buffer (10 mM, pH 5.0). Endothiapepsin (169.2 
µL, stock solution 0.591 mM) was added in the protein samples.  DMSO was added 
to reach a final concentration of DMSO in the DCLs of 5%. The end-volume was 
1 mL. Final concentrations in the DCLs are shown in Table 2. The DCL was left 
shaking at room temperature and was frequently monitored via UPLC-MS.  
Table 2. Final concentrations in the DCLs. 
 Endothiapepsin Blank 
DMSO 5% 5% 
Aniline 10 mM 10 mM 
Aldehyde 200 µM (each) 200 µM (each) 
Hydroxylamine 20 µM (each) 20 µM (each) 





For monitoring via UPLC-MS, 10 μL of the corresponding library was diluted in 
89 µL acetonitrile, the pH was raised to pH > 7 by adding NaOH (1 µL, 1 M) to 
freeze the reaction. The mixture was centrifuged at 10,000 rpm for 2 minutes, 
and the supernatant was analysed via UPLC-MS. 
5.4.3 Cytotoxicity assay; determination of viable cell mass 
HepG2 cells (2 x 105 cells per well) were seeded in 24-well, flat-bottomed plates. 
Culturing of cells, incubation and OD measurement were performed as described 
previously with small modifications.[13] Twenty-four hours after seeding the cells, 
the incubation was started by the addition of compounds in a final DMSO 
concentration of 1%. The living cell mass was determined after 48 hours in a 
PHERAstar microplate reader (BMG labtech, Ortenberg, Germany). Two 
independent measurements were performed for each compound. 
5.4.4 Fluorescence-based Endothiapepsin inhibition assay 
Endothiapepsin was purified as described recently.[14] Stock solutions were 
prepared for all compounds (10 mM DMSO). The final reaction volume was 
200 μL containing 0.8 nM endothiapepsin, 1.8 µM substrate (Abz-Thr-Ile-Nle-p-
nitro-Phe-Gln-Arg-NH₂ trifluoroacetate salt) (Bachem, Bubendorf, Switzerland) 
and 5% DMSO. The final concentration of inhibitors was between 0.1 and 
200 µM. The assay was performed in flat bottom 96-well microplates (Greiner 
Bio-One, Frickenhausen, Germany) using a CLARIOstar microplate reader (BMG 
Labtech, Ortenberg, Germany) at an excitation wavelength of 337 nm and an 
emission wavelength of 414 nm. The assay buffer (0.1 M sodium acetate buffer, 
pH 4.6, containing 0.001% Tween 20) was premixed with the substrate and 
inhibitor; endothiapepsin was added directly before the measurement. The 
reaction was performed at 25 °C for 20 min and accompanied by detection of the 
fluorescence signal once per min. The resulting slopes were related to a DMSO 
control yielding % inhibition values. Each compound was measured at least at 
two different occasions. The final result represents the average of these 
measurements. IC50 values were calculated by using the software OriginPro 2017 
(OriginLab Corporation, Northampton, MA). 
5.4.5 Synthesis 
General procedure for hydroxylamine formation GP1:  
To a rapidly stirred mixture of ammonium chloride (1.2 eq.) and an aryl-nitro 
compound (1 eq.) in H2O/ EtOH (2:5), was zinc dust (3 eq.) added portion-wise. 
The reaction mixture was stirred for one hour at room temperature before 
filtering through a pad of celite with warm water. After cooling to room 
temperature, the mixture was extracted using Et2O (3 x 10 mL), the organic 




the solvent in vacuo, the hydroxylamine was obtained as a crystalline solid in 59 
— 94% yield.[15] 
General procedure for nitrone formation GP2:  
Nitrone (1 eq.) and aldehyde (1 eq.) were dissolved in minimal amount of EtOH 
in a brown-coloured glass-vial. The mixture was stirred at room temperature for 
16 hours. The solvent was removed in vacuo, and the product was washed with 
ice-cold EtOH and purified using column chromatography if needed (DCM/ 
EtOac 1:0 → 0:1).[15] 
N-Phenylhydroxylamine (H1)  
The hydroxylamine was synthesised at room temperature 
following the general procedure GP1, using nitrobenzene (61.6 mg, 
0.5 mmol) in H2O/ EtOH (2:5, 2.5 mL), zinc dust (98 mg, 
1.5 mmol) and ammonium chloride (32 mg, 0.6 mmol). The hydroxylamine H1 
was obtained as a white, crystalline solid (32.1 mg, 59%). 1H-NMR (500 MHz, 
DMSO-d6) δ= 8.27 (s, 1H), 8.23 (s, 1H), 7.15 (t, J = 7.9 Hz, 2H), 6.82 (d, J = 7.9 
Hz, 2H), 6.73 (t, J = 7.9 Hz, 1H). 13C-NMR (126 MHz, DMSO-d6) δ= 152.1, 128.4, 
119.2, 112.9. NMR data were in accordance with those from the literature.[15] 
N-(4-Bromophenyl)hydroxylamine (H2)  
The hydroxylamine was synthesised following the general 
procedure GP1, using 1-bromo-4-nitrobenzene (101 mg, 
0.5 mmol) in H2O/ EtOH (2:5, 2.5 mL), zinc dust (98 mg, 
1,5 mmol) and ammonium chloride (32 mg, 0.6 mmol). The 
hydroxylamine H2 was obtained as a lightbrown, crystalline solid (88.6 mg, 
94%). 1H-NMR (500 MHz, DMSO-d6) δ= 8.43 (s, 1H), 8.41 (s, 1H), 7.30 (d, J = 
8.0 Hz, 2H), 6.77 (d, J = 8.0 Hz, 2H). 13C-NMR (126 MHz, DMSO-d6) δ= 151.4, 
131.1, 114.8, 110.0. NMR data were in accordance with those from the literature. 
[16] 
N-(2,6-Dimethylphenyl)hydroxylamine (H3)  
The hydroxylamine was synthesised following the general 
procedure GP1, using 1,3-dimethyl-2-nitrobenzene (75.6 mg, 
0.5 mmol) in H2O/ EtOH (2:5, 2.5 mL), zinc dust (98 mg, 
1.5 mmol) and ammonium chloride (32 mg, 0.6 mmol). The 
hydroxylamine H3 was obtained as an off-white, crystalline solid (88.6 mg, 94%). 
1H-NMR (500 MHz, DMSO-d6) δ= 8.07 (s, 1H), 7.15 (s, 1H), 6.92 (d, J = 7.4 Hz, 




130.51, 128.24, 123.63, 18.19. NMR data were in accordance with those from the 
literature.[17] 
(Z)-N,1-Diphenylmethanimine oxide (H1A1)  
The nitrone H1A1 was synthesised, using H1 (10 mg, 0.09 
mmol) and benzaldehyde (9.8 µL, 0.09 mmol), following the 
general procedure GP2. 1H-NMR (500 MHz, CDCl3) δ= 8.42 – 
8.39 (m, 2H), 7.93 (s, 1H), 7.81 – 7.76 (m, 2H), 7.49 (m, 6H). 
13C-NMR (126 MHz, CDCl3) δ= 149.2, 135.0, 131.2, 130.8, 
130.1, 129.4, 129.3, 128.8, 122.0. HRMS (ESI) calcd for C13H11NO [M+H]+: 
198.0913, found 198.0900. NMR data were in accordance with those from the 
literature.[15] 
(Z)-N-(4-Bromophenyl)-1-(3-(trifluoromethyl)phenyl)methanimine 
oxide (H2A2)  
The nitrone H2A2 was synthesised, using H2 (15.0 mg, 
0.08 mmol) and 3-(trifluoromethyl)benzaldehyde 
(10.7 µL, 0.08 mmol) following the general procedure 
GP2. After purification by column chromatography, the 
product H2A2 was obtained as a white semi-solid (20.1 mg, 73%). 1H-NMR (500 
MHz, CDCl3) δ = 8.70 (s, 1H), 8.55 (d, J = 8.0 Hz, 1H), 7.98 (s, 1H), 7.74 – 7.58 
(m, 6H). 13C-NMR (126 MHz, CDCl3) δ = 147.8, 133.9, 132.6, 131.9, 131.5, 131.2, 
129.4, 127.6 (q, J=3.6), 125.7 (q, J=3.9), 125.0, 124.5, 123.3. HRMS (ESI) calcd 
for C14H10BrF3NO [M+H]+: 343.9892, found 343.9868. 
(Z)-N-(4-Bromophenyl)-1-(6-bromopyridin-3-yl)methanimine oxide 
(H2A4)  
The nitrone H2A4 was synthesised at room temperature 
using H2 (15.0 mg, 0.08 mmol) and 6-bromo-3-
pyridinecarboxaldehyde (14,8 mg, 0.08 mmol) following 
the general procedure GP2. After purification by column 
chromatography, the product H2A4 was obtained as an off-white solid (20.4 mg, 
72%). 1H-NMR (500 MHz, CDCl3) δ = 8.99 (dd, J = 8.5, 2.3 Hz, 1H), 8.89 (d, 
J=2.3, 1H), 7.94 (s, 1H), 7.69 – 7.58 (m, 5H). 13C-NMR (126 MHz, CDCl3) δ = 150. 
6, 147.5, 143.5, 137.0, 132.6, 130.5, 128.4, 126.4, 124.8, 123.2. HRMS (ESI) calcd 
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5.6 Supporting information  
DCL-N1 pH range: 
 
Scheme S1. DCL-N1, pH window, 20 µM H1, 200 µM A1 and A2. 
 








































































































Figure S4. Dynamic combinatorial library-1 at pH 6.5. Data obtained from single 
experiment. 
 
DCL-N2 pH range: 
 
































































































































































































































































Figure S11. Dynamic combinatorial library-2 at pH 8.0. Data obtained from single 
experiment. 
 
DCL-N3 pH range: 
 


















































































































































Figure S15. Endothiapepsin activity assay, using saquinavir as positive control. Data 
points are the average of two independent measurements, and standard deviation is given 
as error bars. 
 
Figure S16. Endothiapepsin activity assay, using hydroxylamines H1 – H3. Partial 























































Expanding the reaction scope for dynamic combinatorial chemistry (DCC) is 
necessary to further improve the applicability of DCC on protein targets, 
allowing the medicinal chemist to choose from a diverse set of reversible 
reactions. In this chapter, we implement the reversible thiazolidine formation 
for the first time in a protein-templated (pt) DCC setting, using endothiapepsin 
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In 1936, it was proposed that the thiazolidine motif could be of biological interest, 
due to its reversible formation and dissociation in neutral aqueous solution at 
room temperature. The thiazolidine motif can be found in natural compounds as 
well as in drug molecules, and it offers the possibility for multiple interactions in 
ligand–target binding. In 2009, it was shown that thiazolidines could be used in 
dynamic combinatorial chemistry (DCC). However, the application on a target 
was not yet published. In this present work, we present the application of protein-
templated DCC based on this promising scaffold, using endothiapepsin as a target 
protein. Afterwards, the hit compound was analysed for its biochemical 
properties. 
Dynamic combinatorial chemistry (DCC) has evolved into an ever more 
important technique to identify bioactive molecules.[1–10] Proteins, DNA and also 
RNA have been used in target-directed (td) DCC and it can be expected that the 
applicability of DCC will be expanded even further in the future.[6,11–18] Multiple 
reviews and book chapters on DCC have been written[19–21] and recently we 
published a minireview on protein-templated (pt) DCC, giving a brief overview 
and an experimental protocol (see Introduction chapter 1) .[22] The most 
commonly used reaction in DCC is based on acylhydrazone formation (see 
Chapters 3 and 4). This requires hydrazide and aldehyde building blocks which 
form acylhydrazones in a reversible manner. Upon addition of an external 
stimulus, for example a protein, the formation towards one or more favourable 
products can be templated. Other reactions used in DCC so far are based on 
alkene cross metathesis, (boronate) ester-, imine-, hemithioacetal-, disulfide- 
and thioether formation.[17,18,23–29] This limited scope needs to be extended by 
identifying other reversible reactions, which can take place in an aqueous 
environment. Ideally, the type of reaction scaffold would contribute to binding of 
the ligand to the target. An interesting scaffold, which can be found in natural 
products as well as in drugs is the thiazolidine motif. This five-membered 
heterocycle carries a thioether, an amine and can be reversibly formed by 
condensation of an aminothiol with an aldehyde (Scheme 1). 
 
Scheme 1. Reversible thiazolidine formation by the reaction of an aldehyde and an 
aminothiol.  
A few examples of thiazolidine derivatives in different molecules are given in 




Levamisole[31] and Rosiglitazone (Avandia) and Pioglitazone (Actos), which are 
both antidiabetic drugs[32]. 
  
Figure 2. Example of natural compounds and drugs with a thiazolidine-like scaffold. 
The structural motif of 2-arylthiazolidine-4-carboxylic acids was found as a class 
of cytotoxic agents for the treatment of prostate or ovarian cancer. Gududuru et 
al. first introduced a 4-thiazolidinone moiety as a phosphate mimic and then 
optimised it to 2-arylthiazolidine-4-carboxylic acid amides (Figure 2).[33] 
 
Figure 3. Thiazolidine motifs in a class of cytotoxic agents for prostate cancer.[33] 
Although thiazolidines are a common motif in drugs and natural products, they 
have not been used in protein-templated DCC (ptDCC) until now. A lot of 
interesting properties make them a promising scaffold for ptDCC. First of all, the 
nitrogen atom is the only non-metal atom which, by protonation, carries a 
positive charge at physiological pH. Furthermore, the nitrogen atom is able to 
contribute to a lot of different supramolecular interactions: free electrons are able 
to make electrostatic interaction, cations can interact with π-systems and the 
protons which are bound to the nitrogen can act as H-bond donors. Sulfur atoms, 
on the other hand, have low-energy σ* orbitals, also called σ-hole.[34] It gives 
bivalent sulfur atoms the possibility to interact with electron donors like 




aromatic ring by a sulfur-containing heterocycle leads to a new substituent 
trajectory which can be used to optimise the fitting of ligands into a protein 
binding pocket. Taken together, these properties could lead to a new interesting 
scaffold for protein-templated DCC. 
Already in 1936, the first work on thiazolidines was published by Schubert, 
namely the condenstioncysteine was condensed with various aldehydes. It was 
mentioned that due to their reversible formation and dissociation in neutral 
aqueous solution at room temperature, that these structures are of biochemical 
interest.[35] One year later it was shown that not only aldehydes, but also ketones 
can be used.[36] Then in 2009, Mahler and coworkers applied thiazolidines for the 
first time in a DCC experiment. Optimal pH values and temperatures were 
determined for the formation, equilibration and also for the exchange reaction 
between different products and building blocks. It was found that building blocks 
(1 mM) in an acetate buffer at pH 4–5 at room temperature reach equilibrium 
within two days. Methanol was used as cosolvent (acetate buffer / methanol, 2:1). 
To be able to analyse the dynamic combinatorial library (DCL), the pH was 
increased to 7 by the addition of NaHCO3. This `freezes` the equilibrium by 
blocking its reversibility.[37]  
In this work, we present the first application of ptDCC based on thiazolidines. 
Instead of using methanol as a cosolvent, which might not be tolerated by the 
protein, we chose to use DMSO in a final concentration of 5%. This allows the 
building blocks to stay solubilised. Our protein of interest is endothiapepsin, 
which is a member of the family of pepsin-like aspartic proteases. Aspartic 
proteases are involved in numerous biological processes; maturation of the HIV 
virus particle, implication in tumorigenesis by cathepsin D and they are involved 
in malaria, amyloid disease and other diseases.[38] We have used endothiapepsin 
as a model enzyme in DCC before, which was based on acylhydrazone formation. 
We showed that endothiapepsin is stable at pH 4.5 at room temperature for more 
than 20 days.[25,39,40] These conditions fit well with the conditions reported by 
Mahler and coworkers, which gave us an optimal starting point.  
6.2 Results and Discussion 
6.2.1 Design of the libraries.  
The group of Mahler used L-cysteine ethyl ester and a variety of aldehydes to form 
their libraries, so we decided to follow their approach and applied this for the first 
time on a protein target. We designed dynamic combinatorial library-1 (DCL-1) 





Scheme 2. Design of dynamic combinatorial library-1. Final concentration of aldehydes 
and aminothiols, 100 µM each; endothiapepsin, 10 µM; TCEP, 1.0 mM.  
With the knowledge that, under the applied conditions, the equilibrium would be 
reached within two days, we took samples at 4 and 8 hours and 1 and 2 days. Each 
product’s mass was extracted from the chromatogram, and the resulting peak was 
integrated. The relative peak area was then compared between the samples in 
presence and in absence of protein. As can be seen from Figure 4, the equilibrium 
was reached around 1 day since no change was observed after this time point. 
Interestingly, the amplification folds of products with the aromatic aldehydes and 
L-cysteine ethyl ester (T1) decrease and an increase in these products with the 
same aromatic aldehydes with L-cysteine (T3) is observed. As an aspartic 
protease, endothiapepsin is also able to cleave esters. This is most likely the 
reason why an increase in concentration of compounds with L-cysteine (T3) is 
observed in the protein sample. Cysteamine (T2) products on the other hand 
cannot be hydrolysed, and accordingly no change in amplification fold was 
observed.  
It must be noted that the concentrations of nearly all compounds decreased after 
8 hours. This was seen in the blank as well as in the protein sample. Crashing out 
of the compounds could lead to this effect, however, no precipitation was 
observed (the solutions remained clear over time). Another explanation for a 
decrease in concentration could be the formation of disulfides, which would 
influence the equilibrium by taking away the thiolamine building blocks. 
However, hardly any disulfides were observed, presumably owing to the presence 
of tris(2-carboxylethyl)phosphine (TCEP). TCEP is a mild reducing agent, which 
is most commonly used in biochemistry for the selective cleavage of disulfide-





It starts with the nucleophilic attack by the phosphorus atom on one of the sulfur 
atoms.[42] The resulting thiolate is protonated and hydrolysis of the phosphonium 
cation leads to the phosphine oxide. Only the last step of the reaction is 
irreversible because of the high stability of the phosphorus-oxygen bond. The 
reducing agent can therefore not be regenerated, and sequential addition should 
provide the system with a constant reducing power. 
 
Figure 4. Amplification folds for the products of the dynamic combinatorial library-1. 

























































































































Based on the observation that the ethyl ester functionality was cleaved during the 
reaction conditions, we designed a second library in which we omitted the ethyl 
ester (Scheme 4). All products could be observed, except thiazolidines resulting 
from aldehyde A13. This 2-methylindole-3-carboxaldehyde might be sterically 
hindering thiazolidine formation due to its 2-methyl group. Dynamic 
combinatorial library 2 was analysed at 7 hours, 1 day and 2 days. The equilibrium 
was most probably reached at around 1 day, the relative peak areas of the 
products do not change too much anymore (supporting information, Figure S1). 
The amplification folds of all products between day 1 and day 2 is approaching 
towards the value 1, indicating no significant difference between the protein and 
the blank sample (supporting information, Figure S2). The amplification of 
compound T3A2 seems again to be the most, as was also observed in DCL-1. The 
amplification in DCL-2 is much less than in DCL-1, indicating that indeed in DCL-
1 the hydrolysis of the ethyl ester was the major contributor to the amplification 
of T3A2. Even though the amplification of T3A2 was much smaller in DCL-2, we 








Scheme 4. Design of dynamic combinatorial library-2. 
6.3 Cytotoxicity assay 
We were interested to see if hit compound T3A2, which was amplified in DCL-1 
and DCL-2, would show toxicity against a human cell line. For this test, we chose 
the HepG2 cell line, which is the same as in section 5.2.3. This compound does 




6.4 Biochemical evaluation of hit T3A2 via a 
fluorescence-based inhibition assay 
The product T3A2 was evaluated for its inhibitory activity against 
endothiapepsin. The product T3A2 is a very weak inhibitor, having only 14% 
inhibition at 500 µM (Figure 4). This finding is in line with DCL-2, where this 
product was present but not amplified. 
 
Figure 5. Endothiapepsin activity assay showing that T3A2 is a very weak inhibitor. Data 
obtained from single experiment. 
6.5 Expanding the reaction scope to aromatic 
aminothiols 
We wanted to see if the thiazolidine reaction scope could be expanded to products 
which are based on aromatic aminothiols (T5—T7) (Scheme 5). After analysing 
the library, we predominately found the oxidised products, which have a 
conjugated aromatic system. Unfortunately, this makes the reaction irreversible 




































Scheme 5. Initial library resulting in the formation of oxidised products. 
6.6 Conclusions 
From the first two libraries, it can be concluded that thiazolidine formation can 
be applied under the present conditions. Changing from 33% methanol, in the 
work of Mahler, to 5% DMSO allowed us to apply this reaction in a ptDCC setting. 
We illustrated the use of reversible thiazolidine formation with L-cysteine 
derivatives in presence of endothiapepsin, as a protein target. Since 
endothiapepsin belongs to the aspartic protease family, it can cleave peptides as 
well as esters, which we observed in DCL-1. Cleavage of the ester in T1A2 resulted 
in T3A2, which was therefore amplified. By omitting the ester functionality we 
were hoping to see an amplification of one of the products. Unfortunately, no 
significant amplification was observed between the blank and the protein sample. 
Biochemical evaluation of T3A2 showed that it has very weak inhibitory activity 
of endothiapepsin. Therefore, this amplified product of DCL-1 is not a real hit, 
which was also seen in DCL-2, where no product was amplified. The work 
described herein shows that 2-arylthiazolidine-4-carboxylic acids and 2-
arylthiazolidine-4-esters can be used in a ptDCC setting. This work paves the way 
to apply ptDCC on real drug targets as for example in the work of Gududuru et 
al.. These target would be very appropriate since already the activity of these 




As a second part of this work, we tried to expand the reaction scope towards 
aromatic aminothiols. However, this proved unsuccessful. These products oxidise 
rapidly, which makes the reaction irreversible and therefore incompatible for 
DCC. However, when such scaffolds are desired, then the formation of such 
diverse static libraries might still be of interest. MS-binding assays as performed 
by Wanner and coworkers might be a good approach to distinguish binders from 
non-binders.[44,45]  
6.7 Experimental 
6.7.1 Materials and methods 
See section 3.4.1. 
For high-resolution mass spectroscopy, a ThermoScientific Accucore Phenyl 
Hexyl column, 100 x 2.1 mm, was used for separation under the same conditions 
as described before.  
6.7.2 DCC conditions 
The corresponding cysteine derivatives (T1 – T3, each 1 μL, stock solution 
100 mM in DMSO) and the aldehydes (each 1.0 μL, stock solution 100 mM in 
DMSO) were added to an ammonium acetate buffer (100 mM, pH 4.6). 
Endothiapepsin (169.2 µL, stock solution 0.591 mM) was added accordingly.  
DMSO was added to reach a final concentration of DMSO in the DCL of 5%. TCEP 
was added as a disulfide reducing agent (10 µL, 100 mM in DMSO). The end-
volume was 1 mL. Final concentrations in the DCLs are shown in Table 1. The 
DCL was left shaking at room temperature and was frequently monitored via 
UPLC-MS.  
Table 6. Final concentrations in the DCLs. 
 Endothiapepsin Blank 
DMSO 5% 5% 
Cysteine derivatives 100 µM (each) 100 µM (each) 
Aldehyde 100 µM (each) 100 µM (each) 
TCEP 1 mM 1 mM 
Protein 100 µM - 
 
For monitoring via UPLC-MS, 10 μL of the corresponding library was diluted in 
89 µL acetonitrile, the pH was raised to pH > 7 by adding NaOH (1 µL, 1.0 M) to 
freeze the reaction. The mixture was centrifuged at 10,000 rpm for 2 minutes, 




6.7.3 Cytotoxicity assay; determination of viable cell mass 
See section 5.4.3.  
6.7.4 Fluorescence-based endothiapepsin inhibition assay 
See section 5.4.4. 
6.7.5 Synthesis 
(4R)-2-(Pyridin-3-yl)thiazolidine-4-carboxylic acid (T3A2)  
L-Cysteine (1.5 mmol, 181.7 mg) was dissolved in 1 mL distilled 
water and to this a solution of nicotinaldehyde (1.0 mmol, 94 µL) in 
1 mL EtOH and 0.5 mL EtOAc was added dropwise. The mixture 
was stirred over night at room temperature. Excess L-cysteine 
remained as solid in the flask and only the supernatant was taken 
up by pipette. The product was dried in vacuo, and afterwards 
washed with ice-cold water. Remaining solvent was evaporated in 
vacuo to obtain thiazolidine T3A2 as a white, crystalline solid (60 mg, 29%) 
1H-NMR (500 MHz, DMSO-d6) δ = 8.68 (d, J = 2.0 Hz, 0.5H), 8.62 (d, J = 2.1 
Hz, 0.5H), 8.52 (dd, J = 4.8, 1.6 Hz, 0.5H), 8.47 (dd, J = 4.7, 1.5 Hz, 0.5H), 7.98 
(dt, J = 7.9, 1.8 Hz, 0.5H), 7.84 (dt, J = 7.9, 1.8 Hz, 0.5H), 7.40 (dd, J = 7.9, 4.8 
Hz, 0.5H), 7.37 (dd, J = 7.9, 4.8 Hz, 0.5H), 5.74 (s, 0.5H), 5.55 (s, 0.5H), 4.20 (dd, 
J = 6.9, 4.9 Hz, 0.5H), 3.92 (dd, J = 8.9, 6.9 Hz, 0.5H), 3.40 – 3.28 (m, 1H), 3.17 
– 3.06 (m, 1H) HRMS (ESI) calcd for C9H10N2O2S [M+H]+:211.0536, found 
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Figure S1. Dynamic combinatorial library-2: relative peak area of the ion counts of each 











Figure S2. Dynamic combinatorial library-2: amplification fold (P/B); ion counts of 
individual relative peaks in the protein sample were divided by the relative peaks of the 













































































































































































































































7.1 Context and scope of this thesis 
Applying dynamic combinatorial chemistry (DCC) to medicinal chemistry 
projects can be a helpful strategy for finding starting points in the drug-discovery 
process. Especially, when information of the target is known, structure-based or 
fragment-based drug design approaches combined with DCC could lead to potent 
compounds. As a first aim of this thesis, we have applied DCC on a number of 
biologically relevant targets, Chapters 3 and 4. 
As relevant drug target, 14-3-3 proteins play a role in several diseases and many 
biological processes. Proteins of this family engage in protein-protein 
interactions (PPIs), and can do so with numerous different binding partners. By 
forming these PPIs, these proteins regulate their binding partner’s activity. The 
activity can be both up- or down-regulated.  
Another family of relevant targets are glucansucrases, which are important 
enzymes in the initiation and development of cariogenic dental biofilms, 
commonly known as dental plaque. Inhibiting these enzymes might therefore 
prevent dental caries. 
The second aim of this thesis was to extend the list of reversible reactions 
applicable in a tdDCC setting. We have shown in Chapters 5 and 6 that nitrones 
and thiazolidines could be applied in DCC under physiological conditions. Based 
on this finding, we ran ptDCC experiments using these reversible linkages with 
endothiapepsin as a target protein. An important aspect in DCC is the stability of 
compounds, as noted for the nitrones and thiazolidines. Dynamic combinatorial 
libraries (DCLs) of these types of linkages should therefore be carefully 
monitored. Another important aspect in DCC is the analysis of the DCLs, which 
is best performed by determining the surface area under each peak in the UV 
chromatogram of the LC-MS. For the libraries in Chapters 5 and 6, analysis via 
UV was not possible, as most products were not UV-active under the screened 
wavelengths. We therefore analysed these libraries using the total ion counts of 
each product. To avoid possible problems of ionisation efficiency and the 
injection volume, which can deviate per run, we have taken the relative ion 
counts. This gives the ratio of products as a percentage, which allows the 
comparison of the libraries even when factors like injection volume or the 
ionisation might not be identical per run. One could consider adding an internal 
standard, which allows for a quantitative analysis. 
In the last two chapters, endothiapepsin was used for protein-templated DCC 
(ptDCC). Endothiapepsin belongs to the family of the aspartic proteases. Aspartic 
proteases are involved in numerous biological processes and diseases, for 




Throughout this thesis, we focus on applying DCC to various projects. The main 
achievements are: 1) the description of the in-house protocol of DCC, in which 
aspects like solubility of building blocks and products, protein stability and more 
need to be taken in to account, 2) the application of acylhydrazone-based DCC to 
two attractive targets, a (PPI)-target and a glucansucrase, 3) the identification of 
small-molecules, which stabilise PPIs of 14-3-3/ synaptopodin, 4) expanding the 
reaction toolbox of ptDCC by two additional reactions: nitrone and thiazolidine 
formation. 
Here, we summarise the main results reported in this thesis and we give an 
outlook on DCC for medicinal chemistry projects. 
7.2 Summary 
In Chapter 1, provides a clear and concise description of a comprehensive DCC 
protocol. This work focused on important aspects concerning the practical 
handling in ptDCC. The best biological and chemical conditions should be 
harmoniously combined for successful application in ptDCC. Moreover, 
analytical techniques used to determine which compounds are favoured were 
briefly discussed. 
In Chapter 2, we present an overview of modulators of 14-3-3 proteins. We 
critically analysed the known modulators in terms of their structures and 
molecular recognition by 14-3-3 proteins. We proposed small modifications of 
certain modulators, based on reported cocrystal structures.  
In Chapter 3, we describe the identification of modulators of 14-3-3 PPIs via 
DCC. We targeted a PPI-complex of 14-3-3(ζ) with synaptopodin, a 21 amino acid 
peptide chain. Hit compounds of the DCC experiments were analysed for their 
biochemical activities via surface plasmon resonance (SPR). These compounds 
show a stabilising effect on the PPI-complex. Co-crystallisation studies are 
ongoing to confirm the binding mode, setting the stage for SBDD to optimise the 
affinity.   
In Chapter 4, we applied acylhydrazone-based DCC on a glucansucrase. 
Glucansucrases play an important role in cariogenic dental biofilms, which are 
causative for dental caries. Glucansucrase inhibitors should therefore prevent 
caries and may be added as additives in toothpaste. We described the syntheses, 
DCC experiments as well as biochemical characterisation of the hit compounds.  
In Chapter 5, we describe the first application of nitrone-based ptDCC. We 
optimised conditions for ptDCC, keeping in mind both the target protein 
endothiapepsin as well as the applicability of the nitrone reaction. Besides the 




reaction. Synthesis of hit compounds from the DCC experiments enabled 
evaluation of their biochemical activity in a fluorescence-based activity assay. 
Preliminary results on the cytotoxicity of the nitrone linkage showed no 
cytotoxicity on the liver cell line, HepG2.  
In Chapter 6, we portray another new reaction in ptDCC, using thiazolidines. 
Thiazoldines can be found in numerous natural compounds and are therefore 
very attractive scaffolds from a biochemical point of view. We described a number 
of DCC experiments, illustrating that this reaction can also be applied in 
medicinal chemistry projects. Expansion of the reaction scope from cysteine 
derivatives towards aromatic aminothiol building blocks resulted in the oxidation 
of the products. This oxidation makes the reaction irreversible, and therefore 
thiazolidine DCC is limited for now to cysteine derivatives. 
7.3 Perspectives 
As can be seen from this thesis, dynamic combinatorial chemistry can be applied 
to a variety of different targets. It opens up the possibility of finding starting 
points in medicinal-chemistry projects. It can be expected that the number of 
successful DCC projects will increase over time, as more and more research 
groups are showing interest in this technique. The applicability of DCC in a high-
throughput manner is still limited but this might change in the near future, if the 
analysis via LC-MS can be automated. This would open-up the possibility of 
running library sizes over 100 compounds, especially when extracted ion counts 
of each individual product will be used instead of analysis via UV. 
DCC will likely become also more important in optimisation rounds. Hit 
compounds of previous studies, obtained via DCC or via other hit-discovery 
strategies, can be valuable starting points. Molecules can for example also be 
grown by applying DCC. Drug discovery requires multiparameter optimisation, 
focusing on more than just affinity. Therefore, DCC will most likely stay most 
useful in the early phases of the drug-discovery process. 
Since the chemical linkage formed in the reversible reactions used in DCC (for 
example: imine, hydrazone, thiazolidine) is part of the drug-molecule, it could 
also be involved in binding to the protein. Depending on the type of target, it 
would be helpful to have a variety of reversible reaction at hand. This would 
require a constant search for new reactions and the corresponding scaffolds 
which can be applied in a tdDCC setting.  
All in all, we have given examples of the broad utility of DCC, showing why this 






Het toepassen van dynamische combinatorische chemie (DCC) in medicinale-
chemieprojecten kan een waardevolle strategie zijn om startpunten te vinden in 
het medicijn-ontdekkingsproces. Vooral wanneer informatie over het biologische 
doelwit bekend is, kan structuur-gebaseerd medicijnontwerp (SGMO) of 
fragment-gebaseerd medicijnontwerp (FGMO) tot potente verbindingen leiden. 
Als relevante biologische doelwitten, spelen 14-3-3 eiwitten een rol in 
verschillende ziekten en biologische processen. Eiwitten in deze familie gaan 
eiwit-eiwit interacties (EEIs) aan, en kunnen dat doen met een groot aantal 
verschillende interactiepartners. Door het aangaan van deze EEIs, beïnvloeden 
ze de werking van hun interactiepartner. Deze werking kan zowel gestimuleerd 
als ook geremd worden. 
Een andere biologisch relevante familie is die van de glucansucrasen, welke 
belangrijke enzymen zijn in de start en ontwikkeling van cariogene 
gebitsbiofilmen, ook wel bekend als tandplak. 
In de laatste twee hoofdstukken wordt gebruik gemaakt van endothiapepsin in 
eiwit-gerichte (eg) DCC. Endothiapepsin behoort tot de familie van de 
aspartaatproteasen. Deze zijn betrokken bij veel biologische processen en ziekten, 
bijvoorbeeld de rijping van het hiv-virus. 
In dit proefschrift focussen we op het toepassen van DCC in verschillende 
projecten. De belangrijkste resultaten zijn: 1) de beschrijving van ons eigen DCC-
protocol, waarin rekening gehouden wordt met belangrijke aspecten als 
oplosbaarheid van bouwstenen en producten, eiwitstabiliteit en meer, 2) de 
toepassing van acylhydrazon-gebaseerde DCC op twee aantrekkelijke doelwitten, 
een EEI-doelwit en een glucansucrase, 3) de identificatie van kleine moleculen 
die de EEI van 14-3-3/ synaptopodin stabiliseren, 4) het uitbreiden van de 
gereedschapskist van egDCC middels twee aanvullende reacties: nitron en 
thiazolidin formatie. 
In Hoofdstuk 1 van dit proefschrift, geven we een heldere en bondige 
beschrijving van het uitgebreide DCC-protocol. Dit werk concentreert zich op 
belangrijke aspecten betreffende de praktische uitvoering in eiwit-gerichte 
dynamische combinatorische chemie (egDCC). Om een succesvolle toepassing 
van egDCC te bewerkstelligen, moeten de beste biologische en chemische 
condities harmonieus samengevoegd worden. Bovendien bediscussiëren we de 





In Hoofdstuk 2 presenteren we een overzicht van regelaars van 14-3-3 eiwitten. 
We analyseren kritisch de bekende regelaars op hun structuur en de herkenning 
door 14-3-3 eiwitten. We stellen een aantal kleine veranderingen voor een aantal 
regelaars voor, die gebaseerd zijn op gepubliceerde co-kristalstructuren. 
In Hoofdstuk 3 beschrijven we de identificatie van regelaars van 14-3-3 EEIs 
via DCC. We richten ons op een EEI-complex van 14-3-3(ζ) met synaptopodin, 
een peptide van 21 aminozuren. Hit-verbindingen van de DCC-experimenten 
analyseren we op hun biochemische werking via oppervlakte plasmaresonantie 
(OPR). Deze verbindingen blijken een stabiliserende werking te hebben op het 
EEI-complex. Co-kristallisatiestudies worden uitgevoerd om de bindingswijze te 
bevestigen. En als basis voor SGMO om de affiniteit te verbeteren. 
In Hoofdstuk 4 passen we een acylhydrazon-gebaseerde DCC toe op een 
glucansucrase. Glucansucrasen spelen een belangrijke rol in tandplak, dat cariës 
veroorzaakt. Remmers van glucansucrase zouden daarom cariës kunnen 
voorkomen en aan tandpasta toegevoegd kunnen worden. 
In Hoofdstuk 5 beschrijven we de eerste toepassing van een nitron-gebaseerde 
egDCC. We hebben de condities voor de egDCC geoptimaliseerd, daarbij rekening 
gehouden met het eiwit alsook de toepasbaarheid van de nitronreactie. Tevens 
hebben we het optimale pH-venster bepaald voor deze ‘nieuwe’ reactie. De 
synthese van de hit-verbindingen maakte het evalueren van de biochemische 
activiteiten mogelijk via een fluorescentie-gebaseerde activiteits assay. 
In Hoofdstuk 6 laten we nog een nieuwe reactie in egDCC zien waarbij gebruik 
gemaakt wordt van thiazolidinen. Thiazolidinen worden in verscheidene 
natuurstoffen gevonden en zijn daarom zeer attractieve bouwstenen vanuit een 
biochemisch oogpunt. We beschrijven een aantal DCC-experimenten die laten 
zien dat deze reactie ook in medicinale-chemieprojecten toegepast kan worden. 
De uitbreiding van de reactiemogelijkheden van cysteïne derivaten naar 
aromatische aminothiol bouwstenen resulteerde in de oxidatie van de producten. 
De oxidatie maakt de reactie irreversibel waardoor thiazolidin DCC tot dusver 








Die Verwendung dynamisch kombinatorischer Chemie (Dynamic Combinatorial 
Chemistry, DCC) in medizinisch-chemischen Projekten kann eine sehr hilfreiche 
Strategie sein, um Anknüpfungspunkte für die Wirkstoffentdeckung zu finden. 
Insbesondere, wenn Targetinformationen bekannt sind, können mit DCC 
kombinierte struktur- oder fragmentbasierte Wirkstoffdesign-Ansätze zu 
wirksamen Verbindungen führen.  
14-3-3 Proteine spielen als relevantes Target eine Rolle in verschiedenen 
Krankheiten und vielen biologischen Prozessen. Proteine dieser Familie 
beteiligen sich an Protein-Protein-Interaktionen (PPIs) und können diese mit 
zahlreichen Bindungspartnern ausbilden. Durch Bildung dieser PPIs regulieren 
diese Proteine die Aktivität der Bindungspartner. Die Aktivität kann sowohl 
hoch- als auch herabreguliert werden.  
Eine andere Familie relevanter Targets sind die Glukansucrasen, welche wichtige 
Enzyme in der Initiierung und Entwicklung von kariogenen dentalen Biofilmen, 
allgemein bekannt als Plaque, sind. Durch Inhibition dieser Enzyme könnte 
deshalb Karies vorgebeugt werden. 
In den letzten beiden Kapiteln wurde Endothiapepsin für Protein-vermittelte 
DCC (ptDCC) verwendet. Endothiapepsin gehört zur Familie der 
Aspartylproteasen. Aspartylproteasen sind an zahlreichen biologischen 
Prozessen und Krankheiten beteiligt, zum Beispiel an der Reifung des HIV 
Viruspartikels. 
Im Verlauf dieser Arbeit fokussieren wir uns auf die Anwendung von DCC in 
verschiedenen Projekten. Die Hauptleistungen sind: 1) die Beschreibung des 
hausinternen DCC-Protokolls, in welchem Aspekte wie Löslichkeit von 
Bausteinen und Produkten, Proteinstabilität und weiteres wichtige zu beachten 
sind, 2) die Anwendung von Acylhydrazon-basierter DCC auf zwei attraktive 
Targets, eine Glukansucrase und ein PPI-Target, 3) die Identifikation kleiner 
Moleküle, die PPIs von 14-3-3/ Synaptopodin stabilisieren, 4) die Erweiterung 
des Reaktionsspielraums der ptDCC durch zwei zusätzliche Reaktionen: Nitron- 
und Thiazolidinbildung. 
In Kapitel 1 liefert eine klare und knappe Beschreibung eines umfassenden 
DCC-Protokolls. Diese Arbeit fokussierte sich auf wichtige Aspekte hinsichtlich 
der praktischen Handhabung in der ptDCC. Um ptDCC erfolgreich anzuwenden, 
sollten die besten biologischen und chemischen Bedingungen aufeinander 




verwendet wurden, um zu bestimmen, welche Verbindungen die favorisierten 
sind, kurz diskutiert. 
In Kapitel 2 zeigen wir einen Überblick der Modulatoren von 14-3-3 Proteinen. 
Kritisch analysierten wir in Hinblick die bekannten Modulatoren auf ihre 
Strukturen und molekulare Erkennung durch 14-3-3 Proteine. Basierend auf 
publizierten Cokristallstrukturen, schlugen wir kleine Modifikationen 
bestimmter Modulatoren vor. 
In Kapitel 3 beschreiben wir die Identifikation von Modulatoren der 14-3-3 PPIs 
mittels DCC. Wir adressierten einen PPI-Komplex der 14-3-3(ζ) mit 
Synaptopodin, ein aus 21 Aminosäuren bestehendes peptid. Hit-Verbindungen 
der DCC-Experimente wurden auf ihre biologischen Aktivitäten via 
Oberflächenplasmonenresonanz (SPR)-Spektroskopie untersucht. Diese 
Verbindungen zeigen einen stabilisierenden Effekt auf den PPI-Komplex. 
Cokristallisationsstudien laufen um den Bindungsmodus zu bestätigen, und 
SBDD zur Optimierung der Aktivität zu ermöglichen. 
In Kapitel 4 wendeten wir Acylhydrazon-basierte DCC auf eine Glukansucrase 
an. Glukansucrasen spielen in kariogenen dentalen Biofilmen eine wichtige Rolle, 
welche Karies verursachen. Glukansucrase-Inhibitoren sollten daher Karies 
vorbeugen und könnten als Additive in Zahnpasta zugesetzt werden. Wir 
beschrieben die Synthesen, DCC Experimente als auch die biochemische 
Charakterisierung der Hit-Verbindungen. 
In Kapitel 5 beschreiben wir die erste Anwendung von Nitron-basierter ptDCC. 
Wir optimierten die Bedingungen für ptDCC unter Berücksichtigung des 
Targetproteins Endothiapepsin sowie der Anwendbarkeit der Nitronreaktion. 
Neben der Anwendung auf ptDCC, bestimmten wir das optimale pH Fenster 
dieser „neuen“ Reaktion. Die Synthese der Hit-Verbindungen ermöglichte die 
Evaluation ihrer biochemischen Aktivität in einem Fluoreszens-basierten 
Aktivitätsassay. Vorläufige Ergebnisse hinsichtlich der Zytotoxizität des Nitron 
Linkers zeigte keine Zytotoxizität auf der Leberzelllinie HepG2. 
In Kapitel 6 porträtieren wir eine weitere neue Reaktion in ptDCC unter Einsatz 
von Thiazolidinen. Thiazolidine können in zahlreichen Naturstoffen gefunden 
werden und sind deshalb aus biochemischer Sicht sehr attraktive Gerüste. Wir 
beschrieben eine Zahl von DCC-Experimenten, die zeigten dass diese Reaktion 
ebenfalls in Medizinalchemieprojekten verwendet werden kann. Die Erweiterung 
des Reaktionsumfangs von Cysteinderivaten auf aromatischen Aminothiol-
Bausteinen resultierte in der Oxidation der Produkte. Diese Oxidation macht die 
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our research abroad. Thank you Anna, for guiding me during my PhD, for always 
supporting me and for being not only a great mentor but definitely also a friend.  
Not only Anna was a great mentor, but also you, Adri, helped me a lot. During the 
time in Groningen you always showed great interest in my research and you were 
always available for questions and guidance. Even after moving to Saarbrücken, 
you kept supervising me and your feedback on my research progress was very 
valuable to me. Hartelijk dank dat u altijd voor me klaar stond, zeker ook toen we 
als werkweek in Hamburg waren en we wat problemen met het hotel hadden. Ik 
mag me erg gelukkig prijzen met u en Anna als mijn promotoren. 
Dear Rolf, I would like to sincerely thank you for being my co-supervisor from 
Saarbrücken and for your support in all the events I organised at HIPS.  
There are more professors whom I would like to thank. Beste Martin, dankjewel 
dat je je onvermoeid ingezet en nuttige feedback gegeven hebt tijdens de 
groepsbijeenkomsten en daarbuiten om. Lieber Alex und lieber Martin, ich 
möchte euch herzlich für euer Interesse an meiner Forschung und eure Tipps 
danken, die ich von euch bekommen habe. Lieber Prof. Hartmann, vielen Dank, 
dass Sie uns als Fachgruppe so herzlich in Saarbrücken aufgenommen haben. 
I would like to thank all the members of my PhD reading committee, Prof. Frank 
Dekker, Prof. Rolf Müller, Prof. Sijbren Otto, Prof. Martin Witte, Prof. Anna 
Hirsch and Prof. Adri Minnaard, for their comments and feedback. 
Many thanks to the collaborators with whom I had the pleasure to work with. 




jouw inzet was het überhaupt niet mogelijk geweest. Lieber Christian, vielen 
Dank dass du uns die Möglichkeit gegeben hast um DCC zu verwenden mit 
14-3-3. Beste Lubbert en Evelien, ik wil jullie hartelijk danken voor jullie 
samenwerking bij het glucansucrase project. Also at this stage I would like to 
thank you, Varsha, for helping and supporting me with the glucansucrase project. 
main aapake dhairy aur dostee kee bahut saraahana karata hoon. After thanking 
Varsha, I immediately thought of you, Ravi. You are an amazing person, I enjoy 
spending time with you, scientifically and also outside of the labs. I cannot thank 
you enough for reading my manuscripts and also the chapters of this thesis, and 
giving me very useful feedback. ek adbhut dost hone ke lie dhanyavaad. 
My dear Walid, I know it is your pleasure helping your colleagues, and I definitely 
enjoyed working together! I cannot thank you enough for your help with the SPR-
measurements, teaching and guiding me. shukraan litaeawunikum aljamil. I 
would also like to thank you Samir, for always being available to help with the LC-
MS and questions related to synthesis. Merci pour ton aide précieuse. 
One year ago, you joined our group Henni, and I am really happy you did. You 
are calm, capable, extremely intelligent and someone you can trust! Kiitos paljon 
siitä, että autat minua hakemuskirjeteni kanssa, ja ystäväksi. My dear Jelena, also 
you joined our group one year ago. And it has been a really nice time since then. 
Hvala vam što ste mi bili prijatelj i što ste bili tako ljubazni! 
My dear office mates from Saarbrücken: Andreas, Philine, Isabell, Melissa and 
Christina, you guys have made my time in Saarbrücken very pleasant, joyfull and 
valuable. Lieber Andreas, du bist jemand, auf den man sich verlassen kann, danke 
für deine Hilfsbereitschaft, wenn ich Fragen hatte, für die tolle Zeit im Büro und 
deine Freundschaft. Liebe Christina, du hast mir unglaublich gut mit der 
Übersetzung der Zusammenfassung meiner Doktorarbeit und allen anderen 
Briefen sowie E-mails geholfen. Danke für dein Interesse an dem, was ich mache 
und für deine Freundschaft. Meine liebe Philine, wie schön war die Zeit mit dir 
im Büro. Ich schätze dich sehr und bin sehr froh, dass wir zusammen etwas 
publizieren werden, und somit auch unsere Zusammenarbeit verewigt ist. Ich bin 
dir sehr dankbar, dass du mich in euer Büro eingeladen hast. Ciao Melissa, ho 
anche trascorso molto tempo con te in ufficio. Sei una persona meravigliosa, 
grazie per la tua amicizia. 
Another dear Italian, whom I would like to thank, is you Massimo. Grazie mille 
per la tua gentilezza, ospitalità, amicizia e i tuoi deliziosi vini. 
There are more persons I would like to thank from Saarbrücken. Lieber Chris, 
dich konnte ich immer etwas zu Synthesen fragen. Du bist ein genauso guter  




viel mit einander gekämpft, aber das hat uns beiden auch viel Spaß gemacht. Ich 
habe mich immer über unsere Squash-Spiele gefreut. Es tut mir leid, dass ich bei 
dir gequetschte Rippen verursacht habe, ich werde versuchen weniger knochig zu 
werden. Am Anfang warst du auch dabei, Roman. Nachdem ich nach 
Saarbrücken gezogen bin, bist du ziemlich schnell nach Groningen umgezogen. 
Ich hoffe, dass es euch gut geht und bin sicher, dass euch die Stadt gefällt! 
Dear Italian gang, Eleonora, Federica, Melissa, Serena, Vittoria, Saverio and of 
course Claudia, you guys are also very good friends of mine. Grazie per le serate 
di pizza e il tempo divertente insieme. 
Dear Jörg, Mostafa, Ahmed-Saad, Ahmed Merabet, Stefanie, Sandra, Eike, 
Joscha, Olga, Ghamdan, Varvara, Eva, Ali, Alaa, Valentin, Vlad, Dominik, Aylin, 
Julia, Cansu, Alex and most likely many more, thank you all for being great 
colleagues and making my time at HIPS pleasant! 
Dear Robin, Spyros, Judy, Eleonora, Yagiz, Varsha, Ravi and Anna. I think we can 
look back on a successful move from Groningen to Saarbrücken.  We have 
supported each other a lot and found our way around. I am happy that I was part 
of the team! 
My dear Ramon, you did not move with us to Saarbrücken, but you did stay an 
important part of the Hirsch-group. At the beginning in Saarbrücken, we had our 
frequent problem sessions, which you joined via Skype. Dankjewel voor jouw 
vriendschap, hulp en dat je altijd geïnteresseerd was in mijn onderzoek en hoe 
het met mij ging. Het was jammer dat je niet meegegaan bent naar Saarbrücken, 
maar ik begrijp het heel goed dat je fijn samen met Joyce in Groningen gebleven 
bent. Ik wens jullie samen viel geluk en plezier, en hopelijk kun jij binnenkort ook 
je PhD afronden. 
My dearest Simone, Jeannine, Tabea, Dennis, Teresa and Andreas, thanks to all 
of you for the great lunch and coffee breaks we had. Vielen Dank, dass Ihr immer 
für mich da wart, und meine Zeit am HIPS richtig schön gemacht habt. 
Many, many thanks to the ̀ Hausmeister‘, Christian and Frank and to the IT-guys, 
Mark and Michael. Ohne euch kann keiner am HIPS arbeiten, ihr seid die stillen 
Kräfte, auf die man sich verlassen kann. I would also like to thank the people at 
DDEL and MINS, for being great colleagues and friends, especially Olga, 
Rebekka, Justus, Patrick and Benedikt. 
Also many people from Groningen were unmissable. Dankjewel Nabil, voor de 
potjes snooker die we gespeeld hebben en je hulp bij de laatste stapjes voor mijn 




Datzelfde geldt voor Mark, met wie ik ook meerdere potjes snooker heb kunnen 
spelen, en tevens het kantoor gedeeld te hebben in de Linnaeusborg. Dear Kaja, 
thanks a ton for your company in the office and for making the illustration for my 
first review. Dear Leticia, Mira, Jonas, Paul, Niek, Manuel, Jeffrey, Ashmir, 
Ruben, Wiktor, Ilse, Mickel, Michael, Dusan, Friederike, Stella and many more, I 
wish to thank you for the good time we spent in and outside of the Linnaeusborg.  
Dear Yagiz and Milon, you both have been an example for me during my PhD. 
You both were there for me, when I had questions or wanted to discuss other 
things. Dear Yagiz, it was really special, being at your wedding party, I wish you 
and Nour all the best.  
A very special thanks goes to my students: Stef, Barbara, Nathalie and Claudia. It 
was my pleasure being part of your academic journeys, and you have all helped 
me to become a better mentor and scientist myself.  
A big thank you goes to Theodora, Monique, Hilda and Alphons, who make sure 
that everyone can work properly in Groningen! 
Without family and friends, I could not have achieved any of this. I could write 
another book, on what you all mean to me, but I will keep it concise. My dearest 
Corinna, liebe `Schwester`. Wir kennen uns schon ziemlich lange, und du bist 
eine meiner besten Freundinnen. Du warst immer ein Beispiel für mich, gute 
Arbeit zu leisten und Einfluss in Forschung zu haben. Auch danke an deine 
Eltern, die sind auch awesome. Lieve Bram en Tineke, jullie zijn twee geweldige 
vrienden en hebben drie super leuke dochters! Dankjulliewel, ook aan jullie 
familie, voor alle steun en interesse! Beste Jeffrey, samen naar Groningen gegaan 
om te studeren, en dan ga jij naar Duitsland. Toen je terug kwam ging ik bijna 
naar Duitsland. Ik hoop dat ook jij binnenkort je PhD succesvol kunt gaan 
afronden. Lieve Marcella, dankjewel voor je interesse in mijn onderzoek en de 
vriendschap die we al vele jaren hebben. Lieve Renate en Derek, jullie zijn ook 
twee onmisbare personen voor mij, dankjulliewel voor alles. Lieve Marianne & 
Annyttsje, Frits & Willeke en Jolande & Richard, Jasper & Stephany en Melissa, 
ook jullie wil ik hartelijk danken voor jullie steun en interesse! 
Last but certainly not least comes my family. Lieve papa, en zeker ook mama, 
lieve Stefan & Kirsten + Julian, lieve Lysette & Maarten, ik wil jullie heel erg 
bedanken voor alles wat jullie voor mij betekenen. Jullie hebben mij altijd 
gesteund, en me geholpen waar nodig. Lieve zus, dankjewel voor de fantastische 
cover van mijn thesis, dat heb je echt super mooi gedaan! 
Lieber Tobias, dankeschön, dass du mein Freund bist, dass du zuverlässig bist 




uns jeden Tag wieder lieb haben. Ich hoffe, dass wir noch lange zusammen 
bleiben werden. Auch würde ich hier gerne deiner Mutter, Christine, deiner 
Schwester, Alexandra, ihrem Mann, Johannes, und den Kinder herzlich für euer 
Interesse an mir danken. 
For all of you, who I might have missed to thank by name, I am grateful for your 
help, support and trust in me over the past years. 
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